[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOk9dpuFfSZbk7a1Pnu5lnlOLrE-B2AMH2arcN5fKLPs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"University of Aarhus",[4],1280,false,195,41,6796245,36,1004,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Obesity",27,{"name":18,"count":19},"Healthy",26,{"name":21,"count":22},"Type 2 Diabetes",22,{"name":24,"count":25},"Stroke",21,{"name":27,"count":28},"Heart Failure",20,{"name":30,"count":31},"Insulin Resistance",17,{"name":33,"count":31},"Diabetes Mellitus, Type 2",{"name":35,"count":36},"Multiple Sclerosis",16,[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05685927","Investigating Muscle Failure in Diabetic Myopathy","2025-09-30","6-months of medically assisted glycemic improvement",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT01739062","The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice","2025-10-30","Genetic risk assessment",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07160504","Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women","2025-12-31","Vaginal estradiol",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06668714","Does Co-administration of Lactate Affect Postprandial Nutrient Absorption and Fat Disposition?","2026-01","Lactate + mixed meal",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03642509","Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation","2026-01-01","NOAC",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05668026","Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART","2026-03-01","Venetoclax",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04932577","Faecal Microbiota Transplantation for Liver Cirrhosis","2026-05-31","Faecal microbiota transplantation",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06059222","The Optimised Use of Romozosumab Study","2026-08","Romosozumab",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT07429071","Effectiveness of a Vaginal Gel on CIN1\u002F2 Regression and HPV Clearance.","Papilocare Vaginal Gel",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05899465","Perioperative Treatment With Tranexamic Acid in Melanoma","2026-09-01","Tranexamic acid",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,134,156,184,202,224,253,271,297,315,337,355,380,407,425,550,587,613,631,649,671,697,715,736,762,801,823,850,876,901,928,950,968,986,1012,1040,1062,1104,1151,1195,1231,1258,1291,1327,1349,1374,1392,1418,1436,1462,1488,1506,1524,1550,1568,1586,1612,1630,1655,1673,1698,1724,1746,1770,1795,1813,1838,1864,1887,1915,1933,1958,1983,2001,2025,2043,2071,2089,2113,2138,2156,2182,2200,2218,2241,2267,2291,2309,2334,2359,2387,2405,2431,2449,2467,2494,2520,2546,2571,2596,2620,2645,2668,2692,2710,2738,2763,2781,2808,2826,2860,2884,2909,2927,2951,2974,2997,3015,3038,3060,3087,3112,3136,3154,3177,3204,3222,3240,3264,3287,3309,3333,3356,3379,3400,3426,3450,3480,3504,3530,3556,3574,3598,3616,3634,3652,3676,3699,3724,3742,3767,3785,3810,3835,3853,3878,3896,3919,3944,3970,3988,4014,4032,4050,4074,4092,4116,4134,4157,4182,4200,4218,4241,4265,4283,4307,4332,4356,4379,4404,4428,4455,4473,4497,4515,4538,4559,4583,4601,4626,4650,4668,4692,4761,4818,4873,4921,4953,4993,5033,5063,5091,5124,5155,5181,5209,5236,5267,5295,5329,5363,5393,5420,5455,5473,5497,5519,5542,5566,5588,5612,5634,5652,5673,5699,5717,5739,5763,5781,5799,5821,5842,5866,5889,5913,5938,5961,5985,6007,6031,6049,6067,6091,6109,6127,6150,6168,6191,6214,6237,6263,6281,6299,6317,6341,6363,6387,6410,6431,6456,6474,6497,6521,6539,6557,6575,6602,6624,6642,6669,6687,6705,6730,6748,6770,6794,6816,6839,6861,6883,6905,6929,6947,6969,6991,7009,7031,7053,7077,7101,7119,7141,7163,7185,7206,7230,7252,7270,7295,7318,7341,7359,7382,7408,7431,7456,7481,7504,7522,7544,7567,7585,7606,7624,7642,7660,7678,7696,7714,7737,7755,7773,7797,7822],{"intervention":96,"totalTrials":97,"cells":98},"Solifenacin",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":121,"NA":132},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":120,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT06551246","Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","RECRUITING",[91],"2027-12-01","2024-06-27",236,[117],"Urinary Incontinence in Children",[96,119],"Mirabegron",1,{"trials":122,"activeCount":120,"soonestReadout":113},[123],{"nctId":124,"briefTitle":125,"status":111,"phases":126,"primaryCompletion":113,"completion":113,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT06465576","Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)",[92],"2024-05-27",216,[117],[96,119,131],"Solifenacin + Mirabegron",{"trials":133,"activeCount":101},[],{"intervention":119,"totalTrials":97,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":148,"NA":154},{"trials":137,"activeCount":101},[],{"trials":139,"activeCount":101},[],{"trials":141,"activeCount":101},[],{"trials":143,"activeCount":120,"soonestReadout":113},[144],{"nctId":109,"briefTitle":110,"status":111,"phases":145,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":146,"interventions":147},[91],[117],[96,119],{"trials":149,"activeCount":120,"soonestReadout":113},[150],{"nctId":124,"briefTitle":125,"status":111,"phases":151,"primaryCompletion":113,"completion":113,"start":127,"enrollment":128,"conditions":152,"interventions":153},[92],[117],[96,119,131],{"trials":155,"activeCount":101},[],{"intervention":157,"totalTrials":120,"cells":158},"Aspirin",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":182},{"trials":160,"activeCount":101},[],{"trials":162,"activeCount":101},[],{"trials":164,"activeCount":101},[],{"trials":166,"activeCount":101},[],{"trials":168,"activeCount":120,"soonestReadout":173},[169],{"nctId":170,"briefTitle":171,"status":111,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":180},"NCT06710184","Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction",[92],"2029-01-01","2029-07-01","2025-05-01",5076,[178,179],"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","Acute Myocardial Infarction (AMI)",[157,181],"Fondaparinux Sodium",{"trials":183,"activeCount":101},[],{"intervention":181,"totalTrials":120,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":200},{"trials":187,"activeCount":101},[],{"trials":189,"activeCount":101},[],{"trials":191,"activeCount":101},[],{"trials":193,"activeCount":101},[],{"trials":195,"activeCount":120,"soonestReadout":173},[196],{"nctId":170,"briefTitle":171,"status":111,"phases":197,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":198,"interventions":199},[92],[178,179],[157,181],{"trials":201,"activeCount":101},[],{"intervention":52,"totalTrials":120,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":222},{"trials":205,"activeCount":101},[],{"trials":207,"activeCount":101},[],{"trials":209,"activeCount":101},[],{"trials":211,"activeCount":101},[],{"trials":213,"activeCount":120,"soonestReadout":51},[214],{"nctId":49,"briefTitle":50,"status":111,"phases":215,"primaryCompletion":51,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},[92],"2026-12-31","2025-03-21",90,[220],"Vagina Atrophy",[52],{"trials":223,"activeCount":101},[],{"intervention":225,"totalTrials":120,"cells":226},"Intravenous furosemide continuous",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":251},{"trials":228,"activeCount":101},[],{"trials":230,"activeCount":101},[],{"trials":232,"activeCount":101},[],{"trials":234,"activeCount":101},[],{"trials":236,"activeCount":120,"soonestReadout":242},[237],{"nctId":238,"briefTitle":239,"status":240,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},"NCT07577596","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure","NOT_YET_RECRUITING",[92],"2027-09-01","2027-10-01","2026-05-01",436,[247,248],"Acute Heart Failure","Volume Overload",[225,250],"Intravenous furosemide bolus injections",{"trials":252,"activeCount":101},[],{"intervention":250,"totalTrials":120,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":269},{"trials":256,"activeCount":101},[],{"trials":258,"activeCount":101},[],{"trials":260,"activeCount":101},[],{"trials":262,"activeCount":101},[],{"trials":264,"activeCount":120,"soonestReadout":242},[265],{"nctId":238,"briefTitle":239,"status":240,"phases":266,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":267,"interventions":268},[92],[247,248],[225,250],{"trials":270,"activeCount":101},[],{"intervention":272,"totalTrials":120,"cells":273},"Zoledronic acid 4 mg",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":295},{"trials":275,"activeCount":101},[],{"trials":277,"activeCount":101},[],{"trials":279,"activeCount":101},[],{"trials":281,"activeCount":101},[],{"trials":283,"activeCount":120,"soonestReadout":288},[284],{"nctId":285,"briefTitle":286,"status":111,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT06859580","Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism",[92],"2028-02-01","2025-03-01",140,[292],"Primary Hyperparathyroidism",[272,294],"Natriumklorid 9 mg\u002Fml, Fresenius Kabi",{"trials":296,"activeCount":101},[],{"intervention":294,"totalTrials":120,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":313},{"trials":300,"activeCount":101},[],{"trials":302,"activeCount":101},[],{"trials":304,"activeCount":101},[],{"trials":306,"activeCount":101},[],{"trials":308,"activeCount":120,"soonestReadout":288},[309],{"nctId":285,"briefTitle":286,"status":111,"phases":310,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":311,"interventions":312},[92],[292],[272,294],{"trials":314,"activeCount":101},[],{"intervention":77,"totalTrials":120,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":335},{"trials":318,"activeCount":101},[],{"trials":320,"activeCount":101},[],{"trials":322,"activeCount":101},[],{"trials":324,"activeCount":101},[],{"trials":326,"activeCount":120,"soonestReadout":76},[327],{"nctId":74,"briefTitle":75,"status":111,"phases":328,"primaryCompletion":76,"completion":76,"start":329,"enrollment":330,"conditions":331,"interventions":333},[92],"2023-10-02",270,[332],"Osteoporosis",[77,334,77,334,77,334],"Zoledronate",{"trials":336,"activeCount":101},[],{"intervention":334,"totalTrials":120,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":353},{"trials":340,"activeCount":101},[],{"trials":342,"activeCount":101},[],{"trials":344,"activeCount":101},[],{"trials":346,"activeCount":101},[],{"trials":348,"activeCount":120,"soonestReadout":76},[349],{"nctId":74,"briefTitle":75,"status":111,"phases":350,"primaryCompletion":76,"completion":76,"start":329,"enrollment":330,"conditions":351,"interventions":352},[92],[332],[77,334,77,334,77,334],{"trials":354,"activeCount":101},[],{"intervention":356,"totalTrials":120,"cells":357},"Immunoglobulin",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":378},{"trials":359,"activeCount":101},[],{"trials":361,"activeCount":101},[],{"trials":363,"activeCount":101},[],{"trials":365,"activeCount":101},[],{"trials":367,"activeCount":120,"soonestReadout":372},[368],{"nctId":369,"briefTitle":370,"status":111,"phases":371,"primaryCompletion":372,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":377},"NCT04589299","Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)",[92],"2030-12-31","2020-06-04",60,[376],"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",[356],{"trials":379,"activeCount":101},[],{"intervention":381,"totalTrials":120,"cells":382},"Finerenone",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":405},{"trials":384,"activeCount":101},[],{"trials":386,"activeCount":101},[],{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":120,"soonestReadout":216},[393],{"nctId":394,"briefTitle":395,"status":111,"phases":396,"primaryCompletion":216,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":404},"NCT07026539","Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.",[92],"2028-04-30","2024-10-23",80,[401,402,403],"Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","Cardiovascular Diseases",[381],{"trials":406,"activeCount":101},[],{"intervention":131,"totalTrials":120,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":423},{"trials":410,"activeCount":101},[],{"trials":412,"activeCount":101},[],{"trials":414,"activeCount":101},[],{"trials":416,"activeCount":101},[],{"trials":418,"activeCount":120,"soonestReadout":113},[419],{"nctId":124,"briefTitle":125,"status":111,"phases":420,"primaryCompletion":113,"completion":113,"start":127,"enrollment":128,"conditions":421,"interventions":422},[92],[117],[96,119,131],{"trials":424,"activeCount":101},[],{"intervention":426,"totalTrials":427,"cells":428},"Saline",10,{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":449,"PHASE4":459,"NA":515},{"trials":430,"activeCount":101},[],{"trials":432,"activeCount":101},[],{"trials":434,"activeCount":101},[435],{"nctId":436,"briefTitle":437,"status":438,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT03837756","Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV","COMPLETED",[90],"2022-07-01","2023-05-01","2019-05-06",47,[445],"HIV-1-infection",[426,447,448],"Lefitolimod","3BNC117 and 10-1074",{"trials":450,"activeCount":120,"soonestReadout":85},[451],{"nctId":83,"briefTitle":84,"status":111,"phases":452,"primaryCompletion":85,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},[91],"2028-09-01","2023-08-25",1204,[457],"Melanoma",[86,426],{"trials":460,"activeCount":101},[461,473,484,496,505],{"nctId":462,"briefTitle":463,"status":438,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":471},"NCT00964639","Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies",[92],"2013-01","2009-08",12,[469,470],"Postoperative Pain","Cerebral Palsy",[472,426],"Ropivacaine",{"nctId":474,"briefTitle":475,"status":476,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":218,"conditions":480,"interventions":482},"NCT02540837","Obturator and Femoral Nerve Block in Patients With Hip Fracture","UNKNOWN",[92],"2017-04","2015-10",[481],"Hip Fractures",[483,426],"Bupivacaine",{"nctId":485,"briefTitle":486,"status":487,"phases":488,"primaryCompletion":489,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":494},"NCT02248870","Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture","TERMINATED",[92],"2015-09","2015-03",7,[493],"Hip Fracture",[495,426],"Dexamethasone",{"nctId":497,"briefTitle":498,"status":499,"phases":500,"primaryCompletion":501,"completion":502,"start":490,"enrollment":101,"conditions":503,"interventions":504},"NCT02408419","Obturator Nerve Block in Patients With Hip Fracture","WITHDRAWN",[92],"2016-12","2017-03",[481],[483,426],{"nctId":506,"briefTitle":507,"status":438,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":374,"conditions":512,"interventions":513},"NCT00868348","A Comparison of Naropin and Ketorolac for Postoperative Analgesia After Total Knee Arthroplasty",[92],"2011-06","2011-09","2009-05",[469],[514,426],"Ketorolac",{"trials":516,"activeCount":120,"soonestReadout":530},[517,526,539],{"nctId":518,"briefTitle":519,"status":438,"phases":520,"primaryCompletion":521,"completion":521,"start":522,"enrollment":427,"conditions":523,"interventions":524},"NCT02500095","Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting",[93],"2016-11","2015-07",[18],[426,525],"Pegvisomant",{"nctId":527,"briefTitle":528,"status":111,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":427,"conditions":533,"interventions":537},"NCT07359625","Effects of Ketone Bodies on Insulin Sensitivity",[93],"2027-04","2028-04","2025-12-02",[30,534,535,536],"Obesity & Overweight","Energy Metabolism","Ketone Body Metabolism",[538,426],"Growth Hormone, Human",{"nctId":540,"briefTitle":541,"status":438,"phases":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT00512473","Growth Hormone Signaling in Vivo in Humans",[93],"2006-04","2005-09",8,[547],"Intracellular Signaling Peptides and Proteins",[426,549,525],"Human Growth Hormone",{"intervention":551,"totalTrials":97,"cells":552},"Phenylephrine",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":573,"NA":585},{"trials":554,"activeCount":101},[],{"trials":556,"activeCount":101},[],{"trials":558,"activeCount":101},[],{"trials":560,"activeCount":120,"soonestReadout":565},[561],{"nctId":562,"briefTitle":563,"status":111,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT06083948","Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia",[90,91],"2027-12-30","2027-12-31","2023-12-20",32,[570],"Hypotension",[572,551],"Noradrenalin",{"trials":574,"activeCount":101},[575],{"nctId":576,"briefTitle":577,"status":438,"phases":578,"primaryCompletion":579,"completion":579,"start":489,"enrollment":580,"conditions":581,"interventions":583},"NCT02713087","Vasopressor Effects in Anesthetized Patients",[92],"2017-11",48,[582],"Brain Tumor",[584,551],"Ephedrine",{"trials":586,"activeCount":101},[],{"intervention":588,"totalTrials":120,"cells":589},"Glycerol \"OBA\"",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":609,"NA":611},{"trials":591,"activeCount":101},[],{"trials":593,"activeCount":101},[],{"trials":595,"activeCount":101},[],{"trials":597,"activeCount":120,"soonestReadout":602},[598],{"nctId":599,"briefTitle":600,"status":111,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":608},"NCT04087421","Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome",[91],"2026-12","2019-09-17",114,[606,607],"Low Anterior Resection Syndrome","Rectal Cancer",[588],{"trials":610,"activeCount":101},[],{"trials":612,"activeCount":101},[],{"intervention":86,"totalTrials":120,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":627,"NA":629},{"trials":616,"activeCount":101},[],{"trials":618,"activeCount":101},[],{"trials":620,"activeCount":101},[],{"trials":622,"activeCount":120,"soonestReadout":85},[623],{"nctId":83,"briefTitle":84,"status":111,"phases":624,"primaryCompletion":85,"completion":453,"start":454,"enrollment":455,"conditions":625,"interventions":626},[91],[457],[86,426],{"trials":628,"activeCount":101},[],{"trials":630,"activeCount":101},[],{"intervention":572,"totalTrials":120,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":645,"NA":647},{"trials":634,"activeCount":101},[],{"trials":636,"activeCount":101},[],{"trials":638,"activeCount":101},[],{"trials":640,"activeCount":120,"soonestReadout":565},[641],{"nctId":562,"briefTitle":563,"status":111,"phases":642,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":643,"interventions":644},[90,91],[570],[572,551],{"trials":646,"activeCount":101},[],{"trials":648,"activeCount":101},[],{"intervention":72,"totalTrials":120,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":667,"NA":669},{"trials":652,"activeCount":101},[],{"trials":654,"activeCount":101},[],{"trials":656,"activeCount":101},[],{"trials":658,"activeCount":120,"soonestReadout":71},[659],{"nctId":69,"briefTitle":70,"status":111,"phases":660,"primaryCompletion":71,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":666},[90,91],"2027-05-31","2021-07-01",220,[665],"Liver Cirrhosis",[72],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":101},[],{"intervention":672,"totalTrials":120,"cells":673},"Pomalidomide 2 mg",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":675,"activeCount":101},[],{"trials":677,"activeCount":101},[],{"trials":679,"activeCount":120,"soonestReadout":685},[680],{"nctId":681,"briefTitle":682,"status":683,"phases":684,"primaryCompletion":685,"completion":685,"start":686,"enrollment":568,"conditions":687,"interventions":689},"NCT06660498","Pomalidomide as an Immune-enhancing Agent for the Control of HIV","ACTIVE_NOT_RECRUITING",[89,90],"2027-03-31","2025-05-13",[688],"HIV-1 Infection",[672,690],"Aspirin 75 mg",{"trials":692,"activeCount":101},[],{"trials":694,"activeCount":101},[],{"trials":696,"activeCount":101},[],{"intervention":690,"totalTrials":120,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":101},[],{"trials":704,"activeCount":120,"soonestReadout":685},[705],{"nctId":681,"briefTitle":682,"status":683,"phases":706,"primaryCompletion":685,"completion":685,"start":686,"enrollment":568,"conditions":707,"interventions":708},[89,90],[688],[672,690],{"trials":710,"activeCount":101},[],{"trials":712,"activeCount":101},[],{"trials":714,"activeCount":101},[],{"intervention":67,"totalTrials":120,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":718,"activeCount":101},[],{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":120,"soonestReadout":66},[723],{"nctId":64,"briefTitle":65,"status":111,"phases":724,"primaryCompletion":66,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":729},[89,90],"2026-12-01","2024-04-01",18,[445],[67],{"trials":731,"activeCount":101},[],{"trials":733,"activeCount":101},[],{"trials":735,"activeCount":101},[],{"intervention":81,"totalTrials":120,"cells":737},{"EARLY_PHASE1":738,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":739,"activeCount":120,"soonestReadout":76},[740],{"nctId":79,"briefTitle":80,"status":240,"phases":741,"primaryCompletion":76,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":751},[88],"2026-09","2026-03",70,[746,747,748,749,750],"Womens Health","Cervical Dysplasia","Cervical Intraepithelial Neoplasia (CIN)","Non-invasive Treatment","Human Papilloma Virus (HPV)",[81],{"trials":753,"activeCount":101},[],{"trials":755,"activeCount":101},[],{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"intervention":763,"totalTrials":97,"cells":764},"Indocyanine green",{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":766,"activeCount":101},[],{"trials":768,"activeCount":101},[],{"trials":770,"activeCount":101},[],{"trials":772,"activeCount":101},[],{"trials":774,"activeCount":101},[],{"trials":776,"activeCount":120,"soonestReadout":781},[777,789],{"nctId":778,"briefTitle":779,"status":111,"phases":780,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":788},"NCT06325618","Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome",[],"2027-08","2024-01-08",150,[785,403,786,787],"Turner Syndrome","Lymphedema","Inflammation",[763],{"nctId":790,"briefTitle":791,"status":476,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT03572998","Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment",[93],"2019-02","2019-08","2018-09",28,[798],"Secondary Lymphedema",[800],"Indocyanine Green",{"intervention":47,"totalTrials":120,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":101},[],{"trials":808,"activeCount":101},[],{"trials":810,"activeCount":101},[],{"trials":812,"activeCount":101},[],{"trials":814,"activeCount":120,"soonestReadout":46},[815],{"nctId":44,"briefTitle":45,"status":683,"phases":816,"primaryCompletion":46,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},[93],"2031-10-30","2013-02",5000,[821],"Prostate Cancer",[47],{"intervention":824,"totalTrials":120,"cells":825},"Optimal medical therapy",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":827,"activeCount":101},[],{"trials":829,"activeCount":101},[],{"trials":831,"activeCount":101},[],{"trials":833,"activeCount":101},[],{"trials":835,"activeCount":101},[],{"trials":837,"activeCount":120,"soonestReadout":842},[838],{"nctId":839,"briefTitle":840,"status":111,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":399,"conditions":844,"interventions":849},"NCT05834803","Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.",[93],"2027-06-01","2023-06-26",[845,846,27,847,848],"Renovascular Hypertension","Renovascular Hypertension With Renal Failure","Renal Artery Stenosis Atherosclerotic","Percutaneous Transluminal Angioplasty",[824],{"intervention":42,"totalTrials":120,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":853,"activeCount":101},[],{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":101},[],{"trials":859,"activeCount":101},[],{"trials":861,"activeCount":101},[],{"trials":863,"activeCount":120,"soonestReadout":41},[864],{"nctId":39,"briefTitle":40,"status":683,"phases":865,"primaryCompletion":41,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":875},[],"2025-12-30","2022-11-01",108,[870,15,871,872,873,874],"Diabetes Mellitus","Chronic Hyperglycaemia","Weight Loss","Diabetic Myopathy","Sarcopenia",[42],{"intervention":877,"totalTrials":120,"cells":878},"Told ON",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":101},[],{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":101},[],{"trials":888,"activeCount":101},[],{"trials":890,"activeCount":120,"soonestReadout":895},[891],{"nctId":892,"briefTitle":893,"status":111,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT05885061","Effects of Spinal Cord Stimulation",[93],"2028-12-31","2025-01-02",25,[899],"Chronic Pain",[877],{"intervention":902,"totalTrials":120,"cells":903},"Active drug for chronic migraine treatment.",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":905,"activeCount":101},[],{"trials":907,"activeCount":101},[],{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"trials":913,"activeCount":101},[],{"trials":915,"activeCount":120,"soonestReadout":920},[916],{"nctId":917,"briefTitle":918,"status":111,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"enrollment":374,"conditions":922,"interventions":927},"NCT07071506","New Methods for Evaluating Preventive Migraine Treatment",[93],"2028-09","2025-06-19",[923,924,925,926],"Migraine","Migraine With or Without Aura","Headache Disorders","Chronic Migraine, Headache",[902],{"intervention":57,"totalTrials":120,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":940},{"trials":931,"activeCount":101},[],{"trials":933,"activeCount":101},[],{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":101},[],{"trials":939,"activeCount":101},[],{"trials":941,"activeCount":120,"soonestReadout":56},[942],{"nctId":54,"briefTitle":55,"status":111,"phases":943,"primaryCompletion":56,"completion":56,"start":944,"enrollment":897,"conditions":945,"interventions":948},[93],"2024-08-22",[946,947],"Pre Diabetes","Metabolic Syndrome",[57,949],"Mixed meal with 18F-FTHA",{"intervention":949,"totalTrials":120,"cells":951},{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":953,"activeCount":101},[],{"trials":955,"activeCount":101},[],{"trials":957,"activeCount":101},[],{"trials":959,"activeCount":101},[],{"trials":961,"activeCount":101},[],{"trials":963,"activeCount":120,"soonestReadout":56},[964],{"nctId":54,"briefTitle":55,"status":111,"phases":965,"primaryCompletion":56,"completion":56,"start":944,"enrollment":897,"conditions":966,"interventions":967},[93],[946,947],[57,949],{"intervention":538,"totalTrials":120,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":101},[],{"trials":973,"activeCount":101},[],{"trials":975,"activeCount":101},[],{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[],{"trials":981,"activeCount":120,"soonestReadout":530},[982],{"nctId":527,"briefTitle":528,"status":111,"phases":983,"primaryCompletion":530,"completion":531,"start":532,"enrollment":427,"conditions":984,"interventions":985},[93],[30,534,535,536],[538,426],{"intervention":987,"totalTrials":120,"cells":988},"Active drug for acute migraine treatment",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":990,"activeCount":101},[],{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":120,"soonestReadout":920},[1001],{"nctId":1002,"briefTitle":1003,"status":111,"phases":1004,"primaryCompletion":920,"completion":920,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1011},"NCT06617832","Trial Designs for Evaluating Migraine Treatment",[93],"2024-11-13",128,[1008,1009,1010],"Migraine With Aura","Migraine Without Aura","Headache, Migraine",[987],{"intervention":1013,"totalTrials":120,"cells":1014},"Liver biopsy",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1016,"activeCount":101},[],{"trials":1018,"activeCount":101},[],{"trials":1020,"activeCount":101},[],{"trials":1022,"activeCount":101},[],{"trials":1024,"activeCount":101},[],{"trials":1026,"activeCount":120,"soonestReadout":1031},[1027],{"nctId":1028,"briefTitle":1029,"status":111,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1039},"NCT02931513","sCD163 in PBC Patients - Assessment of Treatment Response",[],"2031-01","2031-09","2016-09",40,[1036,1037,1038],"Primary Biliary Cirrhosis","Liver Inflammation","Ursodeoxycholic Acid",[1013],{"intervention":62,"totalTrials":120,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1043,"activeCount":101},[],{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":101},[],{"trials":1051,"activeCount":101},[],{"trials":1053,"activeCount":120,"soonestReadout":61},[1054],{"nctId":59,"briefTitle":60,"status":111,"phases":1055,"primaryCompletion":61,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},[93],"2030-10-01","2019-01-01",750,[1060,24],"Atrial Fibrillation",[62],{"intervention":495,"totalTrials":1063,"cells":1064},3,{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1102},{"trials":1066,"activeCount":101},[],{"trials":1068,"activeCount":101},[],{"trials":1070,"activeCount":101},[],{"trials":1072,"activeCount":101},[],{"trials":1074,"activeCount":101},[1075,1086,1098],{"nctId":1076,"briefTitle":1077,"status":438,"phases":1078,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1034,"conditions":1082,"interventions":1084},"NCT02346110","Protracted Effect of the Ultrasound-guided Saphenous Block",[92],"2015-12","2016-02","2015-04",[1083],"Arthrosis, Unspecified, Ankle and Foot",[1085,495],"Bupivacaine-adrenaline",{"nctId":1087,"briefTitle":1088,"status":438,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1097},"NCT01414569","Dexamethasone for Pain After Shoulder Surgery",[92],"2013-04","2013-06","2011-11",97,[1095,1096],"Shoulder Impingement Syndrome","Arthritis",[495],{"nctId":485,"briefTitle":486,"status":487,"phases":1099,"primaryCompletion":489,"completion":489,"start":490,"enrollment":491,"conditions":1100,"interventions":1101},[92],[493],[495,426],{"trials":1103,"activeCount":101},[],{"intervention":1105,"totalTrials":1063,"cells":1106},"Fentanyl",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1125,"NA":1149},{"trials":1108,"activeCount":101},[],{"trials":1110,"activeCount":101},[],{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[1115],{"nctId":1116,"briefTitle":1117,"status":438,"phases":1118,"primaryCompletion":466,"completion":1119,"start":1120,"enrollment":22,"conditions":1121,"interventions":1123},"NCT00647127","Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain",[91],"2010-01","2008-02",[1122],"Pain",[1124,1105],"Buprenorphine",{"trials":1126,"activeCount":101},[1127,1138],{"nctId":1128,"briefTitle":1129,"status":476,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT05445856","Intraoperative Methadone for Postoperative Pain in Patients Undergoing Tonsillectomy",[92],"2024-01","2024-08","2022-11-28",130,[469],[1137,1105],"Methadone",{"nctId":1139,"briefTitle":1140,"status":438,"phases":1141,"completion":1142,"start":1143,"enrollment":28,"conditions":1144,"interventions":1146},"NCT00115102","Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls",[92],"2005-10","2004-03",[1145],"Odontalgia",[1147,1148],"fentanyl","S-ketamine",{"trials":1150,"activeCount":101},[],{"intervention":1152,"totalTrials":1063,"cells":1153},"Cholecalciferol",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1169,"PHASE4":1182,"NA":1193},{"trials":1155,"activeCount":101},[],{"trials":1157,"activeCount":101},[],{"trials":1159,"activeCount":101},[1160],{"nctId":1161,"briefTitle":1162,"status":438,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":36,"conditions":1166,"interventions":1168},"NCT00812578","Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes",[90],"2010-06","2008-12",[21,1167],"Vitamin D Insufficiency",[1152],{"trials":1170,"activeCount":101},[1171],{"nctId":1172,"briefTitle":1173,"status":438,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1181},"NCT00674154","Effect of Vitamin D Treatment in Primary Hyperparathyroidism",[90,91],"2013-08","2008-05",46,[1179,292,1180],"Vitamin D Deficiency","Hypercalcemia",[1152],{"trials":1183,"activeCount":101},[1184],{"nctId":1185,"briefTitle":1186,"status":438,"phases":1187,"primaryCompletion":1188,"completion":1189,"start":1119,"enrollment":1190,"conditions":1191,"interventions":1192},"NCT01037140","Effects of Vitamin D Supplementation in Obesity",[92],"2011-12","2012-07",55,[1179,15],[1152],{"trials":1194,"activeCount":101},[],{"intervention":1196,"totalTrials":97,"cells":1197},"sildenafil",{"EARLY_PHASE1":1198,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1229},{"trials":1199,"activeCount":101},[1200],{"nctId":1201,"briefTitle":1202,"status":438,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":28,"conditions":1207,"interventions":1209},"NCT04283240","Sildenafil in Acute Pulmonary Embolism",[88],"2017-09-10","2018-09-10","2015-03-01",[1208],"Pulmonary Embolism",[1210],"Sildenafil",{"trials":1212,"activeCount":101},[],{"trials":1214,"activeCount":101},[],{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":101},[1219],{"nctId":1220,"briefTitle":1221,"status":499,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":101,"conditions":1225,"interventions":1228},"NCT00730067","Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension",[92],"2012-12","2012-06",[1226,1227],"COPD","Pulmonary Hypertension",[1196],{"trials":1230,"activeCount":101},[],{"intervention":514,"totalTrials":97,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1256},{"trials":1234,"activeCount":101},[],{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"trials":1242,"activeCount":101},[1243,1252],{"nctId":1244,"briefTitle":1245,"status":438,"phases":1246,"primaryCompletion":509,"completion":510,"start":1247,"enrollment":399,"conditions":1248,"interventions":1250},"NCT01344395","Use of Local Infiltration Analgesia Following Total Hip Arthroplasty",[92],"2010-03",[1249,1122],"Pain, Postoperative",[1251,514],"ropivacaine and ketorolac",{"nctId":506,"briefTitle":507,"status":438,"phases":1253,"primaryCompletion":509,"completion":510,"start":511,"enrollment":374,"conditions":1254,"interventions":1255},[92],[469],[514,426],{"trials":1257,"activeCount":101},[],{"intervention":1259,"totalTrials":97,"cells":1260},"Insulin Aspart",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1275,"PHASE4":1277,"NA":1289},{"trials":1262,"activeCount":101},[],{"trials":1264,"activeCount":101},[],{"trials":1266,"activeCount":101},[1267],{"nctId":1268,"briefTitle":1269,"status":438,"phases":1270,"completion":1271,"start":1272,"enrollment":467,"conditions":1273,"interventions":1274},"NCT00353990","Bioavailability of Insulin Administered in Duodenum",[89,90],"2006-12","2006-08",[870],[1259],{"trials":1276,"activeCount":101},[],{"trials":1278,"activeCount":101},[1279],{"nctId":1280,"briefTitle":1281,"status":438,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":467,"conditions":1285,"interventions":1287},"NCT00497536","Pharmacokinetics of IAsp Following CSII in Patients With T1DM",[92],"2008-07","2007-07",[1286],"Type 1 Diabetes Mellitus",[1259,1288,1259],"Insulin Aspart (IAsp).",{"trials":1290,"activeCount":101},[],{"intervention":1292,"totalTrials":97,"cells":1293},"Bupivacaine-epinephrine",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1325},{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":101},[],{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":101},[],{"trials":1303,"activeCount":101},[1304,1313],{"nctId":1305,"briefTitle":1306,"status":438,"phases":1307,"primaryCompletion":1308,"completion":1308,"start":1309,"enrollment":727,"conditions":1310,"interventions":1312},"NCT02697955","The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery",[92],"2017-02-28","2016-06-21",[1311,1096],"Arthrosis",[1292],{"nctId":1314,"briefTitle":1315,"status":438,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1323},"NCT03064165","Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade",[92],"2018-06-08","2017-08-15",62,[1321,1322],"Obturator Nerve Block","Total Hip Replacement",[1292,1324],"Sodium Chloride 9mg\u002FmL",{"trials":1326,"activeCount":101},[],{"intervention":483,"totalTrials":97,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1347},{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":101},[],{"trials":1336,"activeCount":101},[],{"trials":1338,"activeCount":101},[1339,1343],{"nctId":474,"briefTitle":475,"status":476,"phases":1340,"primaryCompletion":478,"completion":478,"start":479,"enrollment":218,"conditions":1341,"interventions":1342},[92],[481],[483,426],{"nctId":497,"briefTitle":498,"status":499,"phases":1344,"primaryCompletion":501,"completion":502,"start":490,"enrollment":101,"conditions":1345,"interventions":1346},[92],[481],[483,426],{"trials":1348,"activeCount":101},[],{"intervention":1350,"totalTrials":120,"cells":1351},"Methylphenidate",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1372},{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[1362],{"nctId":1363,"briefTitle":1364,"status":487,"phases":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT00396058","The Effect of Methylphenidate on Motor Learning in Stroke Patients",[92],"2008-03","2006-11",13,[1370],"Cerebrovascular Accident",[1350],{"trials":1373,"activeCount":101},[],{"intervention":1251,"totalTrials":120,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1390},{"trials":1377,"activeCount":101},[],{"trials":1379,"activeCount":101},[],{"trials":1381,"activeCount":101},[],{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[1386],{"nctId":1244,"briefTitle":1245,"status":438,"phases":1387,"primaryCompletion":509,"completion":510,"start":1247,"enrollment":399,"conditions":1388,"interventions":1389},[92],[1249,1122],[1251,514],{"trials":1391,"activeCount":101},[],{"intervention":1393,"totalTrials":120,"cells":1394},"Pyridostigmine",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1403,"NA":1416},{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"trials":1402,"activeCount":101},[],{"trials":1404,"activeCount":101},[1405],{"nctId":1406,"briefTitle":1407,"status":476,"phases":1408,"primaryCompletion":1409,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1415},"NCT03510546","Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis",[92],"2020-08-31","2021-08-31","2018-04-09",44,[1414],"Myasthenia Gravis",[1393],{"trials":1417,"activeCount":101},[],{"intervention":1085,"totalTrials":120,"cells":1419},{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1434},{"trials":1421,"activeCount":101},[],{"trials":1423,"activeCount":101},[],{"trials":1425,"activeCount":101},[],{"trials":1427,"activeCount":101},[],{"trials":1429,"activeCount":101},[1430],{"nctId":1076,"briefTitle":1077,"status":438,"phases":1431,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1034,"conditions":1432,"interventions":1433},[92],[1083],[1085,495],{"trials":1435,"activeCount":101},[],{"intervention":1437,"totalTrials":120,"cells":1438},"Remifentanil, propofol and citanest",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1460},{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":101},[],{"trials":1444,"activeCount":101},[],{"trials":1446,"activeCount":101},[],{"trials":1448,"activeCount":101},[1449],{"nctId":1450,"briefTitle":1451,"status":438,"phases":1452,"primaryCompletion":1453,"completion":1175,"start":1092,"enrollment":1454,"conditions":1455,"interventions":1459},"NCT01412632","Comparing Two Types of Sedation to Gynaecological Patients",[92],"2013-07",153,[1456,1457,1458],"Transcervical Resection of Endometrium","Transcervical Resection of Fibroids","Transcervical Resection of Polyp",[1437],{"trials":1461,"activeCount":101},[],{"intervention":1463,"totalTrials":120,"cells":1464},"Efavirenz or Nevirapine",{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1473,"NA":1486},{"trials":1466,"activeCount":101},[],{"trials":1468,"activeCount":101},[],{"trials":1470,"activeCount":101},[],{"trials":1472,"activeCount":101},[],{"trials":1474,"activeCount":101},[1475],{"nctId":1476,"briefTitle":1477,"status":438,"phases":1478,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":1481,"conditions":1482,"interventions":1484},"NCT01192035","PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial",[92],"2014-09","2011-05",400,[1483],"HIV-1",[1463,1485],"Ritonavir-boosted lopinavir",{"trials":1487,"activeCount":101},[],{"intervention":1485,"totalTrials":120,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1494,"PHASE3":1496,"PHASE4":1498,"NA":1504},{"trials":1491,"activeCount":101},[],{"trials":1493,"activeCount":101},[],{"trials":1495,"activeCount":101},[],{"trials":1497,"activeCount":101},[],{"trials":1499,"activeCount":101},[1500],{"nctId":1476,"briefTitle":1477,"status":438,"phases":1501,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":1481,"conditions":1502,"interventions":1503},[92],[1483],[1463,1485],{"trials":1505,"activeCount":101},[],{"intervention":1148,"totalTrials":120,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1522},{"trials":1509,"activeCount":101},[],{"trials":1511,"activeCount":101},[],{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[],{"trials":1517,"activeCount":101},[1518],{"nctId":1139,"briefTitle":1140,"status":438,"phases":1519,"completion":1142,"start":1143,"enrollment":28,"conditions":1520,"interventions":1521},[92],[1145],[1147,1148],{"trials":1523,"activeCount":101},[],{"intervention":1525,"totalTrials":120,"cells":1526},"HP-HMG",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1535,"NA":1548},{"trials":1528,"activeCount":101},[],{"trials":1530,"activeCount":101},[],{"trials":1532,"activeCount":101},[],{"trials":1534,"activeCount":101},[],{"trials":1536,"activeCount":101},[1537],{"nctId":1538,"briefTitle":1539,"status":487,"phases":1540,"primaryCompletion":1189,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1546},"NCT01345812","Time-lapse Evaluation of Embryo Development After Stimulation With One of Two Different Gonadotrophins.",[92],"2012-08","2011-04",291,[1545],"Patients for In Vitro Fertilization(IVF)Treatment",[1525,1547],"recombinant FSH",{"trials":1549,"activeCount":101},[],{"intervention":1547,"totalTrials":120,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1558,"PHASE4":1560,"NA":1566},{"trials":1553,"activeCount":101},[],{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"trials":1561,"activeCount":101},[1562],{"nctId":1538,"briefTitle":1539,"status":487,"phases":1563,"primaryCompletion":1189,"completion":1541,"start":1542,"enrollment":1543,"conditions":1564,"interventions":1565},[92],[1545],[1525,1547],{"trials":1567,"activeCount":101},[],{"intervention":1288,"totalTrials":120,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1584},{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[],{"trials":1579,"activeCount":101},[1580],{"nctId":1280,"briefTitle":1281,"status":438,"phases":1581,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":467,"conditions":1582,"interventions":1583},[92],[1286],[1259,1288,1259],{"trials":1585,"activeCount":101},[],{"intervention":1587,"totalTrials":120,"cells":1588},"Pregabalin",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1610},{"trials":1590,"activeCount":101},[],{"trials":1592,"activeCount":101},[],{"trials":1594,"activeCount":101},[],{"trials":1596,"activeCount":101},[],{"trials":1598,"activeCount":101},[1599],{"nctId":1600,"briefTitle":1601,"status":438,"phases":1602,"primaryCompletion":501,"completion":501,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1608},"NCT01496690","Pregablin for Anxiety-comorbidity in Patients With Schizophrenia",[92],"2012-01",54,[1606,1607],"Schizophrenia","Anxiety-comorbidity to Schizophrenia",[1587,1609],"Pregabalin Placebo",{"trials":1611,"activeCount":101},[],{"intervention":1609,"totalTrials":120,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1620,"PHASE4":1622,"NA":1628},{"trials":1615,"activeCount":101},[],{"trials":1617,"activeCount":101},[],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":101},[],{"trials":1623,"activeCount":101},[1624],{"nctId":1600,"briefTitle":1601,"status":438,"phases":1625,"primaryCompletion":501,"completion":501,"start":1603,"enrollment":1604,"conditions":1626,"interventions":1627},[92],[1606,1607],[1587,1609],{"trials":1629,"activeCount":101},[],{"intervention":1631,"totalTrials":120,"cells":1632},"Glucose-infusion",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1639,"PHASE4":1641,"NA":1653},{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":101},[],{"trials":1640,"activeCount":101},[],{"trials":1642,"activeCount":101},[1643],{"nctId":1644,"briefTitle":1645,"status":438,"phases":1646,"primaryCompletion":1647,"completion":1647,"start":1648,"enrollment":467,"conditions":1649,"interventions":1651},"NCT01209403","Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients",[92],"2011-07","2010-09",[1650],"Kidney Failure, Chronic",[1631,1652],"Glucose-insulin",{"trials":1654,"activeCount":101},[],{"intervention":1652,"totalTrials":120,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1671},{"trials":1658,"activeCount":101},[],{"trials":1660,"activeCount":101},[],{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":101},[],{"trials":1666,"activeCount":101},[1667],{"nctId":1644,"briefTitle":1645,"status":438,"phases":1668,"primaryCompletion":1647,"completion":1647,"start":1648,"enrollment":467,"conditions":1669,"interventions":1670},[92],[1650],[1631,1652],{"trials":1672,"activeCount":101},[],{"intervention":1674,"totalTrials":120,"cells":1675},"Indomethacin",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1696},{"trials":1677,"activeCount":101},[],{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[],{"trials":1683,"activeCount":101},[],{"trials":1685,"activeCount":101},[1686],{"nctId":1687,"briefTitle":1688,"status":438,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},"NCT00226122","The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal",[92],"2009-12","2003-01",56,[1694],"Enuresis",[1674],{"trials":1697,"activeCount":101},[],{"intervention":1699,"totalTrials":120,"cells":1700},"INCS",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1722},{"trials":1702,"activeCount":101},[],{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":101},[],{"trials":1708,"activeCount":101},[],{"trials":1710,"activeCount":101},[1711],{"nctId":1712,"briefTitle":1713,"status":438,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1721},"NCT01657097","Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge",[92],"1997-04","1997-02",24,[1719,1720],"Allergic Rhinitis","Asthma",[1699],{"trials":1723,"activeCount":101},[],{"intervention":1725,"totalTrials":120,"cells":1726},"Dobutamine",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1744},{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[],{"trials":1734,"activeCount":101},[],{"trials":1736,"activeCount":101},[1737],{"nctId":1738,"briefTitle":1739,"status":1740,"phases":1741,"primaryCompletion":1175,"start":509,"enrollment":427,"conditions":1742,"interventions":1743},"NCT01375335","The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement","SUSPENDED",[92],[27],[1725],{"trials":1745,"activeCount":101},[],{"intervention":1747,"totalTrials":120,"cells":1748},"levosimendan",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1768},{"trials":1750,"activeCount":101},[],{"trials":1752,"activeCount":101},[],{"trials":1754,"activeCount":101},[],{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[1759],{"nctId":1760,"briefTitle":1761,"status":487,"phases":1762,"primaryCompletion":1763,"completion":1763,"start":1648,"enrollment":28,"conditions":1764,"interventions":1767},"NCT01188369","Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy",[92],"2013-03",[1765,1766],"Diastolic Dysfunction","Left Ventricular Hypertrophy",[1747],{"trials":1769,"activeCount":101},[],{"intervention":1771,"totalTrials":120,"cells":1772},"ferricarboxymaltose",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1793},{"trials":1774,"activeCount":101},[],{"trials":1776,"activeCount":101},[],{"trials":1778,"activeCount":101},[],{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":101},[1783],{"nctId":1784,"briefTitle":1785,"status":438,"phases":1786,"primaryCompletion":465,"completion":1090,"start":1787,"enrollment":1093,"conditions":1788,"interventions":1791},"NCT00978575","Iron Substitution After Upper Gastro-Intestinal Bleeding",[92],"2010-04",[1789,1790],"Gastrointestinal Hemorrhage","Anemia",[1771,1792],"Ferrosulfate",{"trials":1794,"activeCount":101},[],{"intervention":1792,"totalTrials":120,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1811},{"trials":1798,"activeCount":101},[],{"trials":1800,"activeCount":101},[],{"trials":1802,"activeCount":101},[],{"trials":1804,"activeCount":101},[],{"trials":1806,"activeCount":101},[1807],{"nctId":1784,"briefTitle":1785,"status":438,"phases":1808,"primaryCompletion":465,"completion":1090,"start":1787,"enrollment":1093,"conditions":1809,"interventions":1810},[92],[1789,1790],[1771,1792],{"trials":1812,"activeCount":101},[],{"intervention":1814,"totalTrials":120,"cells":1815},"spironolactone",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1836},{"trials":1817,"activeCount":101},[],{"trials":1819,"activeCount":101},[],{"trials":1821,"activeCount":101},[],{"trials":1823,"activeCount":101},[],{"trials":1825,"activeCount":101},[1826],{"nctId":1827,"briefTitle":1828,"status":1740,"phases":1829,"primaryCompletion":1830,"completion":1188,"start":1831,"enrollment":1034,"conditions":1832,"interventions":1835},"NCT00226109","Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics",[92],"2011-08","2004-04",[1833,1834],"Cardiomyopathy, Alcoholic","Alcoholism",[1814],{"trials":1837,"activeCount":101},[],{"intervention":1839,"totalTrials":120,"cells":1840},"low dose ketamine",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1849,"NA":1862},{"trials":1842,"activeCount":101},[],{"trials":1844,"activeCount":101},[],{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[1851],{"nctId":1852,"briefTitle":1853,"status":487,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1861},"NCT05422001","Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED",[92],"2023-08-15","2022-05-31",116,[1859,1860],"Acute Pain","Opioid Use",[1839],{"trials":1863,"activeCount":101},[],{"intervention":1865,"totalTrials":120,"cells":1866},"Statin",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1885},{"trials":1868,"activeCount":101},[],{"trials":1870,"activeCount":101},[],{"trials":1872,"activeCount":101},[],{"trials":1874,"activeCount":101},[],{"trials":1876,"activeCount":101},[1877],{"nctId":1878,"briefTitle":1879,"status":438,"phases":1880,"completion":1881,"start":1882,"enrollment":727,"conditions":1883,"interventions":1884},"NCT00471549","Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes",[92],"1993-12","1991-06",[21],[1865],{"trials":1886,"activeCount":101},[],{"intervention":1888,"totalTrials":120,"cells":1889},"Beta-blocker, ACE-inhibitor",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1898,"NA":1913},{"trials":1891,"activeCount":101},[],{"trials":1893,"activeCount":101},[],{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":101},[1900],{"nctId":1901,"briefTitle":1902,"status":438,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1911},"NCT01380717","Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)",[92],"2014-02","2011-02",83,[1908,1909,1910],"Chronic Kidney Insufficiency","Hypertension","Vasodilation",[1888,1912],"Calcium Channel Blockers, ACE-Inhibitor",{"trials":1914,"activeCount":101},[],{"intervention":1912,"totalTrials":120,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1923,"PHASE4":1925,"NA":1931},{"trials":1918,"activeCount":101},[],{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[],{"trials":1926,"activeCount":101},[1927],{"nctId":1901,"briefTitle":1902,"status":438,"phases":1928,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1929,"interventions":1930},[92],[1908,1909,1910],[1888,1912],{"trials":1932,"activeCount":101},[],{"intervention":1934,"totalTrials":120,"cells":1935},"Amiodarone",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1956},{"trials":1937,"activeCount":101},[],{"trials":1939,"activeCount":101},[],{"trials":1941,"activeCount":101},[],{"trials":1943,"activeCount":101},[],{"trials":1945,"activeCount":101},[1946],{"nctId":1947,"briefTitle":1948,"status":438,"phases":1949,"completion":1950,"start":1951,"enrollment":1952,"conditions":1953,"interventions":1955},"NCT00287209","Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)",[92],"2005-08","2004-01",250,[1060,1954],"Coronary Artery Bypass Grafting",[1934],{"trials":1957,"activeCount":101},[],{"intervention":1959,"totalTrials":120,"cells":1960},"Gardasil",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1981},{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[],{"trials":1966,"activeCount":101},[],{"trials":1968,"activeCount":101},[],{"trials":1970,"activeCount":101},[1971],{"nctId":1972,"briefTitle":1973,"status":438,"phases":1974,"primaryCompletion":1223,"completion":1175,"start":1830,"enrollment":1975,"conditions":1976,"interventions":1979},"NCT01386164","Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults",[92],92,[1977,1978],"HIV","Human Papillomavirus",[1959,1980],"Cervarix",{"trials":1982,"activeCount":101},[],{"intervention":1980,"totalTrials":120,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1999},{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[],{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[],{"trials":1994,"activeCount":101},[1995],{"nctId":1972,"briefTitle":1973,"status":438,"phases":1996,"primaryCompletion":1223,"completion":1175,"start":1830,"enrollment":1975,"conditions":1997,"interventions":1998},[92],[1977,1978],[1959,1980],{"trials":2000,"activeCount":101},[],{"intervention":2002,"totalTrials":120,"cells":2003},"Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2010,"PHASE4":2012,"NA":2023},{"trials":2005,"activeCount":101},[],{"trials":2007,"activeCount":101},[],{"trials":2009,"activeCount":101},[],{"trials":2011,"activeCount":101},[],{"trials":2013,"activeCount":101},[2014],{"nctId":2015,"briefTitle":2016,"status":487,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2022},"NCT03439787","Popliteal Plexus Block for Total Knee Arthroplasty",[92],"2018-08-23","2018-05-15",15,[1249],[2002],{"trials":2024,"activeCount":101},[],{"intervention":472,"totalTrials":120,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2041},{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":101},[],{"trials":2036,"activeCount":101},[2037],{"nctId":462,"briefTitle":463,"status":438,"phases":2038,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":2039,"interventions":2040},[92],[469,470],[472,426],{"trials":2042,"activeCount":101},[],{"intervention":2044,"totalTrials":120,"cells":2045},"Ticagrelor",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2069},{"trials":2047,"activeCount":101},[],{"trials":2049,"activeCount":101},[],{"trials":2051,"activeCount":101},[],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":101},[2056],{"nctId":2057,"briefTitle":2058,"status":476,"phases":2059,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":399,"conditions":2063,"interventions":2067},"NCT03182855","Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI",[92],"2019-06-01","2019-08-01","2018-09-01",[2064,2065,2066],"Acute Coronary Syndrome","Myocardial Infarction","STEMI - ST Elevation Myocardial Infarction",[2044,2068],"Cangrelor Tetrasodium",{"trials":2070,"activeCount":101},[],{"intervention":2068,"totalTrials":120,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2087},{"trials":2074,"activeCount":101},[],{"trials":2076,"activeCount":101},[],{"trials":2078,"activeCount":101},[],{"trials":2080,"activeCount":101},[],{"trials":2082,"activeCount":101},[2083],{"nctId":2057,"briefTitle":2058,"status":476,"phases":2084,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":399,"conditions":2085,"interventions":2086},[92],[2064,2065,2066],[2044,2068],{"trials":2088,"activeCount":101},[],{"intervention":2090,"totalTrials":120,"cells":2091},"Latanoprost",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2111},{"trials":2093,"activeCount":101},[],{"trials":2095,"activeCount":101},[],{"trials":2097,"activeCount":101},[],{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[2102],{"nctId":2103,"briefTitle":2104,"status":438,"phases":2105,"primaryCompletion":2106,"completion":2106,"start":2107,"enrollment":16,"conditions":2108,"interventions":2110},"NCT01225653","Topical Application of Latanoprost in Diabetic Retinopathy",[92],"2014-12","2010-11",[2109],"Diabetic Retinopathy",[2090],{"trials":2112,"activeCount":101},[],{"intervention":2114,"totalTrials":120,"cells":2115},"Innohep",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2136},{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[],{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[2126],{"nctId":2127,"briefTitle":2128,"status":438,"phases":2129,"primaryCompletion":2130,"completion":2130,"start":1647,"enrollment":2131,"conditions":2132,"interventions":2134},"NCT01390051","Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?",[92],"2016-07",50,[2133],"Fetal Growth Retardation",[2114,2135],"tinzaparin",{"trials":2137,"activeCount":101},[],{"intervention":2135,"totalTrials":120,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2154},{"trials":2141,"activeCount":101},[],{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":101},[],{"trials":2149,"activeCount":101},[2150],{"nctId":2127,"briefTitle":2128,"status":438,"phases":2151,"primaryCompletion":2130,"completion":2130,"start":1647,"enrollment":2131,"conditions":2152,"interventions":2153},[92],[2133],[2114,2135],{"trials":2155,"activeCount":101},[],{"intervention":2157,"totalTrials":120,"cells":2158},"Epidural Ropivacaine, morphine",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2180},{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":101},[],{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[2169],{"nctId":2170,"briefTitle":2171,"status":438,"phases":2172,"primaryCompletion":2173,"completion":2174,"start":2175,"enrollment":399,"conditions":2176,"interventions":2178},"NCT00289419","Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study",[92],"2006-02","2006-03","2005-02",[2177],"Arthroplasty, Replacement, Hip",[2157,2179],"Ropivacaine, Ketorolac and Adrenaline",{"trials":2181,"activeCount":101},[],{"intervention":2179,"totalTrials":120,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2198},{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[2194],{"nctId":2170,"briefTitle":2171,"status":438,"phases":2195,"primaryCompletion":2173,"completion":2174,"start":2175,"enrollment":399,"conditions":2196,"interventions":2197},[92],[2177],[2157,2179],{"trials":2199,"activeCount":101},[],{"intervention":584,"totalTrials":120,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2216},{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[],{"trials":2211,"activeCount":101},[2212],{"nctId":576,"briefTitle":577,"status":438,"phases":2213,"primaryCompletion":579,"completion":579,"start":489,"enrollment":580,"conditions":2214,"interventions":2215},[92],[582],[584,551],{"trials":2217,"activeCount":101},[],{"intervention":2219,"totalTrials":120,"cells":2220},"Lidocaine-adrenaline added gadolinium.",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2239},{"trials":2222,"activeCount":101},[],{"trials":2224,"activeCount":101},[],{"trials":2226,"activeCount":101},[],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[2231],{"nctId":2232,"briefTitle":2233,"status":438,"phases":2234,"primaryCompletion":490,"completion":490,"start":2235,"enrollment":28,"conditions":2236,"interventions":2238},"NCT02255591","Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus",[92],"2015-02",[481,2237,1249],"Anesthesia Local",[2219],{"trials":2240,"activeCount":101},[],{"intervention":2242,"totalTrials":120,"cells":2243},"Mirtazapine",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2265},{"trials":2245,"activeCount":101},[],{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":101},[2254],{"nctId":2255,"briefTitle":2256,"status":438,"phases":2257,"completion":2258,"start":2173,"enrollment":1717,"conditions":2259,"interventions":2264},"NCT00288782","PET Neuroimaging of [11C]Mirtazapine",[92],"2007-04",[2260,2261,2262,2263],"Mental Disorders","Mood Disorders","Affective Disorders","Depressive Disorders",[2242],{"trials":2266,"activeCount":101},[],{"intervention":2268,"totalTrials":120,"cells":2269},"cyclosporine",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2289},{"trials":2271,"activeCount":101},[],{"trials":2273,"activeCount":101},[],{"trials":2275,"activeCount":101},[],{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[2280],{"nctId":2281,"briefTitle":2282,"status":438,"phases":2283,"primaryCompletion":1164,"completion":1092,"start":1366,"enrollment":727,"conditions":2284,"interventions":2287},"NCT00766909","Diabetogenicity of Cyclosporine and Tacrolimus",[92],[2285,2286],"Complications of Transplanted Organs and Tissue","Diabetes Mellitus Nos New Onset",[2268,2288],"tacrolimus",{"trials":2290,"activeCount":101},[],{"intervention":2288,"totalTrials":120,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2301,"NA":2307},{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":101},[2303],{"nctId":2281,"briefTitle":2282,"status":438,"phases":2304,"primaryCompletion":1164,"completion":1092,"start":1366,"enrollment":727,"conditions":2305,"interventions":2306},[92],[2285,2286],[2268,2288],{"trials":2308,"activeCount":101},[],{"intervention":2310,"totalTrials":120,"cells":2311},"PRF is added in the test group.",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2332},{"trials":2313,"activeCount":101},[],{"trials":2315,"activeCount":101},[],{"trials":2317,"activeCount":101},[],{"trials":2319,"activeCount":101},[],{"trials":2321,"activeCount":101},[2322],{"nctId":2323,"briefTitle":2324,"status":438,"phases":2325,"primaryCompletion":2326,"completion":2327,"start":2328,"enrollment":16,"conditions":2329,"interventions":2331},"NCT04350749","The Use of Platelet-rich Fibrin (PRF) Membranes in Lateral Alveolar Ridge Augmentation When Jaw Bone is Missing Before Dental Implant Installation. A Study Comparing an Autogenous Bone Block Graft Covered Either by a (PRF) Membrane (Test) or Bone Substitute and a Barrier Membrane (Control)",[92],"2017-06","2019-05","2015-01-15",[2330],"Tooth-loss",[2310],{"trials":2333,"activeCount":101},[],{"intervention":2335,"totalTrials":120,"cells":2336},"Desmopressin",{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2357},{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":101},[],{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[2347],{"nctId":2348,"briefTitle":2349,"status":438,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":2353,"conditions":2354,"interventions":2356},"NCT03389412","The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.",[92],"2023-01-03","2017-10-01",324,[2355],"Enuresis, Nocturnal",[2335],{"trials":2358,"activeCount":101},[],{"intervention":2360,"totalTrials":120,"cells":2361},"Clonidine",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2368,"PHASE4":2370,"NA":2385},{"trials":2363,"activeCount":101},[],{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[],{"trials":2371,"activeCount":101},[2372],{"nctId":2373,"briefTitle":2374,"status":438,"phases":2375,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":2378,"conditions":2379,"interventions":2383},"NCT05560230","Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis",[92],"2024-08-13","2022-10-03",120,[2380,469,2381,2382],"Endometriosis","Pain, Acute","Pain, Acute Postoperative",[2360,2384],"Isotonic saline",{"trials":2386,"activeCount":101},[],{"intervention":2384,"totalTrials":120,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2395,"PHASE4":2397,"NA":2403},{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"trials":2396,"activeCount":101},[],{"trials":2398,"activeCount":101},[2399],{"nctId":2373,"briefTitle":2374,"status":438,"phases":2400,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":2378,"conditions":2401,"interventions":2402},[92],[2380,469,2381,2382],[2360,2384],{"trials":2404,"activeCount":101},[],{"intervention":2406,"totalTrials":120,"cells":2407},"Insulin detemir",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2416,"NA":2429},{"trials":2409,"activeCount":101},[],{"trials":2411,"activeCount":101},[],{"trials":2413,"activeCount":101},[],{"trials":2415,"activeCount":101},[],{"trials":2417,"activeCount":101},[2418],{"nctId":2419,"briefTitle":2420,"status":438,"phases":2421,"completion":2422,"start":2423,"enrollment":427,"conditions":2424,"interventions":2426},"NCT00566124","Basal Insulins - Pharmacodynamics",[92],"2005-05","2005-01",[2425],"Diabetes",[2406,2427,2428],"Insulin glargine","Insulatard",{"trials":2430,"activeCount":101},[],{"intervention":2427,"totalTrials":120,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2447},{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"trials":2440,"activeCount":101},[],{"trials":2442,"activeCount":101},[2443],{"nctId":2419,"briefTitle":2420,"status":438,"phases":2444,"completion":2422,"start":2423,"enrollment":427,"conditions":2445,"interventions":2446},[92],[2425],[2406,2427,2428],{"trials":2448,"activeCount":101},[],{"intervention":2428,"totalTrials":120,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2465},{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"trials":2460,"activeCount":101},[2461],{"nctId":2419,"briefTitle":2420,"status":438,"phases":2462,"completion":2422,"start":2423,"enrollment":427,"conditions":2463,"interventions":2464},[92],[2425],[2406,2427,2428],{"trials":2466,"activeCount":101},[],{"intervention":2468,"totalTrials":120,"cells":2469},"Fragmin 5000 UNT in 0.2 ML Prefilled Syringe",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2478,"NA":2492},{"trials":2471,"activeCount":101},[],{"trials":2473,"activeCount":101},[],{"trials":2475,"activeCount":101},[],{"trials":2477,"activeCount":101},[],{"trials":2479,"activeCount":101},[2480],{"nctId":2481,"briefTitle":2482,"status":476,"phases":2483,"primaryCompletion":441,"completion":2484,"start":2485,"enrollment":2486,"conditions":2487,"interventions":2491},"NCT05067153","Thromboprophylaxis in Oesophageal Cancer Patients",[92],"2024-05-01","2021-05-01",100,[2488,2489,2490],"Esophageal Neoplasms","Thrombosis","Thromboembolism",[2468],{"trials":2493,"activeCount":101},[],{"intervention":2495,"totalTrials":120,"cells":2496},"Yellow Fever Vaccine",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2518},{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"trials":2502,"activeCount":101},[],{"trials":2504,"activeCount":101},[],{"trials":2506,"activeCount":101},[2507],{"nctId":2508,"briefTitle":2509,"status":476,"phases":2510,"primaryCompletion":2511,"completion":2512,"start":2513,"enrollment":374,"conditions":2514,"interventions":2517},"NCT04083430","Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination",[92],"2025-02-15","2025-12-15","2019-10-08",[18,2515,2516],"Cytotoxicity","Yellow Fever Vaccination Reaction",[2495],{"trials":2519,"activeCount":101},[],{"intervention":2521,"totalTrials":120,"cells":2522},"Morphine hydrochloride",{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2529,"PHASE4":2531,"NA":2544},{"trials":2524,"activeCount":101},[],{"trials":2526,"activeCount":101},[],{"trials":2528,"activeCount":101},[],{"trials":2530,"activeCount":101},[],{"trials":2532,"activeCount":101},[2533],{"nctId":2534,"briefTitle":2535,"status":438,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":11,"conditions":2539,"interventions":2543},"NCT02622022","Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease",[92],"2019-02-06","2016-01",[2540,2541,2542],"Interstitial Lung Disease","Dyspnea","Morphine",[2521],{"trials":2545,"activeCount":101},[],{"intervention":2547,"totalTrials":120,"cells":2548},"Thiamine",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2569},{"trials":2550,"activeCount":101},[],{"trials":2552,"activeCount":101},[],{"trials":2554,"activeCount":101},[],{"trials":2556,"activeCount":101},[],{"trials":2558,"activeCount":101},[2559],{"nctId":2560,"briefTitle":2561,"status":438,"phases":2562,"primaryCompletion":2563,"completion":2564,"start":2565,"enrollment":1034,"conditions":2566,"interventions":2568},"NCT03634735","Thiamin Against Robust IBD Fatigue",[92],"2020-04-21","2020-10-27","2018-11-27",[2567],"Fatigue",[2547],{"trials":2570,"activeCount":101},[],{"intervention":2572,"totalTrials":120,"cells":2573},"Botulinum A toxin",{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2594},{"trials":2575,"activeCount":101},[],{"trials":2577,"activeCount":101},[],{"trials":2579,"activeCount":101},[],{"trials":2581,"activeCount":101},[],{"trials":2583,"activeCount":101},[2584],{"nctId":2585,"briefTitle":2586,"status":476,"phases":2587,"primaryCompletion":1366,"completion":2588,"start":2422,"enrollment":2589,"conditions":2590,"interventions":2593},"NCT00175123","Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele",[92],"2008-06",30,[2591,2592],"Myelomeningocele","Bladder, Neurogenic",[2572],{"trials":2595,"activeCount":101},[],{"intervention":2597,"totalTrials":120,"cells":2598},"Sandostatin® LAR",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2605,"PHASE4":2607,"NA":2618},{"trials":2600,"activeCount":101},[],{"trials":2602,"activeCount":101},[],{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[2609],{"nctId":2610,"briefTitle":2611,"status":438,"phases":2612,"primaryCompletion":2613,"completion":2613,"start":1224,"enrollment":2614,"conditions":2615,"interventions":2617},"NCT01618513","Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target",[92],"2017-01",84,[2616],"Acromegaly",[2597],{"trials":2619,"activeCount":101},[],{"intervention":2621,"totalTrials":120,"cells":2622},"Oxytocin",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2643},{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[],{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":101},[2633],{"nctId":2634,"briefTitle":2635,"status":438,"phases":2636,"primaryCompletion":2637,"completion":2637,"start":2638,"enrollment":2639,"conditions":2640,"interventions":2642},"NCT02553226","Continued Versus Discontinued Oxytocin Stimulation of Labour",[92],"2020-07-01","2016-04",1200,[2641],"Adverse Reaction to Oxytocin",[2621],{"trials":2644,"activeCount":101},[],{"intervention":2646,"totalTrials":120,"cells":2647},"Twinrix",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2666},{"trials":2649,"activeCount":101},[],{"trials":2651,"activeCount":101},[],{"trials":2653,"activeCount":101},[],{"trials":2655,"activeCount":101},[],{"trials":2657,"activeCount":101},[2658],{"nctId":2659,"briefTitle":2660,"status":476,"phases":2661,"primaryCompletion":1453,"completion":1453,"start":2662,"enrollment":1481,"conditions":2663,"interventions":2665},"NCT01451801","Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders",[92],"2011-10",[2664],"Hepatitis B",[2646],{"trials":2667,"activeCount":101},[],{"intervention":2669,"totalTrials":120,"cells":2670},"Melatonin 10 MG",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2677,"PHASE4":2679,"NA":2690},{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[2681],{"nctId":2682,"briefTitle":2683,"status":476,"phases":2684,"primaryCompletion":2685,"completion":2686,"start":2485,"enrollment":1034,"conditions":2687,"interventions":2689},"NCT04864509","The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure",[92],"2022-06-01","2024-06-01",[2688],"Osteoporosis, Postmenopausal",[2669],{"trials":2691,"activeCount":101},[],{"intervention":1324,"totalTrials":120,"cells":2693},{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2708},{"trials":2695,"activeCount":101},[],{"trials":2697,"activeCount":101},[],{"trials":2699,"activeCount":101},[],{"trials":2701,"activeCount":101},[],{"trials":2703,"activeCount":101},[2704],{"nctId":1314,"briefTitle":1315,"status":438,"phases":2705,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":2706,"interventions":2707},[92],[1321,1322],[1292,1324],{"trials":2709,"activeCount":101},[],{"intervention":2711,"totalTrials":120,"cells":2712},"Alfacalcidol",{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2721,"NA":2736},{"trials":2714,"activeCount":101},[],{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[],{"trials":2722,"activeCount":101},[2723],{"nctId":2724,"briefTitle":2725,"status":438,"phases":2726,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2734},"NCT03210688","Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy",[92],"2024-02-14","2025-01-21","2018-05-01",71,[2732,2733],"Minimal Change Disease","Nephrotic Syndrome",[2735,2711],"Prednisolone",{"trials":2737,"activeCount":101},[],{"intervention":2739,"totalTrials":120,"cells":2740},"Ropivacaine, Ketorolac, adrenaline",{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2747,"PHASE4":2749,"NA":2761},{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[],{"trials":2748,"activeCount":101},[],{"trials":2750,"activeCount":101},[2751],{"nctId":2752,"briefTitle":2753,"status":487,"phases":2754,"primaryCompletion":1366,"completion":2755,"start":2756,"enrollment":399,"conditions":2757,"interventions":2759},"NCT00421967","Postoperative Analgesia After Total Knee Arthroplasty",[92],"2008-04","2007-01",[2758],"Arthroplasty, Replacement, Knee",[2739,2760],"Ropivacaine Ketorolac",{"trials":2762,"activeCount":101},[],{"intervention":2760,"totalTrials":120,"cells":2764},{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2779},{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[],{"trials":2772,"activeCount":101},[],{"trials":2774,"activeCount":101},[2775],{"nctId":2752,"briefTitle":2753,"status":487,"phases":2776,"primaryCompletion":1366,"completion":2755,"start":2756,"enrollment":399,"conditions":2777,"interventions":2778},[92],[2758],[2739,2760],{"trials":2780,"activeCount":101},[],{"intervention":2782,"totalTrials":120,"cells":2783},"Salbutamol",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2806},{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"trials":2791,"activeCount":101},[],{"trials":2793,"activeCount":101},[2794],{"nctId":2795,"briefTitle":2796,"status":438,"phases":2797,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2804},"NCT02914652","The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.",[92],"2017-07-01","2018-01-01","2016-10-15",96,[2803],"Ventricular Septal Defect",[2782,2805],"Norflouran",{"trials":2807,"activeCount":101},[],{"intervention":2805,"totalTrials":120,"cells":2809},{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2824},{"trials":2811,"activeCount":101},[],{"trials":2813,"activeCount":101},[],{"trials":2815,"activeCount":101},[],{"trials":2817,"activeCount":101},[],{"trials":2819,"activeCount":101},[2820],{"nctId":2795,"briefTitle":2796,"status":438,"phases":2821,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2822,"interventions":2823},[92],[2803],[2782,2805],{"trials":2825,"activeCount":101},[],{"intervention":2827,"totalTrials":97,"cells":2828},"Vitamin D",{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2846,"PHASE4":2856,"NA":2858},{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[2835],{"nctId":2836,"briefTitle":2837,"status":438,"phases":2838,"primaryCompletion":2839,"completion":2839,"start":1079,"enrollment":2840,"conditions":2841,"interventions":2843},"NCT02944799","Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis",[90],"2021-12-20",69,[2842,332],"Rheumatoid Arthritis",[2844,2845,2827],"Alendronate","Calcium",{"trials":2847,"activeCount":101},[2848],{"nctId":2849,"briefTitle":2850,"status":476,"phases":2851,"completion":1120,"start":544,"enrollment":2852,"conditions":2853,"interventions":2855},"NCT00132184","Vitamin D Treatment for Crohn´s Disease",[90,91],110,[2854],"Crohns Disease",[2827],{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"intervention":2861,"totalTrials":120,"cells":2862},"Adalimumab",{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2869,"PHASE4":2880,"NA":2882},{"trials":2864,"activeCount":101},[],{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[2871],{"nctId":2872,"briefTitle":2873,"status":438,"phases":2874,"primaryCompletion":1188,"completion":1188,"start":2875,"enrollment":2876,"conditions":2877,"interventions":2879},"NCT00660647","Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)",[91],"2007-09",180,[2878],"Arthritis, Rheumatoid",[2861],{"trials":2881,"activeCount":101},[],{"trials":2883,"activeCount":101},[],{"intervention":2885,"totalTrials":120,"cells":2886},"Fidaxomicin",{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2905,"NA":2907},{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":101},[],{"trials":2892,"activeCount":101},[],{"trials":2894,"activeCount":101},[2895],{"nctId":2896,"briefTitle":2897,"status":438,"phases":2898,"primaryCompletion":793,"completion":2899,"start":2638,"enrollment":2900,"conditions":2901,"interventions":2903},"NCT02743234","Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection",[91],"2019-08-31",64,[2902],"Clostridium Difficile Infection",[2885,2904],"Vancomycin",{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[],{"intervention":2904,"totalTrials":120,"cells":2910},{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2923,"NA":2925},{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"trials":2916,"activeCount":101},[],{"trials":2918,"activeCount":101},[2919],{"nctId":2896,"briefTitle":2897,"status":438,"phases":2920,"primaryCompletion":793,"completion":2899,"start":2638,"enrollment":2900,"conditions":2921,"interventions":2922},[91],[2902],[2885,2904],{"trials":2924,"activeCount":101},[],{"trials":2926,"activeCount":101},[],{"intervention":2928,"totalTrials":120,"cells":2929},"Imatinib mesylate",{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2936,"PHASE4":2947,"NA":2949},{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[2938],{"nctId":2939,"briefTitle":2940,"status":438,"phases":2941,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":427,"conditions":2944,"interventions":2946},"NCT00981942","Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec",[91],"2010-12","2009-09",[2945],"Nephrogenic Systemic Fibrosis",[2928],{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"intervention":2952,"totalTrials":120,"cells":2953},"Caffeine 6mg\u002Fkg",{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2960,"PHASE4":2970,"NA":2972},{"trials":2955,"activeCount":101},[],{"trials":2957,"activeCount":101},[],{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[2962],{"nctId":2963,"briefTitle":2964,"status":438,"phases":2965,"primaryCompletion":511,"completion":2943,"start":2966,"enrollment":399,"conditions":2967,"interventions":2969},"NCT00388128","Caffeine and Intermittent Claudication",[91],"2006-09",[2968],"Intermittent Claudication",[2952],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"intervention":2975,"totalTrials":120,"cells":2976},"Salbutamol 4Mg",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2981,"PHASE3":2983,"PHASE4":2993,"NA":2995},{"trials":2978,"activeCount":101},[],{"trials":2980,"activeCount":101},[],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":101},[2985],{"nctId":2986,"briefTitle":2987,"status":476,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":2589,"conditions":2991,"interventions":2992},"NCT03914638","Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis",[90,91],"2021-10-31","2019-04-01",[1414],[2975],{"trials":2994,"activeCount":101},[],{"trials":2996,"activeCount":101},[],{"intervention":1124,"totalTrials":120,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3011,"NA":3013},{"trials":3000,"activeCount":101},[],{"trials":3002,"activeCount":101},[],{"trials":3004,"activeCount":101},[],{"trials":3006,"activeCount":101},[3007],{"nctId":1116,"briefTitle":1117,"status":438,"phases":3008,"primaryCompletion":466,"completion":1119,"start":1120,"enrollment":22,"conditions":3009,"interventions":3010},[91],[1122],[1124,1105],{"trials":3012,"activeCount":101},[],{"trials":3014,"activeCount":101},[],{"intervention":3016,"totalTrials":120,"cells":3017},"Irbesartan",{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3034,"NA":3036},{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":101},[3026],{"nctId":3027,"briefTitle":3028,"status":438,"phases":3029,"primaryCompletion":465,"completion":465,"start":3030,"enrollment":3031,"conditions":3032,"interventions":3033},"NCT00791830","Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan",[91],"2009-04",82,[1650],[3016],{"trials":3035,"activeCount":101},[],{"trials":3037,"activeCount":101},[],{"intervention":3039,"totalTrials":120,"cells":3040},"Gemtuzumab ozogamicin",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3056,"NA":3058},{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[3049],{"nctId":3050,"briefTitle":3051,"status":438,"phases":3052,"primaryCompletion":1603,"completion":1603,"start":1951,"enrollment":1952,"conditions":3053,"interventions":3055},"NCT00476541","NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia",[91],[3054],"Acute Myeloid Leukemia",[3039],{"trials":3057,"activeCount":101},[],{"trials":3059,"activeCount":101},[],{"intervention":3061,"totalTrials":120,"cells":3062},"azithromycin",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3069,"PHASE4":3083,"NA":3085},{"trials":3064,"activeCount":101},[],{"trials":3066,"activeCount":101},[],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[3071],{"nctId":3072,"briefTitle":3073,"status":438,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":2486,"conditions":3077,"interventions":3082},"NCT01531218","Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea",[91],"2013-12","2012-03",[3078,3079,3080,3081],"Diarrhea","Fever","Vomiting","Abdominal Pain",[3061],{"trials":3084,"activeCount":101},[],{"trials":3086,"activeCount":101},[],{"intervention":3088,"totalTrials":120,"cells":3089},"Methadone Hydrochloride",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3096,"PHASE4":3108,"NA":3110},{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"trials":3095,"activeCount":101},[],{"trials":3097,"activeCount":101},[3098],{"nctId":3099,"briefTitle":3100,"status":487,"phases":3101,"primaryCompletion":3102,"completion":3103,"start":3104,"enrollment":374,"conditions":3105,"interventions":3107},"NCT04680286","Intraoperative Methadone in Children Undergoing Surgery",[91],"2024-01-30","2024-02-01","2020-11-16",[2381,1249,3106],"Children, Only",[3088],{"trials":3109,"activeCount":101},[],{"trials":3111,"activeCount":101},[],{"intervention":3113,"totalTrials":120,"cells":3114},"Oral contraception",{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3132,"NA":3134},{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[],{"trials":3120,"activeCount":101},[],{"trials":3122,"activeCount":101},[3123],{"nctId":3124,"briefTitle":3125,"status":487,"phases":3126,"completion":2422,"start":3127,"enrollment":427,"conditions":3128,"interventions":3130},"NCT00266149","Lamotrigine and Oral Contraceptives",[91],"2003-06",[3129],"Epilepsy",[3113,3131],"Lamotrigine",{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[],{"intervention":3131,"totalTrials":120,"cells":3137},{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3144,"PHASE4":3150,"NA":3152},{"trials":3139,"activeCount":101},[],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[],{"trials":3145,"activeCount":101},[3146],{"nctId":3124,"briefTitle":3125,"status":487,"phases":3147,"completion":2422,"start":3127,"enrollment":427,"conditions":3148,"interventions":3149},[91],[3129],[3113,3131],{"trials":3151,"activeCount":101},[],{"trials":3153,"activeCount":101},[],{"intervention":3155,"totalTrials":120,"cells":3156},"Gabapentin",{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3173,"NA":3175},{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[],{"trials":3164,"activeCount":101},[3165],{"nctId":3166,"briefTitle":3167,"status":438,"phases":3168,"primaryCompletion":3169,"completion":3169,"start":1480,"enrollment":3170,"conditions":3171,"interventions":3172},"NCT01116583","The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy",[91],"2013-11",104,[1249],[3155],{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[],{"intervention":3178,"totalTrials":120,"cells":3179},"NPH",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3184,"PHASE3":3186,"PHASE4":3200,"NA":3202},{"trials":3181,"activeCount":101},[],{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[],{"trials":3187,"activeCount":101},[3188],{"nctId":3189,"briefTitle":3190,"status":438,"phases":3191,"primaryCompletion":3192,"completion":3192,"start":3193,"enrollment":3194,"conditions":3195,"interventions":3197},"NCT01461616","Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis",[91],"2012-11","2012-02",19,[3196],"Diabetes Mellitus, Type 1",[3178,3198,3199],"Detemir","Glargine",{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"intervention":3198,"totalTrials":120,"cells":3205},{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3212,"PHASE4":3218,"NA":3220},{"trials":3207,"activeCount":101},[],{"trials":3209,"activeCount":101},[],{"trials":3211,"activeCount":101},[],{"trials":3213,"activeCount":101},[3214],{"nctId":3189,"briefTitle":3190,"status":438,"phases":3215,"primaryCompletion":3192,"completion":3192,"start":3193,"enrollment":3194,"conditions":3216,"interventions":3217},[91],[3196],[3178,3198,3199],{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[],{"intervention":3199,"totalTrials":120,"cells":3223},{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3230,"PHASE4":3236,"NA":3238},{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"trials":3231,"activeCount":101},[3232],{"nctId":3189,"briefTitle":3190,"status":438,"phases":3233,"primaryCompletion":3192,"completion":3192,"start":3193,"enrollment":3194,"conditions":3234,"interventions":3235},[91],[3196],[3178,3198,3199],{"trials":3237,"activeCount":101},[],{"trials":3239,"activeCount":101},[],{"intervention":3241,"totalTrials":120,"cells":3242},"DEB",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3247,"PHASE3":3249,"PHASE4":3260,"NA":3262},{"trials":3244,"activeCount":101},[],{"trials":3246,"activeCount":101},[],{"trials":3248,"activeCount":101},[],{"trials":3250,"activeCount":101},[3251],{"nctId":3252,"briefTitle":3253,"status":476,"phases":3254,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":2876,"conditions":3257,"interventions":3259},"NCT03338647","SBRT or TACE for Advanced HCC",[91],"2023-12-31","2017-10-26",[3258],"Hepatocellular Carcinoma",[3241],{"trials":3261,"activeCount":101},[],{"trials":3263,"activeCount":101},[],{"intervention":3265,"totalTrials":120,"cells":3266},"Byetta, Exenatide",{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3273,"PHASE4":3283,"NA":3285},{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[],{"trials":3274,"activeCount":101},[3275],{"nctId":3276,"briefTitle":3277,"status":438,"phases":3278,"primaryCompletion":2107,"completion":3279,"start":3280,"enrollment":545,"conditions":3281,"interventions":3282},"NCT00747968","The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET",[90,91],"2011-03","2010-02",[21],[3265],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[],{"intervention":3288,"totalTrials":120,"cells":3289},"Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3296,"PHASE4":3305,"NA":3307},{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"trials":3297,"activeCount":101},[3298],{"nctId":3299,"briefTitle":3300,"status":438,"phases":3301,"primaryCompletion":1164,"completion":1164,"start":3302,"enrollment":1717,"conditions":3303,"interventions":3304},"NCT00888732","A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin",[91],"2009-06",[3196],[3288],{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[],{"intervention":3310,"totalTrials":120,"cells":3311},"Darbepoetin Alfa",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3329,"NA":3331},{"trials":3313,"activeCount":101},[],{"trials":3315,"activeCount":101},[],{"trials":3317,"activeCount":101},[],{"trials":3319,"activeCount":101},[3320],{"nctId":3321,"briefTitle":3322,"status":487,"phases":3323,"primaryCompletion":3324,"completion":3324,"start":3325,"enrollment":290,"conditions":3326,"interventions":3328},"NCT00381836","Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer",[90,91],"2007-02","2006-10",[3327,1790],"Prostatic Neoplasms",[3310],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[],{"intervention":3334,"totalTrials":120,"cells":3335},"lithium or lamotrigine",{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3352,"NA":3354},{"trials":3337,"activeCount":101},[],{"trials":3339,"activeCount":101},[],{"trials":3341,"activeCount":101},[],{"trials":3343,"activeCount":101},[3344],{"nctId":3345,"briefTitle":3346,"status":438,"phases":3347,"completion":1271,"start":3348,"enrollment":783,"conditions":3349,"interventions":3351},"NCT00226135","Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder",[91],"2001-03",[3350],"Bipolar Disorder",[3334],{"trials":3353,"activeCount":101},[],{"trials":3355,"activeCount":101},[],{"intervention":3357,"totalTrials":120,"cells":3358},"Ultiva (remifentanil) or placebo",{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3365,"PHASE4":3375,"NA":3377},{"trials":3360,"activeCount":101},[],{"trials":3362,"activeCount":101},[],{"trials":3364,"activeCount":101},[],{"trials":3366,"activeCount":101},[3367],{"nctId":3368,"briefTitle":3369,"status":438,"phases":3370,"primaryCompletion":3193,"completion":3193,"start":509,"enrollment":3371,"conditions":3372,"interventions":3374},"NCT01375348","Relationship Between Cognitive Function and Pain",[91],23,[3373],"Cognitive Ability, General",[3357],{"trials":3376,"activeCount":101},[],{"trials":3378,"activeCount":101},[],{"intervention":3380,"totalTrials":120,"cells":3381},"native glp-1",{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3388,"PHASE4":3396,"NA":3398},{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[],{"trials":3387,"activeCount":101},[],{"trials":3389,"activeCount":101},[3390],{"nctId":3391,"briefTitle":3392,"status":438,"phases":3393,"primaryCompletion":2942,"completion":3279,"start":1164,"enrollment":427,"conditions":3394,"interventions":3395},"NCT01185119","Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET",[90,91],[18],[3380],{"trials":3397,"activeCount":101},[],{"trials":3399,"activeCount":101},[],{"intervention":3401,"totalTrials":120,"cells":3402},"SGLT2 inhibitor",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3422,"NA":3424},{"trials":3404,"activeCount":101},[],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"trials":3410,"activeCount":101},[3411],{"nctId":3412,"briefTitle":3413,"status":476,"phases":3414,"primaryCompletion":3415,"completion":726,"start":3416,"enrollment":3417,"conditions":3418,"interventions":3421},"NCT05241431","Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention",[90,91],"2024-03-01","2022-02-12",106,[3419,3420],"Aortic Stenosis","Left Ventricle Hypertrophied",[3401],{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"intervention":3427,"totalTrials":120,"cells":3428},"Parathyroid hormone",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3446,"NA":3448},{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[3437],{"nctId":3438,"briefTitle":3439,"status":438,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":3442,"enrollment":28,"conditions":3443,"interventions":3445},"NCT01466829","Treatment With PTH After Sternotomy in Cardiac Surgery Patients",[91],"2014-03","2012-10",[3444],"Disruption or Dehiscence of Closure of Sternum or Sternotomy",[3427],{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":101},[],{"intervention":3451,"totalTrials":97,"cells":3452},"Subcutaneous immunoglobulin",{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3454,"activeCount":101},[],{"trials":3456,"activeCount":101},[],{"trials":3458,"activeCount":101},[3459,3467],{"nctId":3460,"briefTitle":3461,"status":438,"phases":3462,"primaryCompletion":1120,"completion":1120,"start":1950,"enrollment":427,"conditions":3463,"interventions":3465},"NCT00268788","Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy",[90],[3464],"Multifocal Motor Neuropathy",[3451,3466],"Intravenous immunoglobulin",{"nctId":3468,"briefTitle":3469,"status":438,"phases":3470,"primaryCompletion":1092,"completion":1092,"start":1787,"enrollment":2589,"conditions":3471,"interventions":3473},"NCT01017159","Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",[90],[3472],"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[3451],{"trials":3475,"activeCount":101},[],{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"intervention":3481,"totalTrials":120,"cells":3482},"Recombinant human intrinsic factor",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[3489],{"nctId":3490,"briefTitle":3491,"status":438,"phases":3492,"completion":3493,"start":1831,"enrollment":3494,"conditions":3495,"interventions":3497},"NCT00279552","Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?",[90],"2004-12",37,[3496],"Vitamin B12 Deficiency",[3481],{"trials":3499,"activeCount":101},[],{"trials":3501,"activeCount":101},[],{"trials":3503,"activeCount":101},[],{"intervention":3505,"totalTrials":120,"cells":3506},"Immunochemotherapy",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3524,"PHASE4":3526,"NA":3528},{"trials":3508,"activeCount":101},[],{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[3513],{"nctId":3514,"briefTitle":3515,"status":438,"phases":3516,"primaryCompletion":3517,"completion":3518,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3523},"NCT01458730","Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma",[90],"2010-10","2022-08","2007-05",66,[3522],"Central Nervous System Lymphoma",[3505],{"trials":3525,"activeCount":101},[],{"trials":3527,"activeCount":101},[],{"trials":3529,"activeCount":101},[],{"intervention":3531,"totalTrials":120,"cells":3532},"Senicapoc",{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[3539],{"nctId":3540,"briefTitle":3541,"status":476,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":3545,"enrollment":1177,"conditions":3546,"interventions":3549},"NCT04594668","Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency",[90],"2021-04-24","2021-12-31","2020-04-24",[3547,3548],"ARDS, Human","COVID",[3531],{"trials":3551,"activeCount":101},[],{"trials":3553,"activeCount":101},[],{"trials":3555,"activeCount":101},[],{"intervention":3466,"totalTrials":120,"cells":3557},{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3559,"activeCount":101},[],{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[3564],{"nctId":3460,"briefTitle":3461,"status":438,"phases":3565,"primaryCompletion":1120,"completion":1120,"start":1950,"enrollment":427,"conditions":3566,"interventions":3567},[90],[3464],[3451,3466],{"trials":3569,"activeCount":101},[],{"trials":3571,"activeCount":101},[],{"trials":3573,"activeCount":101},[],{"intervention":3575,"totalTrials":120,"cells":3576},"Glucocorticoids",{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3581,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3578,"activeCount":101},[],{"trials":3580,"activeCount":101},[],{"trials":3582,"activeCount":101},[3583],{"nctId":3584,"briefTitle":3585,"status":438,"phases":3586,"primaryCompletion":3587,"completion":3587,"start":465,"enrollment":3194,"conditions":3588,"interventions":3590},"NCT01762540","Glucocorticoid Induced Whole Body Catabolisme",[90],"2014-06",[3589],"Whole Body Catabolisme Induced by Glucocorticoids",[3575,3591],"Calcium Supplement",{"trials":3593,"activeCount":101},[],{"trials":3595,"activeCount":101},[],{"trials":3597,"activeCount":101},[],{"intervention":3591,"totalTrials":120,"cells":3599},{"EARLY_PHASE1":3600,"PHASE1":3602,"PHASE2":3604,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[],{"trials":3605,"activeCount":101},[3606],{"nctId":3584,"briefTitle":3585,"status":438,"phases":3607,"primaryCompletion":3587,"completion":3587,"start":465,"enrollment":3194,"conditions":3608,"interventions":3609},[90],[3589],[3575,3591],{"trials":3611,"activeCount":101},[],{"trials":3613,"activeCount":101},[],{"trials":3615,"activeCount":101},[],{"intervention":447,"totalTrials":120,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":101},[],{"trials":3621,"activeCount":101},[],{"trials":3623,"activeCount":101},[3624],{"nctId":436,"briefTitle":437,"status":438,"phases":3625,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":3626,"interventions":3627},[90],[445],[426,447,448],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[],{"trials":3633,"activeCount":101},[],{"intervention":448,"totalTrials":120,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3640,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3637,"activeCount":101},[],{"trials":3639,"activeCount":101},[],{"trials":3641,"activeCount":101},[3642],{"nctId":436,"briefTitle":437,"status":438,"phases":3643,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":3644,"interventions":3645},[90],[445],[426,447,448],{"trials":3647,"activeCount":101},[],{"trials":3649,"activeCount":101},[],{"trials":3651,"activeCount":101},[],{"intervention":3653,"totalTrials":120,"cells":3654},"PREBEN",{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3656,"activeCount":101},[],{"trials":3658,"activeCount":101},[],{"trials":3660,"activeCount":101},[3661],{"nctId":3662,"briefTitle":3663,"status":476,"phases":3664,"primaryCompletion":3665,"completion":3666,"start":1080,"enrollment":374,"conditions":3667,"interventions":3669},"NCT02678299","Phase 1\u002F2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study",[89,90],"2022-02","2025-12",[3668],"Malignant Lymphoma",[3653],{"trials":3671,"activeCount":101},[],{"trials":3673,"activeCount":101},[],{"trials":3675,"activeCount":101},[],{"intervention":3677,"totalTrials":120,"cells":3678},"11C-Carfentanil",{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3683,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3680,"activeCount":101},[],{"trials":3682,"activeCount":101},[],{"trials":3684,"activeCount":101},[3685],{"nctId":3686,"briefTitle":3687,"status":487,"phases":3688,"primaryCompletion":2061,"completion":2061,"start":3689,"enrollment":1063,"conditions":3690,"interventions":3692},"NCT01899170","Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain",[90],"2014-04-01",[3691],"Neuralgia",[3677],{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[],{"intervention":3700,"totalTrials":120,"cells":3701},"Low dose alteplase",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3703,"activeCount":101},[],{"trials":3705,"activeCount":101},[],{"trials":3707,"activeCount":101},[3708],{"nctId":3709,"briefTitle":3710,"status":476,"phases":3711,"primaryCompletion":3712,"completion":3713,"start":3714,"enrollment":374,"conditions":3715,"interventions":3716},"NCT03854266","Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism",[90],"2023-03-10","2024-03-10","2020-03-10",[1208],[3700,3717],"Unfractionated heparin",{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":101},[],{"trials":3723,"activeCount":101},[],{"intervention":3717,"totalTrials":120,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3727,"activeCount":101},[],{"trials":3729,"activeCount":101},[],{"trials":3731,"activeCount":101},[3732],{"nctId":3709,"briefTitle":3710,"status":476,"phases":3733,"primaryCompletion":3712,"completion":3713,"start":3714,"enrollment":374,"conditions":3734,"interventions":3735},[90],[1208],[3700,3717],{"trials":3737,"activeCount":101},[],{"trials":3739,"activeCount":101},[],{"trials":3741,"activeCount":101},[],{"intervention":3743,"totalTrials":120,"cells":3744},"Dalteparin",{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3749,"PHASE3":3761,"PHASE4":3763,"NA":3765},{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[3751],{"nctId":3752,"briefTitle":3753,"status":438,"phases":3754,"primaryCompletion":2484,"completion":2484,"start":3755,"enrollment":3756,"conditions":3757,"interventions":3759},"NCT04850378","Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome",[89,90],"2021-03-25",57,[2733,3758],"Thromboembolic Disease",[3743,3760],"Apixaban",{"trials":3762,"activeCount":101},[],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"intervention":3760,"totalTrials":120,"cells":3768},{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3773,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":101},[],{"trials":3774,"activeCount":101},[3775],{"nctId":3752,"briefTitle":3753,"status":438,"phases":3776,"primaryCompletion":2484,"completion":2484,"start":3755,"enrollment":3756,"conditions":3777,"interventions":3778},[89,90],[2733,3758],[3743,3760],{"trials":3780,"activeCount":101},[],{"trials":3782,"activeCount":101},[],{"trials":3784,"activeCount":101},[],{"intervention":3786,"totalTrials":120,"cells":3787},"Camostat Mesilate",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3804,"PHASE4":3806,"NA":3808},{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":101},[],{"trials":3793,"activeCount":101},[3794],{"nctId":3795,"briefTitle":3796,"status":438,"phases":3797,"primaryCompletion":3798,"completion":441,"start":3799,"enrollment":3800,"conditions":3801,"interventions":3803},"NCT04321096","The Impact of Camostat Mesilate on COVID-19 Infection",[89,90],"2022-01-31","2020-04-04",206,[3802],"Corona Virus Infection",[3786],{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[],{"trials":3809,"activeCount":101},[],{"intervention":3811,"totalTrials":120,"cells":3812},"Pneumococcal vaccines + CPG 7909",{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3829,"PHASE4":3831,"NA":3833},{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[],{"trials":3818,"activeCount":101},[3819],{"nctId":3820,"briefTitle":3821,"status":438,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":1093,"conditions":3825,"interventions":3827},"NCT00562939","Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults",[89,90],"2009-01","2008-01",[3826],"HIV Infections",[3811,3828],"Pneumococcal vaccines",{"trials":3830,"activeCount":101},[],{"trials":3832,"activeCount":101},[],{"trials":3834,"activeCount":101},[],{"intervention":3828,"totalTrials":120,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3838,"activeCount":101},[],{"trials":3840,"activeCount":101},[],{"trials":3842,"activeCount":101},[3843],{"nctId":3820,"briefTitle":3821,"status":438,"phases":3844,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":1093,"conditions":3845,"interventions":3846},[89,90],[3826],[3811,3828],{"trials":3848,"activeCount":101},[],{"trials":3850,"activeCount":101},[],{"trials":3852,"activeCount":101},[],{"intervention":3854,"totalTrials":120,"cells":3855},"Zoledronic acid",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3872,"PHASE4":3874,"NA":3876},{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[3862],{"nctId":3863,"briefTitle":3864,"status":487,"phases":3865,"primaryCompletion":2637,"completion":3866,"start":3192,"enrollment":3867,"conditions":3868,"interventions":3870},"NCT01679080","The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta",[90],"2021-06-01",9,[3869],"Osteogenesis Imperfecta",[3854,3871],"Teriparatide",{"trials":3873,"activeCount":101},[],{"trials":3875,"activeCount":101},[],{"trials":3877,"activeCount":101},[],{"intervention":3871,"totalTrials":120,"cells":3879},{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3890,"PHASE4":3892,"NA":3894},{"trials":3881,"activeCount":101},[],{"trials":3883,"activeCount":101},[],{"trials":3885,"activeCount":101},[3886],{"nctId":3863,"briefTitle":3864,"status":487,"phases":3887,"primaryCompletion":2637,"completion":3866,"start":3192,"enrollment":3867,"conditions":3888,"interventions":3889},[90],[3869],[3854,3871],{"trials":3891,"activeCount":101},[],{"trials":3893,"activeCount":101},[],{"trials":3895,"activeCount":101},[],{"intervention":3897,"totalTrials":120,"cells":3898},"3,4-diaminopyridine",{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[3905],{"nctId":3906,"briefTitle":3907,"status":438,"phases":3908,"completion":3909,"start":3910,"enrollment":2378,"conditions":3911,"interventions":3912},"NCT00342381","Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation",[90],"2007-12","2006-06",[35,2567],[3897],{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[],{"intervention":3920,"totalTrials":120,"cells":3921},"Pamidronatdinatrium",{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":101},[3928],{"nctId":3929,"briefTitle":3930,"status":476,"phases":3931,"primaryCompletion":3932,"completion":3933,"start":479,"enrollment":568,"conditions":3934,"interventions":3937},"NCT02594878","Chronic Non-bacterial Osteomyelitis Treated With Pamidronate",[90],"2018-05","2018-08",[3935,3936],"Immune System Disease","Musculoskeletal Disease",[3920],{"trials":3939,"activeCount":101},[],{"trials":3941,"activeCount":101},[],{"trials":3943,"activeCount":101},[],{"intervention":3945,"totalTrials":120,"cells":3946},"Infusion of 3-OHB",{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3948,"activeCount":101},[],{"trials":3950,"activeCount":101},[],{"trials":3952,"activeCount":101},[3953],{"nctId":3954,"briefTitle":3955,"status":438,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1412,"conditions":3959,"interventions":3962},"NCT03073356","Ketones in Heart Failure - Effects on Cardiac Efficiency",[90],"2017-11-16","2017-03-17",[3960,3961],"Heart Failure, Systolic","Ketonemia",[3945,3963],"Infusion of placebo",{"trials":3965,"activeCount":101},[],{"trials":3967,"activeCount":101},[],{"trials":3969,"activeCount":101},[],{"intervention":3963,"totalTrials":120,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":101},[],{"trials":3975,"activeCount":101},[],{"trials":3977,"activeCount":101},[3978],{"nctId":3954,"briefTitle":3955,"status":438,"phases":3979,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1412,"conditions":3980,"interventions":3981},[90],[3960,3961],[3945,3963],{"trials":3983,"activeCount":101},[],{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"intervention":3989,"totalTrials":120,"cells":3990},"Interleukin-2",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[3997],{"nctId":3998,"briefTitle":3999,"status":476,"phases":4000,"primaryCompletion":1079,"completion":1079,"start":4001,"enrollment":4002,"conditions":4003,"interventions":4005},"NCT01274273","Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer",[90],"2009-10",118,[4004],"Metastatic Renal Cell Carcinoma",[3989,4006,4007],"Interferon Alfa-2b","Bevacizumab",{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"intervention":4006,"totalTrials":120,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[],{"trials":4021,"activeCount":101},[4022],{"nctId":3998,"briefTitle":3999,"status":476,"phases":4023,"primaryCompletion":1079,"completion":1079,"start":4001,"enrollment":4002,"conditions":4024,"interventions":4025},[90],[4004],[3989,4006,4007],{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[],{"trials":4031,"activeCount":101},[],{"intervention":4007,"totalTrials":120,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4038,"PHASE3":4044,"PHASE4":4046,"NA":4048},{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[4040],{"nctId":3998,"briefTitle":3999,"status":476,"phases":4041,"primaryCompletion":1079,"completion":1079,"start":4001,"enrollment":4002,"conditions":4042,"interventions":4043},[90],[4004],[3989,4006,4007],{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[],{"trials":4049,"activeCount":101},[],{"intervention":4051,"totalTrials":120,"cells":4052},"Arm B Vinorelbine",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4057,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4054,"activeCount":101},[],{"trials":4056,"activeCount":101},[],{"trials":4058,"activeCount":101},[4059],{"nctId":4060,"briefTitle":4061,"status":438,"phases":4062,"primaryCompletion":4063,"completion":490,"start":1224,"enrollment":2852,"conditions":4064,"interventions":4066},"NCT01941771","Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer",[90],"2015-01",[4065],"Breast Cancer",[4051,4067],"Arm A Vinorelbine",{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[],{"intervention":4067,"totalTrials":120,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":101},[],{"trials":4079,"activeCount":101},[],{"trials":4081,"activeCount":101},[4082],{"nctId":4060,"briefTitle":4061,"status":438,"phases":4083,"primaryCompletion":4063,"completion":490,"start":1224,"enrollment":2852,"conditions":4084,"interventions":4085},[90],[4065],[4051,4067],{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[],{"intervention":4093,"totalTrials":120,"cells":4094},"Hypoxia",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":101},[],{"trials":4100,"activeCount":101},[4101],{"nctId":4102,"briefTitle":4103,"status":476,"phases":4104,"primaryCompletion":579,"completion":579,"start":4105,"enrollment":28,"conditions":4106,"interventions":4108},"NCT03090087","The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo",[90],"2017-03-22",[4107],"Retinal Artery Occlusion",[4093,4109],"Regadenoson",{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":101},[],{"trials":4115,"activeCount":101},[],{"intervention":4109,"totalTrials":120,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[4124],{"nctId":4102,"briefTitle":4103,"status":476,"phases":4125,"primaryCompletion":579,"completion":579,"start":4105,"enrollment":28,"conditions":4126,"interventions":4127},[90],[4107],[4093,4109],{"trials":4129,"activeCount":101},[],{"trials":4131,"activeCount":101},[],{"trials":4133,"activeCount":101},[],{"intervention":4135,"totalTrials":120,"cells":4136},"Lidocaine-epinephrine added gadoterate meglumine",{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4151,"PHASE4":4153,"NA":4155},{"trials":4138,"activeCount":101},[],{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[4143],{"nctId":4144,"briefTitle":4145,"status":438,"phases":4146,"primaryCompletion":2638,"completion":2638,"start":4147,"enrollment":22,"conditions":4148,"interventions":4150},"NCT02718976","Shamrock - Ultrasound\u002FMR Image Fusion Guided Lumbar Plexus Block",[90],"2016-03",[481,4149,1249],"Anesthesia, Local",[4135],{"trials":4152,"activeCount":101},[],{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"intervention":4158,"totalTrials":120,"cells":4159},"Ularitide",{"EARLY_PHASE1":4160,"PHASE1":4162,"PHASE2":4164,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[],{"trials":4165,"activeCount":101},[4166],{"nctId":4167,"briefTitle":4168,"status":487,"phases":4169,"primaryCompletion":4170,"completion":4170,"start":4171,"enrollment":31,"conditions":4172,"interventions":4175},"NCT04311489","Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.",[90],"2022-11-30","2020-08-01",[4173,4174],"Cirrhosis, Liver","Ascites Hepatic",[4158],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[],{"intervention":2844,"totalTrials":120,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4185,"activeCount":101},[],{"trials":4187,"activeCount":101},[],{"trials":4189,"activeCount":101},[4190],{"nctId":2836,"briefTitle":2837,"status":438,"phases":4191,"primaryCompletion":2839,"completion":2839,"start":1079,"enrollment":2840,"conditions":4192,"interventions":4193},[90],[2842,332],[2844,2845,2827],{"trials":4195,"activeCount":101},[],{"trials":4197,"activeCount":101},[],{"trials":4199,"activeCount":101},[],{"intervention":2845,"totalTrials":120,"cells":4201},{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4203,"activeCount":101},[],{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[4208],{"nctId":2836,"briefTitle":2837,"status":438,"phases":4209,"primaryCompletion":2839,"completion":2839,"start":1079,"enrollment":2840,"conditions":4210,"interventions":4211},[90],[2842,332],[2844,2845,2827],{"trials":4213,"activeCount":101},[],{"trials":4215,"activeCount":101},[],{"trials":4217,"activeCount":101},[],{"intervention":4219,"totalTrials":120,"cells":4220},"Lactose",{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4235,"PHASE4":4237,"NA":4239},{"trials":4222,"activeCount":101},[],{"trials":4224,"activeCount":101},[],{"trials":4226,"activeCount":101},[4227],{"nctId":4228,"briefTitle":4229,"status":476,"phases":4230,"primaryCompletion":1175,"completion":1175,"start":1603,"enrollment":1034,"conditions":4231,"interventions":4233},"NCT01575678","The Effect of Melatonin on Nocturnal Enuresis",[90],[4232],"Nocturnal Enuresis",[4234,4219],"Melatonin",{"trials":4236,"activeCount":101},[],{"trials":4238,"activeCount":101},[],{"trials":4240,"activeCount":101},[],{"intervention":4242,"totalTrials":120,"cells":4243},"a: PTH",{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4245,"activeCount":101},[],{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[4250],{"nctId":4251,"briefTitle":4252,"status":438,"phases":4253,"primaryCompletion":4254,"completion":4254,"start":2588,"enrollment":1319,"conditions":4255,"interventions":4257},"NCT00730210","Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life",[90],"2010-08",[4256],"Hypoparathyroidism",[4242,4258],"b:placebo",{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"intervention":4258,"totalTrials":120,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[],{"trials":4272,"activeCount":101},[4273],{"nctId":4251,"briefTitle":4252,"status":438,"phases":4274,"primaryCompletion":4254,"completion":4254,"start":2588,"enrollment":1319,"conditions":4275,"interventions":4276},[90],[4256],[4242,4258],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[],{"intervention":4284,"totalTrials":120,"cells":4285},"Imipramine treatment",{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4290,"PHASE3":4301,"PHASE4":4303,"NA":4305},{"trials":4287,"activeCount":101},[],{"trials":4289,"activeCount":101},[],{"trials":4291,"activeCount":101},[4292],{"nctId":4293,"briefTitle":4294,"status":438,"phases":4295,"primaryCompletion":2106,"completion":501,"start":1603,"enrollment":4296,"conditions":4297,"interventions":4300},"NCT01518634","Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome",[90],138,[4298,4299],"Somatisation Disorder","Somatoform Disorders",[4284],{"trials":4302,"activeCount":101},[],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"intervention":4308,"totalTrials":120,"cells":4309},"Panobinostat",{"EARLY_PHASE1":4310,"PHASE1":4312,"PHASE2":4314,"PHASE3":4326,"PHASE4":4328,"NA":4330},{"trials":4311,"activeCount":101},[],{"trials":4313,"activeCount":101},[],{"trials":4315,"activeCount":101},[4316],{"nctId":4317,"briefTitle":4318,"status":438,"phases":4319,"primaryCompletion":4320,"completion":4321,"start":4322,"enrollment":2020,"conditions":4323,"interventions":4325},"NCT01680094","Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART",[89,90],"2013-09","2014-01","2012-09",[4324],"HIV Infection",[4308],{"trials":4327,"activeCount":101},[],{"trials":4329,"activeCount":101},[],{"trials":4331,"activeCount":101},[],{"intervention":4333,"totalTrials":120,"cells":4334},"Anti-D",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4350,"PHASE4":4352,"NA":4354},{"trials":4336,"activeCount":101},[],{"trials":4338,"activeCount":101},[],{"trials":4340,"activeCount":101},[4341],{"nctId":4342,"briefTitle":4343,"status":438,"phases":4344,"primaryCompletion":3824,"completion":1165,"start":4345,"enrollment":4346,"conditions":4347,"interventions":4349},"NCT00128882","Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D",[90],"2004-11",45,[4348],"Idiopathic Thrombocytopenic Purpura",[4333],{"trials":4351,"activeCount":101},[],{"trials":4353,"activeCount":101},[],{"trials":4355,"activeCount":101},[],{"intervention":4357,"totalTrials":120,"cells":4358},"MGN1703",{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4373,"PHASE4":4375,"NA":4377},{"trials":4360,"activeCount":101},[],{"trials":4362,"activeCount":101},[],{"trials":4364,"activeCount":101},[4365],{"nctId":4366,"briefTitle":4367,"status":438,"phases":4368,"primaryCompletion":4369,"completion":4370,"start":1081,"enrollment":467,"conditions":4371,"interventions":4372},"NCT02443935","Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection",[89,90],"2017-06-01","2017-06-25",[1977],[4357,4357],{"trials":4374,"activeCount":101},[],{"trials":4376,"activeCount":101},[],{"trials":4378,"activeCount":101},[],{"intervention":4380,"totalTrials":120,"cells":4381},"CHOEP + G-CSF followed by BEAM",{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[4388],{"nctId":4389,"briefTitle":4390,"status":438,"phases":4391,"primaryCompletion":4392,"completion":4254,"start":4393,"enrollment":4394,"conditions":4395,"interventions":4397},"NCT00791947","A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT",[90],"2008-08","2001-10",166,[4396],"Peripheral T-Cell Lymphoma",[4380],{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"intervention":4405,"totalTrials":120,"cells":4406},"Rosiglitazone",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4411,"PHASE3":4422,"PHASE4":4424,"NA":4426},{"trials":4408,"activeCount":101},[],{"trials":4410,"activeCount":101},[],{"trials":4412,"activeCount":101},[4413],{"nctId":4414,"briefTitle":4415,"status":438,"phases":4416,"primaryCompletion":4417,"completion":4417,"start":3824,"enrollment":3756,"conditions":4418,"interventions":4421},"NCT00609362","The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells",[90],"2009-11",[4419,4420],"Change in Bone Mineral Density","Change in Bone Marrow Fat Content",[4405],{"trials":4423,"activeCount":101},[],{"trials":4425,"activeCount":101},[],{"trials":4427,"activeCount":101},[],{"intervention":4429,"totalTrials":120,"cells":4430},"Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units\u002Fml.",{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4432,"activeCount":101},[],{"trials":4434,"activeCount":101},[],{"trials":4436,"activeCount":101},[4437],{"nctId":4438,"briefTitle":4439,"status":438,"phases":4440,"primaryCompletion":489,"completion":4441,"start":1175,"enrollment":11,"conditions":4442,"interventions":4446},"NCT02255604","Effect of Intralymphatic Immunotherapy",[90],"2017-02-01",[4443,4444,4445],"Allergy","Immune Tolerance","Injection Site Discomfort",[4429,4447,4448],"alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units\u002Fml.","0.1 ml Isoton saline",{"trials":4450,"activeCount":101},[],{"trials":4452,"activeCount":101},[],{"trials":4454,"activeCount":101},[],{"intervention":4448,"totalTrials":120,"cells":4456},{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4467,"PHASE4":4469,"NA":4471},{"trials":4458,"activeCount":101},[],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[4463],{"nctId":4438,"briefTitle":4439,"status":438,"phases":4464,"primaryCompletion":489,"completion":4441,"start":1175,"enrollment":11,"conditions":4465,"interventions":4466},[90],[4443,4444,4445],[4429,4447,4448],{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[],{"trials":4472,"activeCount":101},[],{"intervention":4474,"totalTrials":120,"cells":4475},"Niacin",{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4480,"PHASE3":4491,"PHASE4":4493,"NA":4495},{"trials":4477,"activeCount":101},[],{"trials":4479,"activeCount":101},[],{"trials":4481,"activeCount":101},[4482],{"nctId":4483,"briefTitle":4484,"status":438,"phases":4485,"primaryCompletion":4486,"completion":4486,"start":4487,"enrollment":467,"conditions":4488,"interventions":4489},"NCT04703361","Effects of Ketones and Niacin in Heart Failure Patients",[90],"2021-09-03","2021-02-15",[3960,3961],[4474,4490],"Na-3-OHB",{"trials":4492,"activeCount":101},[],{"trials":4494,"activeCount":101},[],{"trials":4496,"activeCount":101},[],{"intervention":4490,"totalTrials":120,"cells":4498},{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4500,"activeCount":101},[],{"trials":4502,"activeCount":101},[],{"trials":4504,"activeCount":101},[4505],{"nctId":4483,"briefTitle":4484,"status":438,"phases":4506,"primaryCompletion":4486,"completion":4486,"start":4487,"enrollment":467,"conditions":4507,"interventions":4508},[90],[3960,3961],[4474,4490],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"intervention":4516,"totalTrials":120,"cells":4517},"Ghrelin and saline",{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4530,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4519,"activeCount":101},[],{"trials":4521,"activeCount":101},[4522],{"nctId":4523,"briefTitle":4524,"status":438,"phases":4525,"primaryCompletion":4526,"completion":4526,"start":1691,"enrollment":545,"conditions":4527,"interventions":4529},"NCT00512525","Ghrelin Decreases Insulin Sensitivity",[89],"2003-10",[4528],"Healthy Subjects",[4516],{"trials":4531,"activeCount":101},[],{"trials":4533,"activeCount":101},[],{"trials":4535,"activeCount":101},[],{"trials":4537,"activeCount":101},[],{"intervention":4539,"totalTrials":120,"cells":4540},"Phenoxymethylpenicillin",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4551,"PHASE3":4553,"PHASE4":4555,"NA":4557},{"trials":4542,"activeCount":101},[],{"trials":4544,"activeCount":101},[4545],{"nctId":4546,"briefTitle":4547,"status":438,"phases":4548,"primaryCompletion":1091,"completion":1175,"start":1603,"enrollment":399,"conditions":4549,"interventions":4550},"NCT01499875","A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children",[89],[4539],[4539],{"trials":4552,"activeCount":101},[],{"trials":4554,"activeCount":101},[],{"trials":4556,"activeCount":101},[],{"trials":4558,"activeCount":101},[],{"intervention":4560,"totalTrials":120,"cells":4561},"11C-CSar",{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4563,"activeCount":101},[],{"trials":4565,"activeCount":101},[4566],{"nctId":4567,"briefTitle":4568,"status":438,"phases":4569,"primaryCompletion":1479,"completion":1479,"start":1091,"enrollment":22,"conditions":4570,"interventions":4573},"NCT01879735","Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET\u002FCT",[89],[4571,4572,1036],"Cholestasis","Primary Sclerosing Cholangitis",[4560,4574],"ICG",{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[],{"intervention":4574,"totalTrials":120,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":101},[4589],{"nctId":4567,"briefTitle":4568,"status":438,"phases":4590,"primaryCompletion":1479,"completion":1479,"start":1091,"enrollment":22,"conditions":4591,"interventions":4592},[89],[4571,4572,1036],[4560,4574],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[],{"intervention":4602,"totalTrials":120,"cells":4603},"N-acetylcysteine",{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4618,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[4608],{"nctId":4609,"briefTitle":4610,"status":438,"phases":4611,"primaryCompletion":4612,"completion":4613,"start":4614,"enrollment":36,"conditions":4615,"interventions":4617},"NCT03679442","Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose",[89],"2015-06-14","2017-02-18","2014-09-08",[4616],"Drug-Induced Acute Liver Injury",[4602],{"trials":4619,"activeCount":101},[],{"trials":4621,"activeCount":101},[],{"trials":4623,"activeCount":101},[],{"trials":4625,"activeCount":101},[],{"intervention":4627,"totalTrials":120,"cells":4628},"Obeticholic acid",{"EARLY_PHASE1":4629,"PHASE1":4640,"PHASE2":4642,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4630,"activeCount":101},[4631],{"nctId":4632,"briefTitle":4633,"status":438,"phases":4634,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":545,"conditions":4637,"interventions":4638},"NCT03253276","Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET\u002FCT",[88],"2018-09-20","2016-05-19",[1036],[4627,4639],"Placebos",{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[],{"trials":4645,"activeCount":101},[],{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":101},[],{"intervention":4639,"totalTrials":120,"cells":4651},{"EARLY_PHASE1":4652,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4653,"activeCount":101},[4654],{"nctId":4632,"briefTitle":4633,"status":438,"phases":4655,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":545,"conditions":4656,"interventions":4657},[88],[1036],[4627,4639],{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[],{"trials":4663,"activeCount":101},[],{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[],{"intervention":4669,"totalTrials":120,"cells":4670},"Blood transfusion",{"EARLY_PHASE1":4671,"PHASE1":4682,"PHASE2":4684,"PHASE3":4686,"PHASE4":4688,"NA":4690},{"trials":4672,"activeCount":101},[4673],{"nctId":4674,"briefTitle":4675,"status":438,"phases":4676,"primaryCompletion":4677,"completion":4678,"start":1119,"enrollment":4679,"conditions":4680,"interventions":4681},"NCT01102010","Postoperative Blood Transfusion for Frail Elderly With Hip Fracture",[88],"2013-10","2014-10",284,[493],[4669],{"trials":4683,"activeCount":101},[],{"trials":4685,"activeCount":101},[],{"trials":4687,"activeCount":101},[],{"trials":4689,"activeCount":101},[],{"trials":4691,"activeCount":101},[],{"intervention":4693,"totalTrials":4694,"cells":4695},"Acipimox",6,{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4697,"activeCount":101},[],{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[4702],{"nctId":4703,"briefTitle":4704,"status":487,"phases":4705,"completion":4706,"start":4707,"enrollment":568,"conditions":4708,"interventions":4709},"NCT00449423","Metabolic Modulation as Treatment in Acute Heart Failure",[90],"2007-10","2007-03",[247],[4710],"acipimox",{"trials":4712,"activeCount":101},[],{"trials":4714,"activeCount":101},[],{"trials":4716,"activeCount":101},[4717,4726,4732,4741,4747],{"nctId":4718,"briefTitle":4719,"status":438,"phases":4720,"primaryCompletion":4678,"completion":479,"start":1224,"enrollment":545,"conditions":4721,"interventions":4724},"NCT01209416","The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin",[93],[4722,30,4723],"Metabolism","Hypopituitarism",[4693,4725],"Ghrelin",{"nctId":4727,"briefTitle":4728,"status":438,"phases":4729,"primaryCompletion":4322,"completion":4322,"start":1542,"enrollment":3867,"conditions":4730,"interventions":4731},"NCT01260376","Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise",[93],[2425,15],[4693],{"nctId":4733,"briefTitle":4734,"status":438,"phases":4735,"primaryCompletion":4736,"completion":4736,"start":4737,"enrollment":545,"conditions":4738,"interventions":4740},"NCT02796950","The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion",[93],"2017-01-20","2016-06",[4739],"Diabetes Mellitus Type 2",[4693],{"nctId":4742,"briefTitle":4743,"status":438,"phases":4744,"primaryCompletion":1165,"completion":511,"start":4706,"enrollment":796,"conditions":4745,"interventions":4746},"NCT00549614","Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure",[93],[27],[4710],{"nctId":4748,"briefTitle":4749,"status":438,"phases":4750,"primaryCompletion":4751,"completion":4751,"start":4752,"enrollment":3867,"conditions":4753,"interventions":4759},"NCT02782208","Lipolytic Effects of GH in Hypopituitary Patients in Vivo",[93],"2016-12-22","2016-02-10",[4723,30,4754,4755,4756,4757,4758],"Endocrine System Diseases","Glucose Metabolism Disorders","Metabolic Diseases","Pituitary Diseases","Brain Diseases",[4693,4760],"GH substitution",{"intervention":4762,"totalTrials":4763,"cells":4764},"Growth hormone",5,{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4771,"PHASE4":4773,"NA":4775},{"trials":4766,"activeCount":101},[],{"trials":4768,"activeCount":101},[],{"trials":4770,"activeCount":101},[],{"trials":4772,"activeCount":101},[],{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[4777,4785,4791,4803,4811],{"nctId":4778,"briefTitle":4779,"status":438,"phases":4780,"primaryCompletion":2943,"completion":2943,"start":1366,"enrollment":1717,"conditions":4781,"interventions":4783},"NCT00646815","Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency",[93],[4782],"Growth Hormone Deficiency",[4784],"growth hormone",{"nctId":4786,"briefTitle":4787,"status":438,"phases":4788,"primaryCompletion":3280,"completion":3280,"start":3909,"enrollment":545,"conditions":4789,"interventions":4790},"NCT00568568","Metabolic Studies- Interactions Between GH and Insulin in GHDA",[93],[30],[4762],{"nctId":4792,"briefTitle":4793,"status":438,"phases":4794,"primaryCompletion":4795,"completion":4796,"start":4797,"enrollment":3867,"conditions":4798,"interventions":4800},"NCT02782221","Lipolytic Effects of GH in Human Subjects in Vivo",[93],"2016-09-22","2017-01-15","2016-05-30",[4756,4799],"Growth Hormone Treatment",[4801,4802],"Growth Hormone","Pegisomant",{"nctId":4804,"briefTitle":4805,"status":438,"phases":4806,"primaryCompletion":3075,"completion":3075,"start":4807,"enrollment":3194,"conditions":4808,"interventions":4809},"NCT01299831","The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity",[93],"2011-01",[18],[4762,4810],"Olbetam",{"nctId":4812,"briefTitle":4813,"status":438,"phases":4814,"primaryCompletion":1647,"completion":1830,"start":4254,"enrollment":467,"conditions":4815,"interventions":4817},"NCT01158612","The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella",[93],[4801,4816],"Elderly",[4801],{"intervention":1137,"totalTrials":4819,"cells":4820},4,{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4847},{"trials":4822,"activeCount":101},[],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[4831,4835],{"nctId":1128,"briefTitle":1129,"status":476,"phases":4832,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":4833,"interventions":4834},[92],[469],[1137,1105],{"nctId":4836,"briefTitle":4837,"status":487,"phases":4838,"primaryCompletion":4839,"completion":4840,"start":4841,"enrollment":604,"conditions":4842,"interventions":4846},"NCT04764825","Methadone for Spinal Fusion Surgery.",[92],"2024-03-19","2024-07-01","2021-02-26",[1249,4843,1860,1137,4844,4845],"Back Pain","Degenerative Spondylolisthesis","Stenosis, Spinal",[1137,2542],{"trials":4848,"activeCount":101},[4849,4864],{"nctId":4850,"briefTitle":4851,"status":438,"phases":4852,"primaryCompletion":1855,"completion":4853,"start":4854,"enrollment":604,"conditions":4855,"interventions":4863},"NCT04475029","Methadone in Cystectomy Patients",[93],"2023-08-17","2020-07-06",[1249,4856,4857,4858,1122,4859,4860,4861,4862],"Postoperative Complications","Pathologic Processes","Bladder Cancer","Signs and Symptoms","Neurologic Manifestations","Neurologic Symptoms","Side Effect of Drug",[1137,2542],{"nctId":4865,"briefTitle":4866,"status":476,"phases":4867,"primaryCompletion":4868,"completion":4869,"start":442,"enrollment":4870,"conditions":4871,"interventions":4872},"NCT03908060","Clinical Effectiveness and Safety of Intraoperative Methadone in Patients Undergoing Laparoscopic Hysterectomy",[93],"2022-07-08","2022-12-01",126,[469],[1137,2542],{"intervention":4234,"totalTrials":4819,"cells":4874},{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4893,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4876,"activeCount":101},[],{"trials":4878,"activeCount":101},[4879],{"nctId":4880,"briefTitle":4881,"status":438,"phases":4882,"primaryCompletion":4883,"completion":4884,"start":4885,"enrollment":31,"conditions":4886,"interventions":4892},"NCT03859934","Metabolic Effects of Melatonin Treatment",[89],"2021-05-03","2021-08-18","2019-09-26",[4887,4888,4889,4890,4891,787],"Metabolic Disease","Insulin Sensitivity","Glucose Metabolism Disorders (Including Diabetes Mellitus)","Type 2 Diabetes Mellitus","Blood Pressure",[4234],{"trials":4894,"activeCount":101},[4895,4904],{"nctId":4896,"briefTitle":4897,"status":438,"phases":4898,"primaryCompletion":4899,"completion":4900,"start":4901,"enrollment":11,"conditions":4902,"interventions":4903},"NCT03204877","Acute Metabolic Effects of Melatonin Treatment",[89,90],"2019-02-27","2020-02-01","2017-08-22",[4755],[4234],{"nctId":4228,"briefTitle":4229,"status":476,"phases":4905,"primaryCompletion":1175,"completion":1175,"start":1603,"enrollment":1034,"conditions":4906,"interventions":4907},[90],[4232],[4234,4219],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[4914],{"nctId":4915,"briefTitle":4916,"status":438,"phases":4917,"primaryCompletion":3587,"completion":3587,"start":3192,"enrollment":4918,"conditions":4919,"interventions":4920},"NCT01690000","Treatment of Osteopenia With Melatonin",[93],81,[332],[4234],{"intervention":2542,"totalTrials":4819,"cells":4922},{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4927,"PHASE3":4929,"PHASE4":4931,"NA":4943},{"trials":4924,"activeCount":101},[],{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[],{"trials":4930,"activeCount":101},[],{"trials":4932,"activeCount":101},[4933,4937],{"nctId":4836,"briefTitle":4837,"status":487,"phases":4934,"primaryCompletion":4839,"completion":4840,"start":4841,"enrollment":604,"conditions":4935,"interventions":4936},[92],[1249,4843,1860,1137,4844,4845],[1137,2542],{"nctId":4938,"briefTitle":4939,"status":438,"phases":4940,"primaryCompletion":4322,"completion":4322,"start":3517,"enrollment":1034,"conditions":4941,"interventions":4942},"NCT01245244","Morphine Modulation of The Brain's Pain Matrix",[92],[1122],[2542],{"trials":4944,"activeCount":101},[4945,4949],{"nctId":4850,"briefTitle":4851,"status":438,"phases":4946,"primaryCompletion":1855,"completion":4853,"start":4854,"enrollment":604,"conditions":4947,"interventions":4948},[93],[1249,4856,4857,4858,1122,4859,4860,4861,4862],[1137,2542],{"nctId":4865,"briefTitle":4866,"status":476,"phases":4950,"primaryCompletion":4868,"completion":4869,"start":442,"enrollment":4870,"conditions":4951,"interventions":4952},[93],[469],[1137,2542],{"intervention":4954,"totalTrials":1063,"cells":4955},"Liraglutide",{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4960,"PHASE3":4962,"PHASE4":4964,"NA":4982},{"trials":4957,"activeCount":101},[],{"trials":4959,"activeCount":101},[],{"trials":4961,"activeCount":101},[],{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[4966,4975],{"nctId":4967,"briefTitle":4968,"status":438,"phases":4969,"primaryCompletion":4970,"completion":4970,"start":4971,"enrollment":374,"conditions":4972,"interventions":4974},"NCT02473809","The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function",[92],"2017-10","2015-08",[4973,332],"Diabetes Complications",[4954],{"nctId":4976,"briefTitle":4977,"status":438,"phases":4978,"primaryCompletion":1904,"completion":1904,"start":1223,"enrollment":4979,"conditions":4980,"interventions":4981},"NCT01664676","Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients",[92],11,[4890],[4954],{"trials":4983,"activeCount":101},[4984],{"nctId":4985,"briefTitle":4986,"status":438,"phases":4987,"primaryCompletion":1090,"completion":1090,"start":1603,"enrollment":4988,"conditions":4989,"interventions":4991},"NCT01469351","Identifying Potential Effects of Liraglutide on Degenerative Changes",[93],34,[4990],"Alzheimers Disease",[4954,4992],"non-active study drug",{"intervention":4994,"totalTrials":1063,"cells":4995},"Insulin",{"EARLY_PHASE1":4996,"PHASE1":4998,"PHASE2":5000,"PHASE3":5010,"PHASE4":5012,"NA":5014},{"trials":4997,"activeCount":101},[],{"trials":4999,"activeCount":101},[],{"trials":5001,"activeCount":101},[5002],{"nctId":5003,"briefTitle":5004,"status":438,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":3030,"enrollment":727,"conditions":5007,"interventions":5008},"NCT01071772","The Effect of Hyperglycemia on LV Function and Exercise Capacity in Diabetics With and Without Heart Failure.",[90],"2010-07",[27,21],[5009],"insulin",{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[5016,5026],{"nctId":5017,"briefTitle":5018,"status":438,"phases":5019,"primaryCompletion":5020,"completion":5020,"start":1175,"enrollment":3867,"conditions":5021,"interventions":5024},"NCT01919788","Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose",[93],"2014-04",[5022,5023],"Diabetes Mellitus Type I","Hypoglycemia",[4994,5025],"Glucose",{"nctId":5027,"briefTitle":5028,"status":438,"phases":5029,"primaryCompletion":2106,"completion":2106,"start":3192,"enrollment":2589,"conditions":5030,"interventions":5032},"NCT01564550","The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism",[],[21,5031],"Dyslipidemia",[4994,5009],{"intervention":525,"totalTrials":1063,"cells":5034},{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5036,"activeCount":101},[],{"trials":5038,"activeCount":101},[],{"trials":5040,"activeCount":101},[],{"trials":5042,"activeCount":101},[],{"trials":5044,"activeCount":101},[],{"trials":5046,"activeCount":101},[5047,5055,5059],{"nctId":5048,"briefTitle":5049,"status":438,"phases":5050,"primaryCompletion":4417,"completion":1480,"start":2588,"enrollment":727,"conditions":5051,"interventions":5053},"NCT00652379","Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients",[93],[2616,30,5052],"Impaired Glucose Tolerance",[525,5054],"Somatostatin analog",{"nctId":518,"briefTitle":519,"status":438,"phases":5056,"primaryCompletion":521,"completion":521,"start":522,"enrollment":427,"conditions":5057,"interventions":5058},[93],[18],[426,525],{"nctId":540,"briefTitle":541,"status":438,"phases":5060,"completion":543,"start":544,"enrollment":545,"conditions":5061,"interventions":5062},[93],[547],[426,549,525],{"intervention":5064,"totalTrials":97,"cells":5065},"glucagon-like-peptide-1",{"EARLY_PHASE1":5066,"PHASE1":5068,"PHASE2":5070,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5067,"activeCount":101},[],{"trials":5069,"activeCount":101},[],{"trials":5071,"activeCount":101},[],{"trials":5073,"activeCount":101},[],{"trials":5075,"activeCount":101},[],{"trials":5077,"activeCount":101},[5078,5085],{"nctId":5079,"briefTitle":5080,"status":438,"phases":5081,"completion":2756,"start":5082,"enrollment":427,"conditions":5083,"interventions":5084},"NCT00256256","The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men",[93],"2005-11",[21,24,2065],[5064],{"nctId":5086,"briefTitle":5087,"status":438,"phases":5088,"primaryCompletion":4706,"completion":1120,"start":2756,"enrollment":427,"conditions":5089,"interventions":5090},"NCT00418288","The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia",[93],[21,24,2065],[5064],{"intervention":5092,"totalTrials":97,"cells":5093},"Hormone replacement therapy",{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5113},{"trials":5095,"activeCount":101},[],{"trials":5097,"activeCount":101},[],{"trials":5099,"activeCount":101},[],{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":101},[5104],{"nctId":5105,"briefTitle":5106,"status":438,"phases":5107,"completion":5108,"start":5109,"enrollment":5110,"conditions":5111,"interventions":5112},"NCT00252408","Danish Osteoporosis Prevention Study",[92],"2003-12","1990-10",2000,[332],[5092],{"trials":5114,"activeCount":101},[5115],{"nctId":5116,"briefTitle":5117,"status":438,"phases":5118,"primaryCompletion":5119,"completion":5120,"start":5121,"enrollment":36,"conditions":5122,"interventions":5123},"NCT00825617","Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy",[93],"1999-10","2000-06","1996-10",[785],[5092],{"intervention":5125,"totalTrials":97,"cells":5126},"Vitamin B12",{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5135,"NA":5145},{"trials":5128,"activeCount":101},[],{"trials":5130,"activeCount":101},[],{"trials":5132,"activeCount":101},[],{"trials":5134,"activeCount":101},[],{"trials":5136,"activeCount":101},[5137],{"nctId":5138,"briefTitle":5139,"status":476,"phases":5140,"primaryCompletion":2942,"completion":2942,"start":5141,"enrollment":2131,"conditions":5142,"interventions":5143},"NCT00326833","How Many Patients Are in Need of Vitamin B12 Injections?",[92],"2006-01",[3496],[5144],"vitamin B12",{"trials":5146,"activeCount":101},[5147],{"nctId":5148,"briefTitle":5149,"status":438,"phases":5150,"completion":1142,"start":2422,"enrollment":5151,"conditions":5152,"interventions":5154},"NCT00306358","Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption",[93],78,[5153],"Vitamin B12 Absorption",[5125],{"intervention":4725,"totalTrials":97,"cells":5156},{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5175},{"trials":5158,"activeCount":101},[],{"trials":5160,"activeCount":101},[5161],{"nctId":5162,"briefTitle":5163,"status":438,"phases":5164,"primaryCompletion":3823,"completion":3823,"start":5165,"enrollment":545,"conditions":5166,"interventions":5168},"NCT00771940","Peripheral Metabolic Effects of Ghrelin",[89],"2008-10",[5167],"Healthy Controls",[4725],{"trials":5170,"activeCount":101},[],{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":101},[],{"trials":5176,"activeCount":101},[5177],{"nctId":4718,"briefTitle":4719,"status":438,"phases":5178,"primaryCompletion":4678,"completion":479,"start":1224,"enrollment":545,"conditions":5179,"interventions":5180},[93],[4722,30,4723],[4693,4725],{"intervention":5182,"totalTrials":97,"cells":5183},"Human acylated ghrelin",{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"trials":5195,"activeCount":101},[5196,5202],{"nctId":5197,"briefTitle":5198,"status":438,"phases":5199,"primaryCompletion":4707,"completion":4707,"start":1142,"enrollment":545,"conditions":5200,"interventions":5201},"NCT00139945","Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients",[93],[4723],[5182],{"nctId":5203,"briefTitle":5204,"status":438,"phases":5205,"completion":5141,"start":5206,"enrollment":31,"conditions":5207,"interventions":5208},"NCT00116025","Pharmacokinetics of Ghrelin",[93],"2005-03",[4528],[5182],{"intervention":5210,"totalTrials":97,"cells":5211},"Actrapid",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5216,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[],{"trials":5221,"activeCount":101},[],{"trials":5223,"activeCount":101},[5224,5230],{"nctId":5225,"briefTitle":5226,"status":438,"phases":5227,"primaryCompletion":4001,"completion":4001,"start":1366,"enrollment":545,"conditions":5228,"interventions":5229},"NCT00654056","Severe Insulin Resistance in Patients With Type 2 Diabetes",[93],[4890],[5210],{"nctId":5231,"briefTitle":5232,"status":438,"phases":5233,"primaryCompletion":2107,"completion":2107,"start":1366,"enrollment":727,"conditions":5234,"interventions":5235},"NCT00653510","The Metabolic Effects of Acute Hyperglycemia in Patients With Type 2 Diabetes",[93],[4890],[5210],{"intervention":5237,"totalTrials":97,"cells":5238},"Escitalopram",{"EARLY_PHASE1":5239,"PHASE1":5241,"PHASE2":5243,"PHASE3":5245,"PHASE4":5247,"NA":5255},{"trials":5240,"activeCount":101},[],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[],{"trials":5246,"activeCount":101},[],{"trials":5248,"activeCount":101},[5249],{"nctId":5250,"briefTitle":5251,"status":499,"phases":5252,"enrollment":101,"conditions":5253,"interventions":5254},"NCT01561092","Escitalopram Treatment In Acute Stroke",[92],[24],[5237],{"trials":5256,"activeCount":101},[5257],{"nctId":5258,"briefTitle":5259,"status":438,"phases":5260,"primaryCompletion":510,"completion":5020,"start":511,"enrollment":374,"conditions":5261,"interventions":5266},"NCT00971815","Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight",[93],[30,5262,21,5263,5264,5265],"Low Birth Weight","Cardiovascular Disease","Melancholic Depression","Anxiety Disorders",[5237],{"intervention":5054,"totalTrials":97,"cells":5268},{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5277,"NA":5279},{"trials":5270,"activeCount":101},[],{"trials":5272,"activeCount":101},[],{"trials":5274,"activeCount":101},[],{"trials":5276,"activeCount":101},[],{"trials":5278,"activeCount":101},[],{"trials":5280,"activeCount":101},[5281,5285],{"nctId":5048,"briefTitle":5049,"status":438,"phases":5282,"primaryCompletion":4417,"completion":1480,"start":2588,"enrollment":727,"conditions":5283,"interventions":5284},[93],[2616,30,5052],[525,5054],{"nctId":5286,"briefTitle":5287,"status":476,"phases":5288,"primaryCompletion":5289,"completion":5290,"start":5291,"enrollment":2486,"conditions":5292,"interventions":5294},"NCT04557137","Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia",[],"2022-09-01","2023-01-01","2020-09-01",[5293],"Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)",[5054],{"intervention":5296,"totalTrials":97,"cells":5297},"Citalopram",{"EARLY_PHASE1":5298,"PHASE1":5300,"PHASE2":5302,"PHASE3":5313,"PHASE4":5315,"NA":5317},{"trials":5299,"activeCount":101},[],{"trials":5301,"activeCount":101},[],{"trials":5303,"activeCount":101},[5304],{"nctId":5305,"briefTitle":5306,"status":438,"phases":5307,"primaryCompletion":5308,"completion":5308,"start":4320,"enrollment":5309,"conditions":5310,"interventions":5312},"NCT01937182","The Efficacy of Citalopram Treatment in Acute Stroke",[90],"2016-12-19",642,[5311],"Stroke, Ischemic",[5296],{"trials":5314,"activeCount":101},[],{"trials":5316,"activeCount":101},[],{"trials":5318,"activeCount":101},[5319],{"nctId":5320,"briefTitle":5321,"status":438,"phases":5322,"primaryCompletion":2875,"completion":2875,"start":5323,"enrollment":5324,"conditions":5325,"interventions":5327},"NCT01575158","Citalopram vs Clomipramine vs Placebo in Recurrent Depression",[93],"1997-10",59,[5326],"Depression",[5296,5328],"Clomipramine",{"intervention":5330,"totalTrials":97,"cells":5331},"Galactose",{"EARLY_PHASE1":5332,"PHASE1":5334,"PHASE2":5336,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[],{"trials":5343,"activeCount":101},[5344,5354],{"nctId":5345,"briefTitle":5346,"status":438,"phases":5347,"primaryCompletion":5348,"completion":5349,"start":4063,"enrollment":2730,"conditions":5350,"interventions":5352},"NCT02528461","Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C",[],"2019-01","2020-01",[5351],"Hepatitis C",[5330,5353],"Sofosbuvir",{"nctId":5355,"briefTitle":5356,"status":438,"phases":5357,"primaryCompletion":5358,"completion":3665,"start":1080,"enrollment":5359,"conditions":5360,"interventions":5362},"NCT02702765","sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis",[93],"2020-02",33,[5361],"Wilsons Disease",[5330],{"intervention":5364,"totalTrials":97,"cells":5365},"acetylsalicylic acid",{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[5378,5387],{"nctId":5379,"briefTitle":5380,"status":438,"phases":5381,"primaryCompletion":2588,"completion":2588,"start":5382,"enrollment":5383,"conditions":5384,"interventions":5386},"NCT00563875","Laboratory Aspirin Resistance in Diabetics and Non-Diabetics",[93],"2007-11",210,[5385],"Drug Resistance",[5364],{"nctId":5388,"briefTitle":5389,"status":438,"phases":5390,"completion":4707,"start":1367,"enrollment":374,"conditions":5391,"interventions":5392},"NCT00389129","Danish Aspirin Resistance Trial - Pilot Study",[93],[5385],[5364],{"intervention":2735,"totalTrials":97,"cells":5394},{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5401,"PHASE4":5403,"NA":5409},{"trials":5396,"activeCount":101},[],{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[],{"trials":5402,"activeCount":101},[],{"trials":5404,"activeCount":101},[5405],{"nctId":2724,"briefTitle":2725,"status":438,"phases":5406,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":2730,"conditions":5407,"interventions":5408},[92],[2732,2733],[2735,2711],{"trials":5410,"activeCount":101},[5411],{"nctId":5412,"briefTitle":5413,"status":438,"phases":5414,"primaryCompletion":5415,"completion":5416,"start":5417,"enrollment":427,"conditions":5418,"interventions":5419},"NCT06035081","CIRcadian Rhythms and CortisoL. Effects on Substrate Metabolism and Clock Gene Expression and Functioning",[93],"2024-04-13","2024-12-01","2023-09-15",[18],[2735],{"intervention":5421,"totalTrials":97,"cells":5422},"Valsartan",{"EARLY_PHASE1":5423,"PHASE1":5425,"PHASE2":5427,"PHASE3":5429,"PHASE4":5431,"NA":5440},{"trials":5424,"activeCount":101},[],{"trials":5426,"activeCount":101},[],{"trials":5428,"activeCount":101},[],{"trials":5430,"activeCount":101},[],{"trials":5432,"activeCount":101},[5433],{"nctId":5434,"briefTitle":5435,"status":438,"phases":5436,"primaryCompletion":5437,"completion":5437,"start":479,"enrollment":4918,"conditions":5438,"interventions":5439},"NCT02572960","Physiologic Interactions Between the Adrenal- and the Parathyroid Glands",[92],"2017-05",[332,1179,5263],[5421],{"trials":5441,"activeCount":101},[5442],{"nctId":5443,"briefTitle":5444,"status":487,"phases":5445,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":5446,"interventions":5448},"NCT00424801","Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris",[93],[5447,1909],"Microvascular Angina",[5449,5421,5450,5451,5452,5453,5454],"Lercanidipine","Nicorandil","Doxazosin","Moxonidin","Pindolol","Amiloride, hydrochlorothiazide",{"intervention":4992,"totalTrials":120,"cells":5456},{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5458,"activeCount":101},[],{"trials":5460,"activeCount":101},[],{"trials":5462,"activeCount":101},[],{"trials":5464,"activeCount":101},[],{"trials":5466,"activeCount":101},[],{"trials":5468,"activeCount":101},[5469],{"nctId":4985,"briefTitle":4986,"status":438,"phases":5470,"primaryCompletion":1090,"completion":1090,"start":1603,"enrollment":4988,"conditions":5471,"interventions":5472},[93],[4990],[4954,4992],{"intervention":5474,"totalTrials":120,"cells":5475},"estradiol",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5480,"PHASE3":5482,"PHASE4":5484,"NA":5486},{"trials":5477,"activeCount":101},[],{"trials":5479,"activeCount":101},[],{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[5488],{"nctId":5489,"briefTitle":5490,"status":438,"phases":5491,"completion":5492,"start":5493,"enrollment":545,"conditions":5494,"interventions":5496},"NCT00435175","Acute Metabolic Effects of Estradiol",[93],"2006-07","2005-06",[5495],"Postmenopause",[5474],{"intervention":5498,"totalTrials":120,"cells":5499},"NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70",{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5506,"PHASE4":5508,"NA":5510},{"trials":5501,"activeCount":101},[],{"trials":5503,"activeCount":101},[],{"trials":5505,"activeCount":101},[],{"trials":5507,"activeCount":101},[],{"trials":5509,"activeCount":101},[],{"trials":5511,"activeCount":101},[5512],{"nctId":5513,"briefTitle":5514,"status":438,"phases":5515,"completion":1272,"start":5141,"enrollment":1717,"conditions":5516,"interventions":5518},"NCT00283218","A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.",[93],[5517],"Type 1 Diabetes",[5498],{"intervention":5520,"totalTrials":120,"cells":5521},"Whey protein-complex",{"EARLY_PHASE1":5522,"PHASE1":5524,"PHASE2":5526,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5523,"activeCount":101},[],{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[],{"trials":5531,"activeCount":101},[],{"trials":5533,"activeCount":101},[5534],{"nctId":5535,"briefTitle":5536,"status":438,"phases":5537,"primaryCompletion":5538,"completion":5538,"start":5539,"enrollment":2589,"conditions":5540,"interventions":5541},"NCT03783273","The Influence of Food Matrix Delivery System on the Bioavailability of Vitamin D3",[93],"2020-05-26","2019-01-08",[1179],[5520],{"intervention":5543,"totalTrials":120,"cells":5544},"Tele Rehab",{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5549,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5546,"activeCount":101},[],{"trials":5548,"activeCount":101},[],{"trials":5550,"activeCount":101},[],{"trials":5552,"activeCount":101},[],{"trials":5554,"activeCount":101},[],{"trials":5556,"activeCount":101},[5557],{"nctId":5558,"briefTitle":5559,"status":476,"phases":5560,"primaryCompletion":5561,"completion":5562,"start":5563,"enrollment":1604,"conditions":5564,"interventions":5565},"NCT03569384","Feasibility & Effect of a Tele-rehabilitation Program for Chronic Obstructive Pulmonary Disease vs. Standard Rehabilitation",[93],"2019-03-30","2020-03-31","2017-03-01",[1226],[5543],{"intervention":5567,"totalTrials":120,"cells":5568},"Glucagon-like-peptide-1 (7-36) amide",{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5570,"activeCount":101},[],{"trials":5572,"activeCount":101},[],{"trials":5574,"activeCount":101},[],{"trials":5576,"activeCount":101},[],{"trials":5578,"activeCount":101},[],{"trials":5580,"activeCount":101},[5581],{"nctId":5582,"briefTitle":5583,"status":438,"phases":5584,"primaryCompletion":3325,"completion":3519,"start":5585,"enrollment":545,"conditions":5586,"interventions":5587},"NCT00285896","GLP-1 Infusion and Long-Time Fasting",[93],"2005-12",[21],[5567],{"intervention":5589,"totalTrials":120,"cells":5590},"Combined Vancomycin and Gentamycin and Meropenem",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5597,"PHASE4":5599,"NA":5601},{"trials":5592,"activeCount":101},[],{"trials":5594,"activeCount":101},[],{"trials":5596,"activeCount":101},[],{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":101},[],{"trials":5602,"activeCount":101},[5603],{"nctId":5604,"briefTitle":5605,"status":438,"phases":5606,"primaryCompletion":5607,"completion":5608,"start":4369,"enrollment":2020,"conditions":5609,"interventions":5611},"NCT03157388","The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis.",[93],"2018-06-01","2018-12-01",[5610],"Alcoholic Hepatitis",[5589],{"intervention":5613,"totalTrials":120,"cells":5614},"ketone",{"EARLY_PHASE1":5615,"PHASE1":5617,"PHASE2":5619,"PHASE3":5621,"PHASE4":5623,"NA":5625},{"trials":5616,"activeCount":101},[],{"trials":5618,"activeCount":101},[],{"trials":5620,"activeCount":101},[],{"trials":5622,"activeCount":101},[],{"trials":5624,"activeCount":101},[],{"trials":5626,"activeCount":101},[5627],{"nctId":5628,"briefTitle":5629,"status":438,"phases":5630,"primaryCompletion":2538,"completion":2538,"start":490,"enrollment":3867,"conditions":5631,"interventions":5633},"NCT02357550","Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study",[93],[536,5632],"Brain Metabolism",[5613],{"intervention":5025,"totalTrials":120,"cells":5635},{"EARLY_PHASE1":5636,"PHASE1":5638,"PHASE2":5640,"PHASE3":5642,"PHASE4":5644,"NA":5646},{"trials":5637,"activeCount":101},[],{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[],{"trials":5645,"activeCount":101},[],{"trials":5647,"activeCount":101},[5648],{"nctId":5017,"briefTitle":5018,"status":438,"phases":5649,"primaryCompletion":5020,"completion":5020,"start":1175,"enrollment":3867,"conditions":5650,"interventions":5651},[93],[5022,5023],[4994,5025],{"intervention":5653,"totalTrials":120,"cells":5654},"Somatostatin",{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5659,"PHASE3":5661,"PHASE4":5663,"NA":5665},{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":101},[],{"trials":5662,"activeCount":101},[],{"trials":5664,"activeCount":101},[],{"trials":5666,"activeCount":101},[5667],{"nctId":5668,"briefTitle":5669,"status":438,"phases":5670,"primaryCompletion":3280,"completion":3280,"start":4001,"enrollment":545,"conditions":5671,"interventions":5672},"NCT01062529","Peripheral Metabolic Effects of Somatostatin",[93],[2616,4782,2425],[5653],{"intervention":5674,"totalTrials":120,"cells":5675},"Oral Sodium Lactate",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5682,"PHASE4":5684,"NA":5686},{"trials":5677,"activeCount":101},[],{"trials":5679,"activeCount":101},[],{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[],{"trials":5685,"activeCount":101},[],{"trials":5687,"activeCount":101},[5688],{"nctId":5689,"briefTitle":5690,"status":438,"phases":5691,"primaryCompletion":5692,"completion":5692,"start":5693,"enrollment":427,"conditions":5694,"interventions":5697},"NCT04299815","Lactate in the Gut",[93],"2020-07-29","2020-04-01",[5695,18,5696],"Lactate","Hyperlactatemia",[5674,5698],"Intravenous sodium lactate",{"intervention":5698,"totalTrials":120,"cells":5700},{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5705,"PHASE3":5707,"PHASE4":5709,"NA":5711},{"trials":5702,"activeCount":101},[],{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[],{"trials":5708,"activeCount":101},[],{"trials":5710,"activeCount":101},[],{"trials":5712,"activeCount":101},[5713],{"nctId":5689,"briefTitle":5690,"status":438,"phases":5714,"primaryCompletion":5692,"completion":5692,"start":5693,"enrollment":427,"conditions":5715,"interventions":5716},[93],[5695,18,5696],[5674,5698],{"intervention":5718,"totalTrials":120,"cells":5719},"Magnesium Sulfate",{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5724,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":101},[],{"trials":5725,"activeCount":101},[],{"trials":5727,"activeCount":101},[],{"trials":5729,"activeCount":101},[],{"trials":5731,"activeCount":101},[5732],{"nctId":5733,"briefTitle":5734,"status":438,"phases":5735,"primaryCompletion":4321,"completion":4321,"start":1223,"enrollment":427,"conditions":5736,"interventions":5738},"NCT01113138","Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers",[93],[1720,5737],"Chronic Obstructive Pulmonary Disease",[5718],{"intervention":5740,"totalTrials":120,"cells":5741},"methylprednisolone",{"EARLY_PHASE1":5742,"PHASE1":5744,"PHASE2":5746,"PHASE3":5748,"PHASE4":5750,"NA":5752},{"trials":5743,"activeCount":101},[],{"trials":5745,"activeCount":101},[],{"trials":5747,"activeCount":101},[],{"trials":5749,"activeCount":101},[],{"trials":5751,"activeCount":101},[],{"trials":5753,"activeCount":101},[5754],{"nctId":5755,"briefTitle":5756,"status":438,"phases":5757,"primaryCompletion":2107,"completion":2107,"start":4392,"enrollment":5758,"conditions":5759,"interventions":5760},"NCT00805298","Assessment of the Operative Course in Connection With Removal of Lower Third Molars",[93],154,[469,787],[5740,5761,5762],"xyloplyin adrenalin","marcain adrenalin",{"intervention":5761,"totalTrials":120,"cells":5764},{"EARLY_PHASE1":5765,"PHASE1":5767,"PHASE2":5769,"PHASE3":5771,"PHASE4":5773,"NA":5775},{"trials":5766,"activeCount":101},[],{"trials":5768,"activeCount":101},[],{"trials":5770,"activeCount":101},[],{"trials":5772,"activeCount":101},[],{"trials":5774,"activeCount":101},[],{"trials":5776,"activeCount":101},[5777],{"nctId":5755,"briefTitle":5756,"status":438,"phases":5778,"primaryCompletion":2107,"completion":2107,"start":4392,"enrollment":5758,"conditions":5779,"interventions":5780},[93],[469,787],[5740,5761,5762],{"intervention":5762,"totalTrials":120,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5789,"PHASE4":5791,"NA":5793},{"trials":5784,"activeCount":101},[],{"trials":5786,"activeCount":101},[],{"trials":5788,"activeCount":101},[],{"trials":5790,"activeCount":101},[],{"trials":5792,"activeCount":101},[],{"trials":5794,"activeCount":101},[5795],{"nctId":5755,"briefTitle":5756,"status":438,"phases":5796,"primaryCompletion":2107,"completion":2107,"start":4392,"enrollment":5758,"conditions":5797,"interventions":5798},[93],[469,787],[5740,5761,5762],{"intervention":5800,"totalTrials":120,"cells":5801},"E. coli endotoxin, US standard",{"EARLY_PHASE1":5802,"PHASE1":5804,"PHASE2":5806,"PHASE3":5808,"PHASE4":5810,"NA":5812},{"trials":5803,"activeCount":101},[],{"trials":5805,"activeCount":101},[],{"trials":5807,"activeCount":101},[],{"trials":5809,"activeCount":101},[],{"trials":5811,"activeCount":101},[],{"trials":5813,"activeCount":101},[5814],{"nctId":5815,"briefTitle":5816,"status":438,"phases":5817,"primaryCompletion":3075,"completion":3075,"start":3442,"enrollment":545,"conditions":5818,"interventions":5820},"NCT01705782","The Effects of Amino Acid Supplement During Acute Inflammation.",[93],[5819,787,4756],"Febrile Illness Acute",[5800],{"intervention":5822,"totalTrials":120,"cells":5823},"GH hormone",{"EARLY_PHASE1":5824,"PHASE1":5826,"PHASE2":5828,"PHASE3":5830,"PHASE4":5832,"NA":5834},{"trials":5825,"activeCount":101},[],{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[],{"trials":5831,"activeCount":101},[],{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":101},[5836],{"nctId":5837,"briefTitle":5838,"status":438,"phases":5839,"primaryCompletion":510,"completion":510,"start":1648,"enrollment":427,"conditions":5840,"interventions":5841},"NCT01209429","Importance of the GH\u002FIGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction",[93],[18],[5822],{"intervention":5843,"totalTrials":120,"cells":5844},"oestrogen",{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5851,"PHASE4":5853,"NA":5855},{"trials":5846,"activeCount":101},[],{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"trials":5854,"activeCount":101},[],{"trials":5856,"activeCount":101},[5857],{"nctId":5858,"briefTitle":5859,"status":438,"phases":5860,"completion":5861,"start":5862,"enrollment":5863,"conditions":5864,"interventions":5865},"NCT00572390","Oestrogen Withdrawal in Hypopituitary Women",[93],"2002-02","2001-01",38,[4723],[5843],{"intervention":5867,"totalTrials":120,"cells":5868},"recombinant human erythropoietin",{"EARLY_PHASE1":5869,"PHASE1":5871,"PHASE2":5873,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5870,"activeCount":101},[],{"trials":5872,"activeCount":101},[],{"trials":5874,"activeCount":101},[],{"trials":5876,"activeCount":101},[],{"trials":5878,"activeCount":101},[],{"trials":5880,"activeCount":101},[5881],{"nctId":5882,"briefTitle":5883,"status":438,"phases":5884,"primaryCompletion":1189,"completion":1189,"start":1830,"enrollment":5885,"conditions":5886,"interventions":5888},"NCT01320449","Identification of New Serum Markers for Detection of Abuse With Erythropoietin",[93],35,[5887],"Substance Abuse Problem",[5867],{"intervention":5890,"totalTrials":120,"cells":5891},"Trichuris trichiura eggs",{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5898,"PHASE4":5900,"NA":5902},{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[],{"trials":5899,"activeCount":101},[],{"trials":5901,"activeCount":101},[],{"trials":5903,"activeCount":101},[5904],{"nctId":5905,"briefTitle":5906,"status":438,"phases":5907,"primaryCompletion":1223,"completion":1223,"start":3193,"enrollment":120,"conditions":5908,"interventions":5912},"NCT02399683","Immune Modulation From Trichuris Trichiura",[],[5909,5910,5911],"Crohn Disease","Colitis, Ulcerative","Intestinal Helminthiasis",[5890],{"intervention":5914,"totalTrials":120,"cells":5915},"biological treatment",{"EARLY_PHASE1":5916,"PHASE1":5918,"PHASE2":5920,"PHASE3":5922,"PHASE4":5924,"NA":5926},{"trials":5917,"activeCount":101},[],{"trials":5919,"activeCount":101},[],{"trials":5921,"activeCount":101},[],{"trials":5923,"activeCount":101},[],{"trials":5925,"activeCount":101},[],{"trials":5927,"activeCount":101},[5928],{"nctId":5929,"briefTitle":5930,"status":438,"phases":5931,"primaryCompletion":489,"completion":5932,"start":3279,"enrollment":4870,"conditions":5933,"interventions":5937},"NCT01356758","Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents",[],"2015-11",[5934,5935,5936],"Psoriasis","Atopic Dermatitis","Atherosclerosis",[5914],{"intervention":5939,"totalTrials":120,"cells":5940},"hydrocortisone substitution therapy versus withdrawal",{"EARLY_PHASE1":5941,"PHASE1":5943,"PHASE2":5945,"PHASE3":5947,"PHASE4":5949,"NA":5951},{"trials":5942,"activeCount":101},[],{"trials":5944,"activeCount":101},[],{"trials":5946,"activeCount":101},[],{"trials":5948,"activeCount":101},[],{"trials":5950,"activeCount":101},[],{"trials":5952,"activeCount":101},[5953],{"nctId":5954,"briefTitle":5955,"status":438,"phases":5956,"completion":1691,"start":5957,"enrollment":427,"conditions":5958,"interventions":5960},"NCT00442390","Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure",[93],"2002-01",[5959],"Addison Syndrome",[5939],{"intervention":5962,"totalTrials":120,"cells":5963},"Trichuris trichiura",{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[],{"trials":5969,"activeCount":101},[],{"trials":5971,"activeCount":101},[],{"trials":5973,"activeCount":101},[],{"trials":5975,"activeCount":101},[5976],{"nctId":5977,"briefTitle":5978,"status":438,"phases":5979,"primaryCompletion":603,"completion":603,"start":5980,"enrollment":120,"conditions":5981,"interventions":5984},"NCT04227925","The Longevity of Trichuris Trichiura Colonization",[],"2013-04-08",[5982,5983],"Helminthiasis","Helminth Infection",[5962],{"intervention":5986,"totalTrials":120,"cells":5987},"Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo",{"EARLY_PHASE1":5988,"PHASE1":5990,"PHASE2":5992,"PHASE3":5994,"PHASE4":5996,"NA":5998},{"trials":5989,"activeCount":101},[],{"trials":5991,"activeCount":101},[],{"trials":5993,"activeCount":101},[],{"trials":5995,"activeCount":101},[],{"trials":5997,"activeCount":101},[],{"trials":5999,"activeCount":101},[6000],{"nctId":6001,"briefTitle":6002,"status":438,"phases":6003,"primaryCompletion":2943,"completion":2943,"start":2875,"enrollment":467,"conditions":6004,"interventions":6006},"NCT00613288","Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism",[93],[6005],"Hypogonadism",[5986],{"intervention":6008,"totalTrials":120,"cells":6009},"Latanoprost, diclofenac and dorzolamide",{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6020},{"trials":6011,"activeCount":101},[],{"trials":6013,"activeCount":101},[],{"trials":6015,"activeCount":101},[],{"trials":6017,"activeCount":101},[],{"trials":6019,"activeCount":101},[],{"trials":6021,"activeCount":101},[6022],{"nctId":6023,"briefTitle":6024,"status":438,"phases":6025,"primaryCompletion":2942,"completion":2942,"start":2875,"enrollment":6026,"conditions":6027,"interventions":6028},"NCT00619034","Pharmacological Intervention in Diabetic Retinopathy",[93],87,[2109],[6008,6029,6030],"Diclofenac","Dorzolamide",{"intervention":6029,"totalTrials":120,"cells":6032},{"EARLY_PHASE1":6033,"PHASE1":6035,"PHASE2":6037,"PHASE3":6039,"PHASE4":6041,"NA":6043},{"trials":6034,"activeCount":101},[],{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":101},[],{"trials":6040,"activeCount":101},[],{"trials":6042,"activeCount":101},[],{"trials":6044,"activeCount":101},[6045],{"nctId":6023,"briefTitle":6024,"status":438,"phases":6046,"primaryCompletion":2942,"completion":2942,"start":2875,"enrollment":6026,"conditions":6047,"interventions":6048},[93],[2109],[6008,6029,6030],{"intervention":6030,"totalTrials":120,"cells":6050},{"EARLY_PHASE1":6051,"PHASE1":6053,"PHASE2":6055,"PHASE3":6057,"PHASE4":6059,"NA":6061},{"trials":6052,"activeCount":101},[],{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[],{"trials":6058,"activeCount":101},[],{"trials":6060,"activeCount":101},[],{"trials":6062,"activeCount":101},[6063],{"nctId":6023,"briefTitle":6024,"status":438,"phases":6064,"primaryCompletion":2942,"completion":2942,"start":2875,"enrollment":6026,"conditions":6065,"interventions":6066},[93],[2109],[6008,6029,6030],{"intervention":6068,"totalTrials":120,"cells":6069},"COX-inhibitor",{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6074,"PHASE3":6076,"PHASE4":6078,"NA":6080},{"trials":6071,"activeCount":101},[],{"trials":6073,"activeCount":101},[],{"trials":6075,"activeCount":101},[],{"trials":6077,"activeCount":101},[],{"trials":6079,"activeCount":101},[],{"trials":6081,"activeCount":101},[6082],{"nctId":6083,"briefTitle":6084,"status":438,"phases":6085,"primaryCompletion":2235,"completion":4971,"start":1904,"enrollment":28,"conditions":6086,"interventions":6088},"NCT02059018","The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia",[93],[6087],"Retinal Hypoxia",[6068,6089,6090],"Nitroglycerin","COX-inhibitor + Nitroglycerin",{"intervention":6089,"totalTrials":120,"cells":6092},{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6101,"NA":6103},{"trials":6094,"activeCount":101},[],{"trials":6096,"activeCount":101},[],{"trials":6098,"activeCount":101},[],{"trials":6100,"activeCount":101},[],{"trials":6102,"activeCount":101},[],{"trials":6104,"activeCount":101},[6105],{"nctId":6083,"briefTitle":6084,"status":438,"phases":6106,"primaryCompletion":2235,"completion":4971,"start":1904,"enrollment":28,"conditions":6107,"interventions":6108},[93],[6087],[6068,6089,6090],{"intervention":6090,"totalTrials":120,"cells":6110},{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6117,"PHASE4":6119,"NA":6121},{"trials":6112,"activeCount":101},[],{"trials":6114,"activeCount":101},[],{"trials":6116,"activeCount":101},[],{"trials":6118,"activeCount":101},[],{"trials":6120,"activeCount":101},[],{"trials":6122,"activeCount":101},[6123],{"nctId":6083,"briefTitle":6084,"status":438,"phases":6124,"primaryCompletion":2235,"completion":4971,"start":1904,"enrollment":28,"conditions":6125,"interventions":6126},[93],[6087],[6068,6089,6090],{"intervention":6128,"totalTrials":120,"cells":6129},"Icodextrin",{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6136,"PHASE4":6138,"NA":6140},{"trials":6131,"activeCount":101},[],{"trials":6133,"activeCount":101},[],{"trials":6135,"activeCount":101},[],{"trials":6137,"activeCount":101},[],{"trials":6139,"activeCount":101},[],{"trials":6141,"activeCount":101},[6142],{"nctId":6143,"briefTitle":6144,"status":487,"phases":6145,"primaryCompletion":3823,"completion":1119,"start":5141,"enrollment":2020,"conditions":6146,"interventions":6148},"NCT00119990","Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis",[93],[6147],"Peritoneal Dialysis",[6128,6149],"Physioneal (dialysate) 1.36% and 2.27%",{"intervention":6149,"totalTrials":120,"cells":6151},{"EARLY_PHASE1":6152,"PHASE1":6154,"PHASE2":6156,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6153,"activeCount":101},[],{"trials":6155,"activeCount":101},[],{"trials":6157,"activeCount":101},[],{"trials":6159,"activeCount":101},[],{"trials":6161,"activeCount":101},[],{"trials":6163,"activeCount":101},[6164],{"nctId":6143,"briefTitle":6144,"status":487,"phases":6165,"primaryCompletion":3823,"completion":1119,"start":5141,"enrollment":2020,"conditions":6166,"interventions":6167},[93],[6147],[6128,6149],{"intervention":6169,"totalTrials":120,"cells":6170},"Genotropin miniquick 0.5 mg,",{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6177,"PHASE4":6179,"NA":6181},{"trials":6172,"activeCount":101},[],{"trials":6174,"activeCount":101},[],{"trials":6176,"activeCount":101},[],{"trials":6178,"activeCount":101},[],{"trials":6180,"activeCount":101},[],{"trials":6182,"activeCount":101},[6183],{"nctId":6184,"briefTitle":6185,"status":476,"phases":6186,"primaryCompletion":6187,"completion":3544,"start":6188,"enrollment":467,"conditions":6189,"interventions":6190},"NCT03878992","Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle",[93],"2021-03-01","2019-04-30",[4782,4799],[6169],{"intervention":6192,"totalTrials":120,"cells":6193},"Propranololhydrochlorid",{"EARLY_PHASE1":6194,"PHASE1":6196,"PHASE2":6198,"PHASE3":6200,"PHASE4":6202,"NA":6204},{"trials":6195,"activeCount":101},[],{"trials":6197,"activeCount":101},[],{"trials":6199,"activeCount":101},[],{"trials":6201,"activeCount":101},[],{"trials":6203,"activeCount":101},[],{"trials":6205,"activeCount":101},[6206],{"nctId":6207,"briefTitle":6208,"status":476,"phases":6209,"primaryCompletion":4322,"completion":4322,"start":1830,"enrollment":36,"conditions":6210,"interventions":6213},"NCT01333150","Effect of Propranolol on the Autonomic Nervous System and Muscle Pain",[93],[6211,6212],"Temporomandibular Joint Disorders","Myofascial Temporomandibular Disorders",[6192],{"intervention":6215,"totalTrials":120,"cells":6216},"LPS",{"EARLY_PHASE1":6217,"PHASE1":6219,"PHASE2":6221,"PHASE3":6223,"PHASE4":6225,"NA":6227},{"trials":6218,"activeCount":101},[],{"trials":6220,"activeCount":101},[],{"trials":6222,"activeCount":101},[],{"trials":6224,"activeCount":101},[],{"trials":6226,"activeCount":101},[],{"trials":6228,"activeCount":101},[6229],{"nctId":6230,"briefTitle":6231,"status":438,"phases":6232,"primaryCompletion":490,"completion":489,"start":3587,"enrollment":3867,"conditions":6233,"interventions":6236},"NCT02157155","A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis",[93],[6234,6235],"Ketoacidosis","Diabetes Mellitus Type 1",[6215],{"intervention":6238,"totalTrials":120,"cells":6239},"Systematic aerobic training",{"EARLY_PHASE1":6240,"PHASE1":6242,"PHASE2":6244,"PHASE3":6246,"PHASE4":6248,"NA":6250},{"trials":6241,"activeCount":101},[],{"trials":6243,"activeCount":101},[],{"trials":6245,"activeCount":101},[],{"trials":6247,"activeCount":101},[],{"trials":6249,"activeCount":101},[],{"trials":6251,"activeCount":101},[6252],{"nctId":6253,"briefTitle":6254,"status":438,"phases":6255,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":783,"conditions":6258,"interventions":6259},"NCT04913012","Exercise Booster Sessions in People With Multiple Sclerosis",[93],"2024-10-04","2021-08-01",[35],[6238,6260,6261,6262],"Systematic resistance training","Aerobic training booster sessions","Resistance training booster sessions",{"intervention":6260,"totalTrials":120,"cells":6264},{"EARLY_PHASE1":6265,"PHASE1":6267,"PHASE2":6269,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6266,"activeCount":101},[],{"trials":6268,"activeCount":101},[],{"trials":6270,"activeCount":101},[],{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[],{"trials":6276,"activeCount":101},[6277],{"nctId":6253,"briefTitle":6254,"status":438,"phases":6278,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":783,"conditions":6279,"interventions":6280},[93],[35],[6238,6260,6261,6262],{"intervention":6261,"totalTrials":120,"cells":6282},{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6287,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6284,"activeCount":101},[],{"trials":6286,"activeCount":101},[],{"trials":6288,"activeCount":101},[],{"trials":6290,"activeCount":101},[],{"trials":6292,"activeCount":101},[],{"trials":6294,"activeCount":101},[6295],{"nctId":6253,"briefTitle":6254,"status":438,"phases":6296,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":783,"conditions":6297,"interventions":6298},[93],[35],[6238,6260,6261,6262],{"intervention":6262,"totalTrials":120,"cells":6300},{"EARLY_PHASE1":6301,"PHASE1":6303,"PHASE2":6305,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6302,"activeCount":101},[],{"trials":6304,"activeCount":101},[],{"trials":6306,"activeCount":101},[],{"trials":6308,"activeCount":101},[],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[6313],{"nctId":6253,"briefTitle":6254,"status":438,"phases":6314,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":783,"conditions":6315,"interventions":6316},[93],[35],[6238,6260,6261,6262],{"intervention":6318,"totalTrials":120,"cells":6319},"3-hydroxybutyrate",{"EARLY_PHASE1":6320,"PHASE1":6322,"PHASE2":6324,"PHASE3":6326,"PHASE4":6328,"NA":6330},{"trials":6321,"activeCount":101},[],{"trials":6323,"activeCount":101},[],{"trials":6325,"activeCount":101},[],{"trials":6327,"activeCount":101},[],{"trials":6329,"activeCount":101},[],{"trials":6331,"activeCount":101},[6332],{"nctId":6333,"briefTitle":6334,"status":438,"phases":6335,"primaryCompletion":6336,"completion":6336,"start":6337,"enrollment":28,"conditions":6338,"interventions":6340},"NCT04656236","Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls",[93],"2022-03-01","2021-01-01",[1286,6339],"Diabetic Ketoacidosis",[6318],{"intervention":6342,"totalTrials":120,"cells":6343},"ReFacto (Recombinant factor VIII) and Tranexamic acid",{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6348,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6345,"activeCount":101},[],{"trials":6347,"activeCount":101},[],{"trials":6349,"activeCount":101},[],{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[6356],{"nctId":6357,"briefTitle":6358,"status":438,"phases":6359,"completion":3910,"start":5141,"enrollment":545,"conditions":6360,"interventions":6362},"NCT00279578","Clot Formation and Clot Stability in Patients With Severe Haemophilia A",[93],[6361],"Hemophilia A",[6342],{"intervention":6364,"totalTrials":120,"cells":6365},"Protein C deficiency",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6374,"NA":6376},{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[],{"trials":6371,"activeCount":101},[],{"trials":6373,"activeCount":101},[],{"trials":6375,"activeCount":101},[],{"trials":6377,"activeCount":101},[6378],{"nctId":6379,"briefTitle":6380,"status":476,"phases":6381,"primaryCompletion":6382,"completion":6383,"start":5349,"enrollment":374,"conditions":6384,"interventions":6386},"NCT04180657","Ghrelin Levels in Patients With Protein C Deficiency",[],"2020-04","2020-07",[6385],"Protein C Deficiency",[6364],{"intervention":6388,"totalTrials":120,"cells":6389},"Suprasensory",{"EARLY_PHASE1":6390,"PHASE1":6392,"PHASE2":6394,"PHASE3":6396,"PHASE4":6398,"NA":6400},{"trials":6391,"activeCount":101},[],{"trials":6393,"activeCount":101},[],{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[],{"trials":6399,"activeCount":101},[],{"trials":6401,"activeCount":101},[6402],{"nctId":6403,"briefTitle":6404,"status":438,"phases":6405,"primaryCompletion":6406,"completion":6406,"start":4320,"enrollment":25,"conditions":6407,"interventions":6409},"NCT01948973","Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome",[93],"2018-03",[6408],"Irritable Bowel Syndrome",[6388],{"intervention":6411,"totalTrials":120,"cells":6412},"Serdolect",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6419,"PHASE4":6421,"NA":6423},{"trials":6414,"activeCount":101},[],{"trials":6416,"activeCount":101},[],{"trials":6418,"activeCount":101},[],{"trials":6420,"activeCount":101},[],{"trials":6422,"activeCount":101},[],{"trials":6424,"activeCount":101},[6425],{"nctId":6426,"briefTitle":6427,"status":438,"phases":6428,"primaryCompletion":1648,"completion":1648,"start":2966,"enrollment":2131,"conditions":6429,"interventions":6430},"NCT00345982","Augmenting Clozapine With Sertindole - SERCLOZ",[93],[1606],[6411],{"intervention":6432,"totalTrials":120,"cells":6433},"Dimethyl Malonate",{"EARLY_PHASE1":6434,"PHASE1":6436,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6435,"activeCount":101},[],{"trials":6437,"activeCount":101},[],{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[],{"trials":6443,"activeCount":101},[],{"trials":6445,"activeCount":101},[6446],{"nctId":6447,"briefTitle":6448,"status":438,"phases":6449,"primaryCompletion":6450,"completion":6450,"start":501,"enrollment":6451,"conditions":6452,"interventions":6454},"NCT02993484","The Role of Mitochondrial Respiration in the Cardioprotective Capacity of IPC in Diabetic and Non-diabetic Patients",[93],"2019-02-01",39,[6453],"Reperfusion Injuries, Myocardial",[6432,6455],"Ischemic preconditioning",{"intervention":6455,"totalTrials":120,"cells":6457},{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6462,"PHASE3":6464,"PHASE4":6466,"NA":6468},{"trials":6459,"activeCount":101},[],{"trials":6461,"activeCount":101},[],{"trials":6463,"activeCount":101},[],{"trials":6465,"activeCount":101},[],{"trials":6467,"activeCount":101},[],{"trials":6469,"activeCount":101},[6470],{"nctId":6447,"briefTitle":6448,"status":438,"phases":6471,"primaryCompletion":6450,"completion":6450,"start":501,"enrollment":6451,"conditions":6472,"interventions":6473},[93],[6453],[6432,6455],{"intervention":6475,"totalTrials":120,"cells":6476},"Cyclosporine A",{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6481,"PHASE3":6483,"PHASE4":6485,"NA":6487},{"trials":6478,"activeCount":101},[],{"trials":6480,"activeCount":101},[],{"trials":6482,"activeCount":101},[],{"trials":6484,"activeCount":101},[],{"trials":6486,"activeCount":101},[],{"trials":6488,"activeCount":101},[6489],{"nctId":6490,"briefTitle":6491,"status":438,"phases":6492,"primaryCompletion":6493,"completion":1951,"start":6494,"enrollment":28,"conditions":6495,"interventions":6496},"NCT02226068","Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis",[93],"2003-08","2002-06",[5935],[6475],{"intervention":6498,"totalTrials":120,"cells":6499},"Polyethylene Glycols",{"EARLY_PHASE1":6500,"PHASE1":6502,"PHASE2":6504,"PHASE3":6506,"PHASE4":6508,"NA":6510},{"trials":6501,"activeCount":101},[],{"trials":6503,"activeCount":101},[],{"trials":6505,"activeCount":101},[],{"trials":6507,"activeCount":101},[],{"trials":6509,"activeCount":101},[],{"trials":6511,"activeCount":101},[6512],{"nctId":6513,"briefTitle":6514,"status":438,"phases":6515,"primaryCompletion":6516,"completion":6516,"start":867,"enrollment":2131,"conditions":6517,"interventions":6520},"NCT05570318","Effect of MiniGo As Add-on to Oral Laxatives for Children with Constipation and Fecal Incontinence",[93],"2024-08-20",[6518,6519],"Functional Constipation","Fecal Incontinence in Children",[6498],{"intervention":4802,"totalTrials":120,"cells":6522},{"EARLY_PHASE1":6523,"PHASE1":6525,"PHASE2":6527,"PHASE3":6529,"PHASE4":6531,"NA":6533},{"trials":6524,"activeCount":101},[],{"trials":6526,"activeCount":101},[],{"trials":6528,"activeCount":101},[],{"trials":6530,"activeCount":101},[],{"trials":6532,"activeCount":101},[],{"trials":6534,"activeCount":101},[6535],{"nctId":4792,"briefTitle":4793,"status":438,"phases":6536,"primaryCompletion":4795,"completion":4796,"start":4797,"enrollment":3867,"conditions":6537,"interventions":6538},[93],[4756,4799],[4801,4802],{"intervention":5328,"totalTrials":120,"cells":6540},{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6547,"PHASE4":6549,"NA":6551},{"trials":6542,"activeCount":101},[],{"trials":6544,"activeCount":101},[],{"trials":6546,"activeCount":101},[],{"trials":6548,"activeCount":101},[],{"trials":6550,"activeCount":101},[],{"trials":6552,"activeCount":101},[6553],{"nctId":5320,"briefTitle":5321,"status":438,"phases":6554,"primaryCompletion":2875,"completion":2875,"start":5323,"enrollment":5324,"conditions":6555,"interventions":6556},[93],[5326],[5296,5328],{"intervention":4810,"totalTrials":120,"cells":6558},{"EARLY_PHASE1":6559,"PHASE1":6561,"PHASE2":6563,"PHASE3":6565,"PHASE4":6567,"NA":6569},{"trials":6560,"activeCount":101},[],{"trials":6562,"activeCount":101},[],{"trials":6564,"activeCount":101},[],{"trials":6566,"activeCount":101},[],{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[6571],{"nctId":4804,"briefTitle":4805,"status":438,"phases":6572,"primaryCompletion":3075,"completion":3075,"start":4807,"enrollment":3194,"conditions":6573,"interventions":6574},[93],[18],[4762,4810],{"intervention":6576,"totalTrials":120,"cells":6577},"Treatment with anti-STI and anti-schistosoma regimens",{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6579,"activeCount":101},[],{"trials":6581,"activeCount":101},[],{"trials":6583,"activeCount":101},[],{"trials":6585,"activeCount":101},[],{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[6590],{"nctId":6591,"briefTitle":6592,"status":438,"phases":6593,"primaryCompletion":6594,"completion":6595,"start":6596,"enrollment":6597,"conditions":6598,"interventions":6601},"NCT00713999","Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar",[93],"2002-04","2003-09","2001-08",680,[6599,6600],"Sexually Transmitted Infections","Schistosoma Haematobium",[6576],{"intervention":6603,"totalTrials":120,"cells":6604},"Bisoprolol",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6609,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6606,"activeCount":101},[],{"trials":6608,"activeCount":101},[],{"trials":6610,"activeCount":101},[],{"trials":6612,"activeCount":101},[],{"trials":6614,"activeCount":101},[],{"trials":6616,"activeCount":101},[6617],{"nctId":6618,"briefTitle":6619,"status":438,"phases":6620,"primaryCompletion":501,"completion":501,"start":3030,"enrollment":25,"conditions":6621,"interventions":6623},"NCT00882856","Treating Clozapine-induced Sinustachycardia With Bisoprolol",[93],[6622],"Clozapine-induced Sinustachycardia",[6603],{"intervention":5353,"totalTrials":120,"cells":6625},{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6630,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6627,"activeCount":101},[],{"trials":6629,"activeCount":101},[],{"trials":6631,"activeCount":101},[],{"trials":6633,"activeCount":101},[],{"trials":6635,"activeCount":101},[],{"trials":6637,"activeCount":101},[6638],{"nctId":5345,"briefTitle":5346,"status":438,"phases":6639,"primaryCompletion":5348,"completion":5349,"start":4063,"enrollment":2730,"conditions":6640,"interventions":6641},[],[5351],[5330,5353],{"intervention":6643,"totalTrials":120,"cells":6644},"Sorafenib",{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6651,"PHASE4":6653,"NA":6655},{"trials":6646,"activeCount":101},[],{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[],{"trials":6652,"activeCount":101},[],{"trials":6654,"activeCount":101},[],{"trials":6656,"activeCount":101},[6657],{"nctId":6658,"briefTitle":6659,"status":438,"phases":6660,"primaryCompletion":6661,"completion":6661,"start":521,"enrollment":6662,"conditions":6663,"interventions":6666},"NCT02973204","Circulating Tumor Cells and Tumor DNA in HCC and NET",[],"2020-01-08",167,[6664,6665],"Carcinoma, Hepatocellular","Neuroendocrine Tumors",[6643,6667,6668],"Everolimus","Lanreotide",{"intervention":6667,"totalTrials":120,"cells":6670},{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6675,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6672,"activeCount":101},[],{"trials":6674,"activeCount":101},[],{"trials":6676,"activeCount":101},[],{"trials":6678,"activeCount":101},[],{"trials":6680,"activeCount":101},[],{"trials":6682,"activeCount":101},[6683],{"nctId":6658,"briefTitle":6659,"status":438,"phases":6684,"primaryCompletion":6661,"completion":6661,"start":521,"enrollment":6662,"conditions":6685,"interventions":6686},[],[6664,6665],[6643,6667,6668],{"intervention":6668,"totalTrials":120,"cells":6688},{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6693,"PHASE3":6695,"PHASE4":6697,"NA":6699},{"trials":6690,"activeCount":101},[],{"trials":6692,"activeCount":101},[],{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[],{"trials":6698,"activeCount":101},[],{"trials":6700,"activeCount":101},[6701],{"nctId":6658,"briefTitle":6659,"status":438,"phases":6702,"primaryCompletion":6661,"completion":6661,"start":521,"enrollment":6662,"conditions":6703,"interventions":6704},[],[6664,6665],[6643,6667,6668],{"intervention":6706,"totalTrials":120,"cells":6707},"Nitrousoxide-oxygen and atmospheric air",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6714,"PHASE4":6716,"NA":6718},{"trials":6709,"activeCount":101},[],{"trials":6711,"activeCount":101},[],{"trials":6713,"activeCount":101},[],{"trials":6715,"activeCount":101},[],{"trials":6717,"activeCount":101},[],{"trials":6719,"activeCount":101},[6720],{"nctId":6721,"briefTitle":6722,"status":438,"phases":6723,"primaryCompletion":1188,"completion":1188,"start":3823,"enrollment":1692,"conditions":6724,"interventions":6728},"NCT01022294","Analgetic Effect of Nitrousoxide-oxygen Inhalation for Dental Treatment of Children",[93],[6725,6726,6727],"Dental Pain","Muscle Sensitivity to Pressure","Skin Sensitivity to Electric Stimulation",[6706,6729],"Atmospheric air; nitrousoxide-oxygen",{"intervention":6729,"totalTrials":120,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6738,"PHASE4":6740,"NA":6742},{"trials":6733,"activeCount":101},[],{"trials":6735,"activeCount":101},[],{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[],{"trials":6743,"activeCount":101},[6744],{"nctId":6721,"briefTitle":6722,"status":438,"phases":6745,"primaryCompletion":1188,"completion":1188,"start":3823,"enrollment":1692,"conditions":6746,"interventions":6747},[93],[6725,6726,6727],[6706,6729],{"intervention":6749,"totalTrials":120,"cells":6750},"Anesthesia",{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6761},{"trials":6752,"activeCount":101},[],{"trials":6754,"activeCount":101},[],{"trials":6756,"activeCount":101},[],{"trials":6758,"activeCount":101},[],{"trials":6760,"activeCount":101},[],{"trials":6762,"activeCount":101},[6763],{"nctId":6764,"briefTitle":6765,"status":487,"phases":6766,"primaryCompletion":501,"completion":501,"start":3075,"enrollment":1063,"conditions":6767,"interventions":6769},"NCT01948999","Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study",[93],[6768],"Treatment-refractory Schizophrenia",[6749],{"intervention":6771,"totalTrials":120,"cells":6772},"Trichuris suis eggs",{"EARLY_PHASE1":6773,"PHASE1":6775,"PHASE2":6777,"PHASE3":6779,"PHASE4":6781,"NA":6783},{"trials":6774,"activeCount":101},[],{"trials":6776,"activeCount":101},[],{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[],{"trials":6782,"activeCount":101},[],{"trials":6784,"activeCount":101},[6785],{"nctId":6786,"briefTitle":6787,"status":438,"phases":6788,"primaryCompletion":6789,"completion":6789,"start":6790,"enrollment":120,"conditions":6791,"interventions":6793},"NCT03079700","Immune Modulation From Trichuris Suis",[],"2012-12-31","2012-08-01",[5909,6792,5911],"Ulcerative Colitis",[6771],{"intervention":6795,"totalTrials":120,"cells":6796},"Pioglitazone",{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6803,"PHASE4":6805,"NA":6807},{"trials":6798,"activeCount":101},[],{"trials":6800,"activeCount":101},[],{"trials":6802,"activeCount":101},[],{"trials":6804,"activeCount":101},[],{"trials":6806,"activeCount":101},[],{"trials":6808,"activeCount":101},[6809],{"nctId":6810,"briefTitle":6811,"status":438,"phases":6812,"completion":2174,"start":6813,"enrollment":28,"conditions":6814,"interventions":6815},"NCT00459940","The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients",[93],"2004-09",[4782],[6795],{"intervention":6817,"totalTrials":120,"cells":6818},"memantine",{"EARLY_PHASE1":6819,"PHASE1":6821,"PHASE2":6823,"PHASE3":6825,"PHASE4":6827,"NA":6829},{"trials":6820,"activeCount":101},[],{"trials":6822,"activeCount":101},[],{"trials":6824,"activeCount":101},[],{"trials":6826,"activeCount":101},[],{"trials":6828,"activeCount":101},[],{"trials":6830,"activeCount":101},[6831],{"nctId":6832,"briefTitle":6833,"status":438,"phases":6834,"completion":2966,"start":6835,"enrollment":467,"conditions":6836,"interventions":6838},"NCT00375778","Parkinson's Disease Evaluated by PET and the Effect of Memantine",[93],"2005-04",[6837],"Parkinson's Disease",[6817],{"intervention":6840,"totalTrials":120,"cells":6841},"Octreotide",{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6848,"PHASE4":6850,"NA":6852},{"trials":6843,"activeCount":101},[],{"trials":6845,"activeCount":101},[],{"trials":6847,"activeCount":101},[],{"trials":6849,"activeCount":101},[],{"trials":6851,"activeCount":101},[],{"trials":6853,"activeCount":101},[6854],{"nctId":6855,"briefTitle":6856,"status":438,"phases":6857,"primaryCompletion":4147,"completion":4147,"start":1091,"enrollment":5359,"conditions":6858,"interventions":6860},"NCT01865760","Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia",[93],[15,5023,6859],"Surgery",[6840],{"intervention":6862,"totalTrials":120,"cells":6863},"Systematic exercise training",{"EARLY_PHASE1":6864,"PHASE1":6866,"PHASE2":6868,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6865,"activeCount":101},[],{"trials":6867,"activeCount":101},[],{"trials":6869,"activeCount":101},[],{"trials":6871,"activeCount":101},[],{"trials":6873,"activeCount":101},[],{"trials":6875,"activeCount":101},[6876],{"nctId":6877,"briefTitle":6878,"status":438,"phases":6879,"primaryCompletion":3544,"completion":3544,"start":6880,"enrollment":2614,"conditions":6881,"interventions":6882},"NCT03322761","Early Exercise Efforts in Multiple Sclerosis",[93],"2018-04-01",[35],[6862],{"intervention":6884,"totalTrials":120,"cells":6885},"intravenous gammaglobulin",{"EARLY_PHASE1":6886,"PHASE1":6888,"PHASE2":6890,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6887,"activeCount":101},[],{"trials":6889,"activeCount":101},[],{"trials":6891,"activeCount":101},[],{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[],{"trials":6897,"activeCount":101},[6898],{"nctId":6899,"briefTitle":6900,"status":438,"phases":6901,"completion":6902,"start":1950,"enrollment":4979,"conditions":6903,"interventions":6904},"NCT00305266","Study of CIDP Patients During IVIG Treatment",[],"2007-08",[3472],[6884],{"intervention":6906,"totalTrials":120,"cells":6907},"Na-lactate",{"EARLY_PHASE1":6908,"PHASE1":6910,"PHASE2":6912,"PHASE3":6914,"PHASE4":6916,"NA":6918},{"trials":6909,"activeCount":101},[],{"trials":6911,"activeCount":101},[],{"trials":6913,"activeCount":101},[],{"trials":6915,"activeCount":101},[],{"trials":6917,"activeCount":101},[],{"trials":6919,"activeCount":101},[6920],{"nctId":6921,"briefTitle":6922,"status":438,"phases":6923,"primaryCompletion":6924,"completion":6924,"start":6925,"enrollment":545,"conditions":6926,"interventions":6927},"NCT04710875","The Role of Lactate in Lipolysis and Catabolism in Humans",[93],"2021-06-29","2021-03-10",[5696,18,5695],[6906,6928],"Sodium chloride",{"intervention":6928,"totalTrials":120,"cells":6930},{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6935,"PHASE3":6937,"PHASE4":6939,"NA":6941},{"trials":6932,"activeCount":101},[],{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"trials":6938,"activeCount":101},[],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[6943],{"nctId":6921,"briefTitle":6922,"status":438,"phases":6944,"primaryCompletion":6924,"completion":6924,"start":6925,"enrollment":545,"conditions":6945,"interventions":6946},[93],[5696,18,5695],[6906,6928],{"intervention":6948,"totalTrials":120,"cells":6949},"Somatropin and pegvisomant",{"EARLY_PHASE1":6950,"PHASE1":6952,"PHASE2":6954,"PHASE3":6956,"PHASE4":6958,"NA":6960},{"trials":6951,"activeCount":101},[],{"trials":6953,"activeCount":101},[],{"trials":6955,"activeCount":101},[],{"trials":6957,"activeCount":101},[],{"trials":6959,"activeCount":101},[],{"trials":6961,"activeCount":101},[6962],{"nctId":6963,"briefTitle":6964,"status":438,"phases":6965,"primaryCompletion":5382,"completion":2588,"start":1272,"enrollment":427,"conditions":6966,"interventions":6968},"NCT00476879","Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content",[93],[4722,6967],"Fatty Liver",[6948],{"intervention":6970,"totalTrials":120,"cells":6971},"Sertindole",{"EARLY_PHASE1":6972,"PHASE1":6974,"PHASE2":6976,"PHASE3":6978,"PHASE4":6980,"NA":6982},{"trials":6973,"activeCount":101},[],{"trials":6975,"activeCount":101},[],{"trials":6977,"activeCount":101},[],{"trials":6979,"activeCount":101},[],{"trials":6981,"activeCount":101},[],{"trials":6983,"activeCount":101},[6984],{"nctId":6985,"briefTitle":6986,"status":487,"phases":6987,"primaryCompletion":3192,"completion":3192,"start":3030,"enrollment":4979,"conditions":6988,"interventions":6989},"NCT00885690","Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)",[93],[1606],[6970,6990],"Olanzapine",{"intervention":6990,"totalTrials":120,"cells":6992},{"EARLY_PHASE1":6993,"PHASE1":6995,"PHASE2":6997,"PHASE3":6999,"PHASE4":7001,"NA":7003},{"trials":6994,"activeCount":101},[],{"trials":6996,"activeCount":101},[],{"trials":6998,"activeCount":101},[],{"trials":7000,"activeCount":101},[],{"trials":7002,"activeCount":101},[],{"trials":7004,"activeCount":101},[7005],{"nctId":6985,"briefTitle":6986,"status":487,"phases":7006,"primaryCompletion":3192,"completion":3192,"start":3030,"enrollment":4979,"conditions":7007,"interventions":7008},[93],[1606],[6970,6990],{"intervention":7010,"totalTrials":120,"cells":7011},"Growth hormone, saline and GH receptor blockade",{"EARLY_PHASE1":7012,"PHASE1":7014,"PHASE2":7016,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":7013,"activeCount":101},[],{"trials":7015,"activeCount":101},[],{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[],{"trials":7021,"activeCount":101},[],{"trials":7023,"activeCount":101},[7024],{"nctId":7025,"briefTitle":7026,"status":476,"phases":7027,"primaryCompletion":3255,"completion":3255,"start":6257,"enrollment":427,"conditions":7028,"interventions":7030},"NCT04998500","Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis",[93],[7029],"Fibrosis",[7010],{"intervention":7032,"totalTrials":120,"cells":7033},"Poly methylmetacrylate, PMMA",{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7040,"PHASE4":7042,"NA":7044},{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[],{"trials":7043,"activeCount":101},[],{"trials":7045,"activeCount":101},[7046],{"nctId":7047,"briefTitle":7048,"status":438,"phases":7049,"primaryCompletion":3824,"completion":3824,"start":1143,"enrollment":16,"conditions":7050,"interventions":7052},"NCT00203554","Percutaneous Vertebroplasty Versus Conservative Treatment of Pain",[93],[1122,332,7051],"Fracture",[7032],{"intervention":7054,"totalTrials":120,"cells":7055},"dDAVP",{"EARLY_PHASE1":7056,"PHASE1":7058,"PHASE2":7060,"PHASE3":7062,"PHASE4":7064,"NA":7066},{"trials":7057,"activeCount":101},[],{"trials":7059,"activeCount":101},[],{"trials":7061,"activeCount":101},[],{"trials":7063,"activeCount":101},[],{"trials":7065,"activeCount":101},[],{"trials":7067,"activeCount":101},[7068],{"nctId":7069,"briefTitle":7070,"status":438,"phases":7071,"primaryCompletion":2106,"completion":2106,"start":7072,"enrollment":2900,"conditions":7073,"interventions":7076},"NCT02068560","The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion",[93],"2012-05",[7074,7075,4232],"Gender Difference in V2 Receptor Function in Response to dDAVP Infusion","Nocturia",[7054],{"intervention":7078,"totalTrials":120,"cells":7079},"Amlodipine",{"EARLY_PHASE1":7080,"PHASE1":7082,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7081,"activeCount":101},[],{"trials":7083,"activeCount":101},[],{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[7092],{"nctId":7093,"briefTitle":7094,"status":438,"phases":7095,"primaryCompletion":7096,"completion":7096,"start":5492,"enrollment":897,"conditions":7097,"interventions":7099},"NCT00337298","The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes",[93],"2009-02",[5517,2109,7098,4973],"Eye Diseases",[7078,7100],"Lisinopril",{"intervention":7100,"totalTrials":120,"cells":7102},{"EARLY_PHASE1":7103,"PHASE1":7105,"PHASE2":7107,"PHASE3":7109,"PHASE4":7111,"NA":7113},{"trials":7104,"activeCount":101},[],{"trials":7106,"activeCount":101},[],{"trials":7108,"activeCount":101},[],{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"trials":7114,"activeCount":101},[7115],{"nctId":7093,"briefTitle":7094,"status":438,"phases":7116,"primaryCompletion":7096,"completion":7096,"start":5492,"enrollment":897,"conditions":7117,"interventions":7118},[93],[5517,2109,7098,4973],[7078,7100],{"intervention":7120,"totalTrials":120,"cells":7121},"L-thyroxine",{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7126,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7123,"activeCount":101},[],{"trials":7125,"activeCount":101},[],{"trials":7127,"activeCount":101},[],{"trials":7129,"activeCount":101},[],{"trials":7131,"activeCount":101},[],{"trials":7133,"activeCount":101},[7134],{"nctId":7135,"briefTitle":7136,"status":438,"phases":7137,"primaryCompletion":1272,"completion":1272,"start":1143,"enrollment":22,"conditions":7138,"interventions":7140},"NCT00524238","Metabolic Changes in Hypothyroid Patients",[93],[7139],"Hypothyroidism",[7120],{"intervention":7142,"totalTrials":120,"cells":7143},"Voriconazole",{"EARLY_PHASE1":7144,"PHASE1":7146,"PHASE2":7148,"PHASE3":7150,"PHASE4":7152,"NA":7154},{"trials":7145,"activeCount":101},[],{"trials":7147,"activeCount":101},[],{"trials":7149,"activeCount":101},[],{"trials":7151,"activeCount":101},[],{"trials":7153,"activeCount":101},[],{"trials":7155,"activeCount":101},[7156],{"nctId":7157,"briefTitle":7158,"status":487,"phases":7159,"primaryCompletion":501,"completion":501,"start":490,"enrollment":467,"conditions":7160,"interventions":7162},"NCT02396225","Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration",[93],[7161],"Invasive Aspergillosis",[7142],{"intervention":7164,"totalTrials":120,"cells":7165},"GnRH agonist",{"EARLY_PHASE1":7166,"PHASE1":7168,"PHASE2":7170,"PHASE3":7172,"PHASE4":7174,"NA":7176},{"trials":7167,"activeCount":101},[],{"trials":7169,"activeCount":101},[],{"trials":7171,"activeCount":101},[],{"trials":7173,"activeCount":101},[],{"trials":7175,"activeCount":101},[],{"trials":7177,"activeCount":101},[7178],{"nctId":7179,"briefTitle":7180,"status":476,"phases":7181,"primaryCompletion":1479,"completion":1479,"start":4320,"enrollment":374,"conditions":7182,"interventions":7184},"NCT01944488","LH Response to GnRH Test in Prepubescent Girls Under 6 Years",[93],[7183],"Precocious Puberty",[7164],{"intervention":7186,"totalTrials":120,"cells":7187},"Somatropin",{"EARLY_PHASE1":7188,"PHASE1":7190,"PHASE2":7192,"PHASE3":7194,"PHASE4":7196,"NA":7198},{"trials":7189,"activeCount":101},[],{"trials":7191,"activeCount":101},[],{"trials":7193,"activeCount":101},[],{"trials":7195,"activeCount":101},[],{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[7200],{"nctId":7201,"briefTitle":7202,"status":438,"phases":7203,"primaryCompletion":4970,"completion":4970,"start":2538,"enrollment":427,"conditions":7204,"interventions":7205},"NCT02655263","Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion",[93],[18],[7186],{"intervention":7207,"totalTrials":120,"cells":7208},"Blood products",{"EARLY_PHASE1":7209,"PHASE1":7211,"PHASE2":7213,"PHASE3":7215,"PHASE4":7217,"NA":7219},{"trials":7210,"activeCount":101},[],{"trials":7212,"activeCount":101},[],{"trials":7214,"activeCount":101},[],{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[7221],{"nctId":7222,"briefTitle":7223,"status":438,"phases":7224,"primaryCompletion":7225,"completion":7225,"start":4883,"enrollment":2378,"conditions":7226,"interventions":7229},"NCT04879485","Prehospital Transfusion Strategy in Bleeding Patients",[93],"2024-12-31",[7227,7228],"Hemorrhage","Blood Component Transfusion",[7207],{"intervention":7231,"totalTrials":120,"cells":7232},"genotropin",{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7237,"PHASE3":7239,"PHASE4":7241,"NA":7243},{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"trials":7240,"activeCount":101},[],{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[7245],{"nctId":7246,"briefTitle":7247,"status":438,"phases":7248,"primaryCompletion":7249,"completion":7249,"start":1223,"enrollment":727,"conditions":7250,"interventions":7251},"NCT01723748","Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects",[93],"2015-05",[2616,4756],[7231],{"intervention":4760,"totalTrials":120,"cells":7253},{"EARLY_PHASE1":7254,"PHASE1":7256,"PHASE2":7258,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7255,"activeCount":101},[],{"trials":7257,"activeCount":101},[],{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[7266],{"nctId":4748,"briefTitle":4749,"status":438,"phases":7267,"primaryCompletion":4751,"completion":4751,"start":4752,"enrollment":3867,"conditions":7268,"interventions":7269},[93],[4723,30,4754,4755,4756,4757,4758],[4693,4760],{"intervention":7271,"totalTrials":120,"cells":7272},"COVID-19 vaccine",{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7277,"PHASE3":7279,"PHASE4":7281,"NA":7283},{"trials":7274,"activeCount":101},[],{"trials":7276,"activeCount":101},[],{"trials":7278,"activeCount":101},[],{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[],{"trials":7284,"activeCount":101},[7285],{"nctId":7286,"briefTitle":7287,"status":438,"phases":7288,"primaryCompletion":7289,"completion":7289,"start":7290,"enrollment":7291,"conditions":7292,"interventions":7294},"NCT04928911","Expectations About the COVID-19 Vaccines",[],"2023-03-31","2021-06-11",1176,[7293],"Vaccine Adverse Reaction",[7271],{"intervention":7296,"totalTrials":120,"cells":7297},"Polyethylene Glycol 3350",{"EARLY_PHASE1":7298,"PHASE1":7300,"PHASE2":7302,"PHASE3":7304,"PHASE4":7306,"NA":7308},{"trials":7299,"activeCount":101},[],{"trials":7301,"activeCount":101},[],{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[],{"trials":7307,"activeCount":101},[],{"trials":7309,"activeCount":101},[7310],{"nctId":7311,"briefTitle":7312,"status":476,"phases":7313,"primaryCompletion":7314,"completion":7314,"start":5289,"enrollment":2486,"conditions":7315,"interventions":7317},"NCT05318365","Bladder and Bowel Dysfunction in Children",[93],"2025-12-01",[7316],"Bladder and Bowel Dysfunction",[7296],{"intervention":7319,"totalTrials":120,"cells":7320},"CGMP protein",{"EARLY_PHASE1":7321,"PHASE1":7323,"PHASE2":7325,"PHASE3":7327,"PHASE4":7329,"NA":7331},{"trials":7322,"activeCount":101},[],{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"trials":7328,"activeCount":101},[],{"trials":7330,"activeCount":101},[],{"trials":7332,"activeCount":101},[7333],{"nctId":7334,"briefTitle":7335,"status":438,"phases":7336,"primaryCompletion":1479,"completion":2106,"start":1603,"enrollment":1717,"conditions":7337,"interventions":7339},"NCT01534312","Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)",[93],[5910,7338],"Inflammatory Bowel Diseases",[7319,7340],"Maximal oral 5ASA",{"intervention":7340,"totalTrials":120,"cells":7342},{"EARLY_PHASE1":7343,"PHASE1":7345,"PHASE2":7347,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7344,"activeCount":101},[],{"trials":7346,"activeCount":101},[],{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[7355],{"nctId":7334,"briefTitle":7335,"status":438,"phases":7356,"primaryCompletion":1479,"completion":2106,"start":1603,"enrollment":1717,"conditions":7357,"interventions":7358},[93],[5910,7338],[7319,7340],{"intervention":7360,"totalTrials":120,"cells":7361},"Alemtuzumab",{"EARLY_PHASE1":7362,"PHASE1":7364,"PHASE2":7366,"PHASE3":7368,"PHASE4":7370,"NA":7372},{"trials":7363,"activeCount":101},[],{"trials":7365,"activeCount":101},[],{"trials":7367,"activeCount":101},[],{"trials":7369,"activeCount":101},[],{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[7374],{"nctId":7375,"briefTitle":7376,"status":438,"phases":7377,"primaryCompletion":7378,"completion":7379,"start":5563,"enrollment":31,"conditions":7380,"interventions":7381},"NCT03806387","Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment",[],"2020-07-30","2021-06-30",[35],[7360],{"intervention":7383,"totalTrials":120,"cells":7384},"Denosumab",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7389,"PHASE3":7391,"PHASE4":7393,"NA":7395},{"trials":7386,"activeCount":101},[],{"trials":7388,"activeCount":101},[],{"trials":7390,"activeCount":101},[],{"trials":7392,"activeCount":101},[],{"trials":7394,"activeCount":101},[],{"trials":7396,"activeCount":101},[7397],{"nctId":7398,"briefTitle":7399,"status":438,"phases":7400,"primaryCompletion":7401,"completion":7402,"start":7403,"enrollment":4694,"conditions":7404,"interventions":7407},"NCT05736640","Osseointegrated Transdermal Femoral Amputation Prostheses",[93],"2016-09-20","2016-09-30","2013-09-01",[7405,7406],"Osseointegrated Implants","Bone Mineral Density",[7383],{"intervention":7409,"totalTrials":120,"cells":7410},"dehydroepiandrosterone",{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7417,"PHASE4":7419,"NA":7421},{"trials":7412,"activeCount":101},[],{"trials":7414,"activeCount":101},[],{"trials":7416,"activeCount":101},[],{"trials":7418,"activeCount":101},[],{"trials":7420,"activeCount":101},[],{"trials":7422,"activeCount":101},[7423],{"nctId":7424,"briefTitle":7425,"status":438,"phases":7426,"completion":7427,"start":4393,"enrollment":427,"conditions":7428,"interventions":7430},"NCT00471900","Six Months DHEA Treatment in Female Adrenal Failure",[93],"2003-02",[7429],"Adrenal Insufficiency",[7409],{"intervention":7432,"totalTrials":120,"cells":7433},"Laboratory blood samples",{"EARLY_PHASE1":7434,"PHASE1":7436,"PHASE2":7438,"PHASE3":7440,"PHASE4":7442,"NA":7444},{"trials":7435,"activeCount":101},[],{"trials":7437,"activeCount":101},[],{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[],{"trials":7445,"activeCount":101},[7446],{"nctId":7447,"briefTitle":7448,"status":438,"phases":7449,"primaryCompletion":7450,"completion":7450,"start":489,"enrollment":7451,"conditions":7452,"interventions":7455},"NCT02652975","Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium",[93],"2018-06",76,[7453,7454,5263,947],"Breast Neoplasms","Endothelial Dysfunction",[7432],{"intervention":7457,"totalTrials":120,"cells":7458},"3D-Transit during treatment with Pyridostigmine",{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7465,"PHASE4":7467,"NA":7469},{"trials":7460,"activeCount":101},[],{"trials":7462,"activeCount":101},[],{"trials":7464,"activeCount":101},[],{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[7471],{"nctId":7472,"briefTitle":7473,"status":487,"phases":7474,"primaryCompletion":7475,"completion":7475,"start":479,"enrollment":1034,"conditions":7476,"interventions":7480},"NCT02573519","Gastrointestinal Motility Among Diabetes Patients",[93],"2019-02-11",[7477,7478,870,7479],"Diabetic Autonomic Neuropathy","Gastrointestinal Motility Disorder","Change of Transit or Circulation",[7457],{"intervention":7482,"totalTrials":120,"cells":7483},"Platelet Rich Plasma",{"EARLY_PHASE1":7484,"PHASE1":7486,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7485,"activeCount":101},[],{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[7496],{"nctId":7497,"briefTitle":7498,"status":438,"phases":7499,"primaryCompletion":2662,"completion":2662,"start":3823,"enrollment":374,"conditions":7500,"interventions":7502},"NCT01109446","Treatment of Lateral Epicondylitis: Platelet Rich Plasma Versus Steroid Versus Saline Solution",[93],[7501],"Lateral Epicondylitis",[7482,7503],"Triamcinolonacetonid",{"intervention":7503,"totalTrials":120,"cells":7505},{"EARLY_PHASE1":7506,"PHASE1":7508,"PHASE2":7510,"PHASE3":7512,"PHASE4":7514,"NA":7516},{"trials":7507,"activeCount":101},[],{"trials":7509,"activeCount":101},[],{"trials":7511,"activeCount":101},[],{"trials":7513,"activeCount":101},[],{"trials":7515,"activeCount":101},[],{"trials":7517,"activeCount":101},[7518],{"nctId":7497,"briefTitle":7498,"status":438,"phases":7519,"primaryCompletion":2662,"completion":2662,"start":3823,"enrollment":374,"conditions":7520,"interventions":7521},[93],[7501],[7482,7503],{"intervention":7523,"totalTrials":120,"cells":7524},"Epinephrine",{"EARLY_PHASE1":7525,"PHASE1":7527,"PHASE2":7529,"PHASE3":7531,"PHASE4":7533,"NA":7535},{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[],{"trials":7530,"activeCount":101},[],{"trials":7532,"activeCount":101},[],{"trials":7534,"activeCount":101},[],{"trials":7536,"activeCount":101},[7537],{"nctId":7538,"briefTitle":7539,"status":438,"phases":7540,"primaryCompletion":4417,"completion":1119,"start":7541,"enrollment":427,"conditions":7542,"interventions":7543},"NCT01116609","Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs",[93],"2004-10",[18],[7523],{"intervention":7545,"totalTrials":120,"cells":7546},"Insulin withdrawal",{"EARLY_PHASE1":7547,"PHASE1":7549,"PHASE2":7551,"PHASE3":7553,"PHASE4":7555,"NA":7557},{"trials":7548,"activeCount":101},[],{"trials":7550,"activeCount":101},[],{"trials":7552,"activeCount":101},[],{"trials":7554,"activeCount":101},[],{"trials":7556,"activeCount":101},[],{"trials":7558,"activeCount":101},[7559],{"nctId":7560,"briefTitle":7561,"status":438,"phases":7562,"primaryCompletion":489,"completion":489,"start":7563,"enrollment":3867,"conditions":7564,"interventions":7565},"NCT02077348","Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.",[93],"2014-05",[5022,6234],[7545,7566],"Norditropin",{"intervention":7566,"totalTrials":120,"cells":7568},{"EARLY_PHASE1":7569,"PHASE1":7571,"PHASE2":7573,"PHASE3":7575,"PHASE4":7577,"NA":7579},{"trials":7570,"activeCount":101},[],{"trials":7572,"activeCount":101},[],{"trials":7574,"activeCount":101},[],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[7581],{"nctId":7560,"briefTitle":7561,"status":438,"phases":7582,"primaryCompletion":489,"completion":489,"start":7563,"enrollment":3867,"conditions":7583,"interventions":7584},[93],[5022,6234],[7545,7566],{"intervention":7586,"totalTrials":120,"cells":7587},"Levothyroxin",{"EARLY_PHASE1":7588,"PHASE1":7590,"PHASE2":7592,"PHASE3":7594,"PHASE4":7596,"NA":7598},{"trials":7589,"activeCount":101},[],{"trials":7591,"activeCount":101},[],{"trials":7593,"activeCount":101},[],{"trials":7595,"activeCount":101},[],{"trials":7597,"activeCount":101},[],{"trials":7599,"activeCount":101},[7600],{"nctId":7601,"briefTitle":7602,"status":487,"phases":7603,"primaryCompletion":1119,"completion":4807,"start":1119,"enrollment":101,"conditions":7604,"interventions":7605},"NCT00770016","Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism",[93],[7139],[7586],{"intervention":5449,"totalTrials":120,"cells":7607},{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7612,"PHASE3":7614,"PHASE4":7616,"NA":7618},{"trials":7609,"activeCount":101},[],{"trials":7611,"activeCount":101},[],{"trials":7613,"activeCount":101},[],{"trials":7615,"activeCount":101},[],{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[7620],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7621,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7622,"interventions":7623},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":5450,"totalTrials":120,"cells":7625},{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7630,"PHASE3":7632,"PHASE4":7634,"NA":7636},{"trials":7627,"activeCount":101},[],{"trials":7629,"activeCount":101},[],{"trials":7631,"activeCount":101},[],{"trials":7633,"activeCount":101},[],{"trials":7635,"activeCount":101},[],{"trials":7637,"activeCount":101},[7638],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7639,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7640,"interventions":7641},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":5451,"totalTrials":120,"cells":7643},{"EARLY_PHASE1":7644,"PHASE1":7646,"PHASE2":7648,"PHASE3":7650,"PHASE4":7652,"NA":7654},{"trials":7645,"activeCount":101},[],{"trials":7647,"activeCount":101},[],{"trials":7649,"activeCount":101},[],{"trials":7651,"activeCount":101},[],{"trials":7653,"activeCount":101},[],{"trials":7655,"activeCount":101},[7656],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7657,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7658,"interventions":7659},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":5452,"totalTrials":120,"cells":7661},{"EARLY_PHASE1":7662,"PHASE1":7664,"PHASE2":7666,"PHASE3":7668,"PHASE4":7670,"NA":7672},{"trials":7663,"activeCount":101},[],{"trials":7665,"activeCount":101},[],{"trials":7667,"activeCount":101},[],{"trials":7669,"activeCount":101},[],{"trials":7671,"activeCount":101},[],{"trials":7673,"activeCount":101},[7674],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7675,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7676,"interventions":7677},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":5453,"totalTrials":120,"cells":7679},{"EARLY_PHASE1":7680,"PHASE1":7682,"PHASE2":7684,"PHASE3":7686,"PHASE4":7688,"NA":7690},{"trials":7681,"activeCount":101},[],{"trials":7683,"activeCount":101},[],{"trials":7685,"activeCount":101},[],{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[],{"trials":7691,"activeCount":101},[7692],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7693,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7694,"interventions":7695},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":5454,"totalTrials":120,"cells":7697},{"EARLY_PHASE1":7698,"PHASE1":7700,"PHASE2":7702,"PHASE3":7704,"PHASE4":7706,"NA":7708},{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[],{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[],{"trials":7707,"activeCount":101},[],{"trials":7709,"activeCount":101},[7710],{"nctId":5443,"briefTitle":5444,"status":487,"phases":7711,"primaryCompletion":1165,"completion":1165,"start":2756,"enrollment":427,"conditions":7712,"interventions":7713},[93],[5447,1909],[5449,5421,5450,5451,5452,5453,5454],{"intervention":7715,"totalTrials":120,"cells":7716},"PET3",{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7721,"PHASE3":7723,"PHASE4":7725,"NA":7727},{"trials":7718,"activeCount":101},[],{"trials":7720,"activeCount":101},[],{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[],{"trials":7728,"activeCount":101},[7729],{"nctId":7730,"briefTitle":7731,"status":438,"phases":7732,"primaryCompletion":1033,"completion":1033,"start":4678,"enrollment":1717,"conditions":7733,"interventions":7735},"NCT03285945","FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment",[],[7734],"Giant Cell Arteritis",[7715,7736],"PET10",{"intervention":7736,"totalTrials":120,"cells":7738},{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7745,"PHASE4":7747,"NA":7749},{"trials":7740,"activeCount":101},[],{"trials":7742,"activeCount":101},[],{"trials":7744,"activeCount":101},[],{"trials":7746,"activeCount":101},[],{"trials":7748,"activeCount":101},[],{"trials":7750,"activeCount":101},[7751],{"nctId":7730,"briefTitle":7731,"status":438,"phases":7752,"primaryCompletion":1033,"completion":1033,"start":4678,"enrollment":1717,"conditions":7753,"interventions":7754},[],[7734],[7715,7736],{"intervention":549,"totalTrials":120,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7763,"PHASE4":7765,"NA":7767},{"trials":7758,"activeCount":101},[],{"trials":7760,"activeCount":101},[],{"trials":7762,"activeCount":101},[],{"trials":7764,"activeCount":101},[],{"trials":7766,"activeCount":101},[],{"trials":7768,"activeCount":101},[7769],{"nctId":540,"briefTitle":541,"status":438,"phases":7770,"completion":543,"start":544,"enrollment":545,"conditions":7771,"interventions":7772},[93],[547],[426,549,525],{"intervention":7774,"totalTrials":120,"cells":7775},"Cabergoline 0.5 MG",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7782,"PHASE4":7784,"NA":7786},{"trials":7777,"activeCount":101},[],{"trials":7779,"activeCount":101},[],{"trials":7781,"activeCount":101},[],{"trials":7783,"activeCount":101},[],{"trials":7785,"activeCount":101},[],{"trials":7787,"activeCount":101},[7788],{"nctId":7789,"briefTitle":7790,"status":438,"phases":7791,"primaryCompletion":7792,"completion":7793,"start":7794,"enrollment":11,"conditions":7795,"interventions":7796},"NCT05525611","Cabergoline as a Preventive Treatment for Chronic Migraine",[93],"2023-06-13","2023-08-08","2022-09-05",[923],[7774],{"intervention":7798,"totalTrials":120,"cells":7799},"Antibiotics",{"EARLY_PHASE1":7800,"PHASE1":7802,"PHASE2":7804,"PHASE3":7806,"PHASE4":7808,"NA":7810},{"trials":7801,"activeCount":101},[],{"trials":7803,"activeCount":101},[],{"trials":7805,"activeCount":101},[],{"trials":7807,"activeCount":101},[],{"trials":7809,"activeCount":101},[],{"trials":7811,"activeCount":101},[7812],{"nctId":7813,"briefTitle":7814,"status":438,"phases":7815,"primaryCompletion":7816,"completion":7816,"start":7817,"enrollment":2900,"conditions":7818,"interventions":7820},"NCT04003181","The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon",[93],"2021-05-26","2017-09-28",[7819,3078],"Colon Adenocarcinoma",[7798,7821],"Bile Acid Binder",{"intervention":7821,"totalTrials":120,"cells":7823},{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7828,"PHASE3":7830,"PHASE4":7832,"NA":7834},{"trials":7825,"activeCount":101},[],{"trials":7827,"activeCount":101},[],{"trials":7829,"activeCount":101},[],{"trials":7831,"activeCount":101},[],{"trials":7833,"activeCount":101},[],{"trials":7835,"activeCount":101},[7836],{"nctId":7813,"briefTitle":7814,"status":438,"phases":7837,"primaryCompletion":7816,"completion":7816,"start":7817,"enrollment":2900,"conditions":7838,"interventions":7839},[93],[7819,3078],[7798,7821]]